# EDGAR Filing Document

**Accession Number:** 0001141103
**File Stem:** 0001140361-25-039458
**Filing Date:** 2025-10
**Character Count:** 250421
**Document Hash:** 2a51264b527b937ff45db4096b16a0e0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-039458.hdr.sgml**: 20251027

**ACCESSION NUMBER**: 0001140361-25-039458

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 47

**CONFORMED PERIOD OF REPORT**: 20251209

**FILED AS OF DATE**: 20251027

**DATE AS OF CHANGE**: 20251027

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CROSS COUNTRY HEALTHCARE INC
- **CENTRAL INDEX KEY:** 0001141103
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HELP SUPPLY SERVICES [7363]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 134066229
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-33169
- **FILM NUMBER:** 251419919

**BUSINESS ADDRESS:**
- **STREET 1:** 6551 PARK OF COMMERCE BOULEVARD, N.W.
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33487
- **BUSINESS PHONE:** 8003472264

**MAIL ADDRESS:**
- **STREET 1:** 6551 PARK OF COMMERCE BOULEVARD, N.W.
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33487

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CROSS COUNTRY INC
- **DATE OF NAME CHANGE:** 20010521

?xml version='1.0' encoding='ASCII'?

#### **TABLE OF CONTENTS**

#### UNITED STATES

#### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### SCHEDULE 14A

#### Proxy Statement Pursuant to Section 14(a) of

#### the Securities Exchange Act of 1934
Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

&nbsp;&nbsp;&nbsp;&nbsp;☒ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

---

| |
|:---|
| **<u>CROSS COUNTRY HEALTHCARE, INC.</u>**  |
| **(Name of Registrant as Specified In Its Charter)**  |
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) |

---

Payment of Filing Fee (Check the appropriate box):

☒ No fee required. 

☐ Fee paid previously with preliminary materials. 

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

------

#### **TABLE OF CONTENTS**
![](logo_crosscountryhc3.jpg)

6551 Park of Commerce Boulevard, N.W.

Boca Raton, FL 33487

Dear Cross Country stockholders,

In 2024 and 2025 thus far, Cross Country navigated changes across the healthcare industry. Workforce shortages, economic pressures, and evolving client needs challenged the entire sector. Through it all, we remain focused on disciplined execution, operational efficiency, and delivering reliable workforce solutions to the clients and professionals who depended on us.

Our approach is deliberate — strengthen our operational foundation, advance technology capabilities, and position the company to adapt to the changing needs of healthcare, homecare, and education markets. We believe that these efforts helped us close 2024 with greater resilience and stability, which positioned us well for 2025.

#### 2024 Highlights
In 2024, we:

&nbsp;&nbsp;&nbsp;&nbsp;• Generated $1.3 billion in revenue across our portfolio.

&nbsp;&nbsp;&nbsp;&nbsp;• Maintained a strong balance sheet with $82 million of cash on hand and no debt as of year-end.

&nbsp;&nbsp;&nbsp;&nbsp;• Drove cost savings by significantly expanding our investment in our low-cost center of excellence in India.

&nbsp;&nbsp;&nbsp;&nbsp;• Repurchased and retired over 2.4 million shares of common stock for $36.8 million.

&nbsp;&nbsp;&nbsp;&nbsp;• Physician and Homecare Staffing experienced year-over-year revenue growth.

&nbsp;&nbsp;&nbsp;&nbsp;• Advanced technology investments, expanding Intellify<sup>®</sup> across managed service programs (MSP) and elevating the Xperience™ app, a mobile-first platform for healthcare professionals to manage assignments, scheduling, and real-time engagement.

&nbsp;&nbsp;&nbsp;&nbsp;• Entered into a Merger Agreement with Aya Healthcare, Inc. on December 4, 2024.

#### 2025 and Looking Ahead
During 2025, our focus has continued to extend beyond operational excellence and technology adoption to strengthen relationships with both clients and the professionals who make our work possible — the clinicians, educators, and homecare professionals delivering care and education across the country.

We also expect our proposed merger with Aya Healthcare, Inc. to close in the fourth quarter of 2025.

#### Moving Forward Together
Cross Country remains committed to delivering consistent, reliable workforce solutions, while balancing operational rigor with ongoing innovation. We ask for your support in approving the proposals outlined in this proxy statement, as we strive to continue building on our progress and strengthening our ability to deliver value for clients, professionals, and stakeholders alike.

Sincerely,

---

| | |
|:---|:---|
| ![](sig_kclark.jpg)<br>| ![](sig_jmartins.jpg)<br>|
| Kevin C. Clark,<br>Chairman of the Board of Directors | John A. Martins, <br>President and Chief Executive Officer |

---

------

#### **TABLE OF CONTENTS**
![](logo_crosscountryhc3.jpg)

#### 6551 Park of Commerce Boulevard, N.W.

#### Boca Raton, Florida 33487

#### NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

---

| | |
|:---|:---|
| ![](ny20055089x1_date.jpg)<br>| **Date and Time** <br>**Tuesday, December 9, 2025 at 12:00 p.m. Eastern Time**  |
| ![](ny20055089x1_location.jpg) <br>| **Location** <br>**Cross Country Healthcare, Inc. will have a virtual-only Annual Meeting of Stockholders in 2025 conducted exclusively via live audio cast at <u>www.virtualshareholdermeeting.com/CCRN2025</u>. There will not be a physical location for our 2025 Meeting of Stockholders. Cross Country Healthcare Inc.'s Proxy Statement for the 2025 Annual Meeting of Stockholders and 2024 Annual Report are available at <u>www.proxyvote.com</u>.** |

---

Cross Country Healthcare, Inc. (the "Company," "we," "us," or "our") will hold the 2025 Annual Meeting of Stockholders (the "Annual Meeting") as a virtual only meeting via live audio cast on the internet for the following purposes:

---

| | | |
|:---|:---|:---|
| **<u>Agenda</u>** | **<u>Agenda</u>** | **<u>Board's Voting Recommendation</u>**  |
| **Proposal 1** | To elect seven director nominees to serve for a one-year term | **✓FOR each director nominee**  |
| **Proposal 2** | To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025 | **✓FOR**  |
| **Proposal 3** | To approve, on a non-binding, advisory basis, the compensation paid to our named executive officers in 2024 ("say on pay" vote) | **✓FOR** |

---

We will consider and act upon other business that may properly come before the Annual Meeting or its adjournment, postponement, or continuation.

Only the Company's stockholders of record at the close of business on October 14, 2025 (the "Record Date") are entitled to receive this Notice of Internet Availability of Proxy Materials (this "Notice") and to vote during the Annual Meeting or its adjournment, postponement, or continuation.

To attend, vote at, and submit questions during the Annual Meeting, visit <u>www.virtualshareholdermeeting.com/CCRN2025</u> and enter the 16-digit control number included in your Notice, voting instruction form, or proxy card. Please allow ample time for online check-in, which will begin at 11:45 a.m. Eastern Time on December 9, 2025. The date on which the Proxy Statement is first being made available to the Company's stockholders is on or about October 27, 2025. The Proxy Statement, which more fully describes the matters to be considered at the Annual Meeting, is attached to this Notice. Copies of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (including the financial statements and schedules thereto, as filed with the Securities and Exchange Commission (the "SEC")) accompany this Notice, but are not deemed to be part of the Proxy Statement.

------

#### **TABLE OF CONTENTS**
It is important that your shares be represented at the Annual Meeting. We urge you to review the attached Proxy Statement and, whether or not you plan to participate in the Annual Meeting, to vote your shares promptly by completing, signing, and returning the accompanying proxy card. You do not need to affix postage to the enclosed reply envelope if you mail it within the United States. If you participate in the virtual meeting, you may withdraw your proxy and vote your share electronically during the Annual Meeting.

While the Company expects the merger to close in the fourth quarter of 2025, we encourage you to vote your shares should the closing not occur prior to the Annual Meeting. As previously disclosed, the Company will not hold the Annual Meeting if the merger with Aya Healthcare, Inc. is completed prior to December 9, 2025.

By Order of the Board of Directors,

![](sig_sball.jpg)

Susan E. Ball

*Executive Vice President, Chief Administrative Officer,*

*General Counsel and Secretary*

October 27, 2025

**IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD DECEMBER 9, 2025: Cross Country Healthcare Inc.'s 2025 Proxy Statement for the 2025 Annual Meeting of Stockholders and 2024 Annual Report are available via the Internet at <u>www.proxyvote.com</u>.**<br>

------

**Table of Contents**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**[Forward Looking Statements](#tFLS)** | [1](#tFLS) |
| &nbsp;&nbsp;&nbsp;**[Website References](#tWR)** | [1](#tWR) |
| **[OUR BOARD OF DIRECTORS](#tOBOD)** | [2](#tOBOD) |
| [WHO WE ARE](#tOBOD) | [2](#tOBOD) |
| [OUR SKILLS, EXPERIENCES, AND ATTRIBUTES](#tOSEA) | [8](#tOSEA) |
| &nbsp;&nbsp;&nbsp;**[Board Skills and Tenure](#tBSTD)** | [9](#tBSTD) |
| [HOW WE ARE SELECTED, ELECTED, AND SERVE](#tHWASE) | [11](#tHWASE) |
| [WHAT WE ACCOMPLISHED](#tWWACC) | [12](#tWWACC) |
| [HOW WE ARE EVALUATED](#tHWAE) | [12](#tHWAE) |
| [HOW WE GOVERN AND ARE GOVERNED](#tHWGAAG) | [13](#tHWGAAG) |
| &nbsp;&nbsp;&nbsp;**[Board Independence](#tBI)** | [13](#tBI) |
| &nbsp;&nbsp;&nbsp;**[Governance Policies](#tGFP)** | [13](#tGFP) |
| &nbsp;&nbsp;&nbsp;**[Delinquent Section 16(a) Reports](#tDSR)** | [13](#tDSR) |
| &nbsp;&nbsp;&nbsp;**[Board Committees](#tBCO)** | [14](#tBCO) |
| &nbsp;&nbsp;&nbsp;**[Board and Committee Meetings](#tBCM)** | [17](#tBCM) |
| &nbsp;&nbsp;&nbsp;**[Risk Oversight](#tROV)** | [17](#tROV) |
| &nbsp;&nbsp;&nbsp;**[Board Leadership Structure](#tBLS)** | [19](#tBLS) |
| [HOW YOU CAN COMMUNICATE WITH US](#tHYC) | [19](#tHYC) |
| &nbsp;&nbsp;&nbsp;**[Stockholder Engagement](#tSE)** | [19](#tSE) |
| [NON-EMPLOYEE DIRECTOR COMPENSATION](#tNEDC) | [20](#tNEDC) |
| &nbsp;&nbsp;&nbsp;**[Cash Compensation](#tCC)** | [21](#tCC) |
| &nbsp;&nbsp;&nbsp;**[Equity Compensation](#tEC)** | [21](#tEC) |
| &nbsp;&nbsp;&nbsp;**[Travel Reimbursement](#tTRE)** | [21](#tTRE) |
| &nbsp;&nbsp;&nbsp;**[Stock Ownership Requirement](#tSOR)** | [21](#tSOR) |
| [2024 DIRECTOR COMPENSATION TABLE](#tDCT) | [22](#tDCT) |
| **[OUR COMPANY](#tOCM)** | [23](#tOCM) |
| [WHAT WE DO](#tWWD) | [23](#tWWD) |
| [WHO WE ARE](#tWWA) | [24](#tWWA) |
| [HOW WE DO WHAT WE DO](#tHWDW) | [29](#tHWDW) |
| [HOW WE DID](#tHWDI) | [30](#tHWDI) |
| [RELATED PARTY TRANSACTIONS](#tRPT) | [30](#tRPT) |
| **[OUR STOCKHOLDERS](#tOSH)** | [32](#tOSH) |
| [SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT](#tSOCB) | [32](#tSOCB) |

---

---

| | |
|:---|:---|
| **[AUDIT MATTERS](#tAMA)** | [34](#tAMA) |
| [REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS](#tRACTB) | [34](#tRACTB) |
| [AUDIT FEES](#tAFE) | [35](#tAFE) |
| [POLICY ON AUDIT COMMITTEE PRE-APPROVAL OF AUDIT AND NON-AUDIT SERVICES OF THE INDEPENDENT REGISTERED ACCOUNTING FIRM](#tPACAN) | [36](#tPACAN) |
| **[COMPENSATION DISCUSSION AND ANALYSIS](#tCDA)** | [37](#tCDA) |
| [COMPENSATION PHILOSOPHY AND OBJECTIVES](#tCPAO) | [38](#tCPAO) |
| &nbsp;&nbsp;&nbsp;**[Consideration of Say-on-Pay Vote](#tCSAV)** | [39](#tCSAV) |
| [DETERMINATION OF COMPENSATION](#tDOC) | [39](#tDOC) |
| &nbsp;&nbsp;&nbsp;**[Role of the Compensation Committee](#tRCC)** | [39](#tRCC) |
| &nbsp;&nbsp;&nbsp;**[Role of Management](#tRM)** | [40](#tRM) |
| &nbsp;&nbsp;&nbsp;**[Role of the Compensation Consultant](#tRCOCO)** | [40](#tRCOCO) |
| &nbsp;&nbsp;&nbsp;**[Role of Benchmarking](#tRB)** | [41](#tRB) |
| [COMPONENTS OF FISCAL 2024 NEO COMPENSATION PROGRAM](#tCFNCP) | [41](#tCFNCP) |
| &nbsp;&nbsp;&nbsp;**[Base Salary](#tBS)** | [41](#tBS) |
| &nbsp;&nbsp;&nbsp;**[Annual Cash Incentive Program](#tACIP)** | [42](#tACIP) |
| &nbsp;&nbsp;&nbsp;**[Long-Term Incentive Compensation](#tLTIC)** | [44](#tLTIC) |
| [OTHER COMPENSATION AND BENEFITS](#tOCB) | [47](#tOCB) |
| &nbsp;&nbsp;&nbsp;**[Nonqualified Deferred Compensation Plans](#tNDCP)** | [47](#tNDCP) |
| &nbsp;&nbsp;&nbsp;**[401(k) Plan and Other Benefits](#tFKPOB)** | [47](#tFKPOB) |
| &nbsp;&nbsp;&nbsp;**[Perquisites](#tP)** | [47](#tP) |
| &nbsp;&nbsp;&nbsp;**[Employment Agreements](#tEA)** | [48](#tEA) |
| &nbsp;&nbsp;&nbsp;**[Severance & Change of Control Arrangements](#tSCCA)** | [51](#tSCCA) |
| &nbsp;&nbsp;&nbsp;**[Anti-Hedging Policy](#tAHP)** | [52](#tAHP) |
| &nbsp;&nbsp;&nbsp;**[Stock Ownership Guidelines](#tSOG)** | [52](#tSOG) |
| &nbsp;&nbsp;&nbsp;**[Impact of Accounting and Tax Matters](#tIATM)** | [52](#tIATM) |
| &nbsp;&nbsp;&nbsp;**[Compensation Recoupment Policy](#tICRCP)** | [52](#tICRCP) |
| &nbsp;&nbsp;&nbsp;**[Compensation Risk Management](#tCRM)** | [53](#tCRM) |
| [COMPENSATION COMMITTEE REPORT](#tCCR) | [54](#tCCR) |
| [SUMMARY COMPENSATION TABLE](#tSCT) | [55](#tSCT) |
| [GRANTS OF PLAN BASED AWARDS](#tGPBA) | [56](#tGPBA) |
| [OUTSTANDING EQUITY AWARDS AT 2024 YEAR-END](#tOEAYE) | [57](#tOEAYE) |

---

-i-<br>

------

---

| | |
|:---|:---|
| [OPTION EXERCISES AND STOCK VESTED IN 2024](#tOESV) | [58](#tOESV) |
| [NONQUALIFIED DEFERRED COMPENSATION 2024](#tNDC) | [58](#tNDC) |
| &nbsp;&nbsp;&nbsp;**[Potential Payments Upon Termination or Change in Control](#tPPUTCC)** | [58](#tPPUTCC) |
| &nbsp;&nbsp;&nbsp;**[CEO Pay Ratio](#tCPR)** | [62](#tCPR) |
| &nbsp;&nbsp;&nbsp;**[Pay versus Performance](#tPVP)** | [64](#tPVP) |
| &nbsp;&nbsp;&nbsp;**[2024 Most Important Measures (Unranked)](#tMIMU)** | [69](#tMIMU) |
| &nbsp;&nbsp;&nbsp;**[Relationship between "Compensation Actually Paid" and Performance Measures](#tRCAPPM)** | [69](#tRCAPPM) |
| **[OUR ANNUAL MEETING & OTHER INFORMATION](#tOAMOI)** | [72](#tOAMOI) |
| [OUR PROPOSALS](#tOPR) | [72](#tOPR) |
| **[PROPOSAL NO. 1: ELECTION OF DIRECTORS](#tPROP1)** | [72](#tPROP1) |
| **[PROPOSAL NO. 2: RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM](#tPROP2)** | [73](#tPROP2) |
| **[PROPOSAL NO. 3: NON-BINDING ADVISORY VOTE TO APPROVE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS](#tPROP3)** | [74](#tPROP3) |

---

---

| | |
|:---|:---|
| [GENERAL PROXY INFORMATION](#tGPI) | [75](#tGPI) |
| [ANNUAL MEETING AND VOTING INFORMATION](#tAMVI) | [75](#tAMVI) |
| &nbsp;&nbsp;&nbsp;**[2025 Annual Meeting of Stockholders](#tAMoS)** | [75](#tAMoS) |
| &nbsp;&nbsp;&nbsp;**[Matters to be Voted Upon](#tMVU)** | [75](#tMVU) |
| &nbsp;&nbsp;&nbsp;**[How to Attend the Virtual Annual Meeting](#tHAVAM)** | [75](#tHAVAM) |
| &nbsp;&nbsp;&nbsp;**[Who May Vote](#tWMV)** | [76](#tWMV) |
| &nbsp;&nbsp;&nbsp;**[Electronic Notice and Mailing](#tENM)** | [76](#tENM) |
| &nbsp;&nbsp;&nbsp;**[How to Vote](#tHV)** | [77](#tHV) |
| &nbsp;&nbsp;&nbsp;**[Board's Voting Recommendations](#tBVR)** | [78](#tBVR) |
| &nbsp;&nbsp;&nbsp;**[Required Vote](#tRV)** | [78](#tRV) |
| &nbsp;&nbsp;&nbsp;**[Revoking Your Proxy](#tRYP)** | [79](#tRYP) |
| &nbsp;&nbsp;&nbsp;**[Proxy Cards](#tPC)** | [80](#tPC) |
| &nbsp;&nbsp;&nbsp;**[Quorum](#tQUOR)** | [80](#tQUOR) |
| &nbsp;&nbsp;&nbsp;**[Solicitation of Proxies](#tSOP)** | [80](#tSOP) |
| &nbsp;&nbsp;&nbsp;**[Information Regarding Director Nominations and Stockholder Proposals](#tIRDN)** | [80](#tIRDN) |
| &nbsp;&nbsp;&nbsp;**[Householding of Proxy Materials](#tHPM)** | [81](#tHPM) |
| **[ANNUAL REPORT](#tAREP)** | [82](#tAREP) |
| **[ANNEX A RECONCILIATION OF GAAP AND NON-GAAP FINANCIAL MEASURES](#tANNEXA)** | [83](#tANNEXA) |

---

-ii-<br>

------

**Forward Looking Statements** <br>

This Proxy Statement includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current facts, including statements regarding our environmental, social, and other sustainability plans, initiatives, projections, goals, commitments, expectations, or prospects, are forward-looking. Forward-looking statements include those containing such words as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," or other words of similar meaning. Forward-looking statements reflect management's current expectations and are inherently uncertain. These forward-looking statements rely on assumptions and involve risks and uncertainties, including, but not limited to, factors detailed herein and under Part I, "Item 1A. Risk Factors" and in other sections of our 2024 Annual Report and in other filings with the SEC.

Any standards of measurement and performance made in reference to our environmental, social, and other sustainability plans and goals are developing and based on assumptions, and no assurance can be given that any such plan, initiative, projection, goal, commitment, expectation, or prospect can or will be achieved.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on our forward- looking statements. Each forward-looking statement speaks only as of the date of the particular statement, and, except as required by law, we undertake no duty to update or revise any forward-looking statement.

**Website References** <br>

This document includes several website addresses. These website addresses are intended to provide inactive, textual references only. The content of information on these websites is not part of this Proxy Statement.

1<br>

------

![](logo_crosscountryhc3.jpg)

#### 6551 Park of Commerce Boulevard, N.W.

#### Boca Raton, Florida 33487

#### PROXY STATEMENT

#### FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS

### OUR BOARD OF DIRECTORS

### WHO WE ARE
The Board of Directors (the "Board") of the Company currently consists of seven members. The current terms of all seven members expire at the Annual Meeting, and all are standing for re-election at the Annual Meeting to hold office until the next annual meeting of stockholders and until their successors are elected. The Board previously consisted of eight directors; however, following the passing of Mark Perlberg on March 11, 2025, the Board reduced the size of the Board from eight directors to seven directors. Biographical information regarding each of the directors currently serving on the Board is set forth below.

The following seven directors have been nominated for election at the Annual Meeting for a one-year term ending upon the 2026 Annual Meeting of Stockholders:

---

| | |
|:---|:---|
| ![](ny20055089x1_kcclark.jpg)<br>**KEVIN C. CLARK,** 65 <br>Co-Founder and Chairman of <br>the Board of Directors,<br>Cross Country Healthcare<br>*Director since 2019* | **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• President, Chief Executive Officer and Director, Cross Country Healthcare, Inc. (2019–March 2022)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Chair and Chief Executive Officer, Hire Innovations, Inc. (formerly Talivity, Inc.) (2015-2018)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Chair and Chief Executive Officer, OGH, LLC (2002–2015)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Chair and Chief Executive Officer, Pinnacor Inc. (1999–2001)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Chair and Chief Executive Officer, Poppe Tyson, Inc. (1996–1998)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Chair and Chief Executive Officer, Cross Country, Inc. (1986–1994)<br>**Education:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• BBA, Florida Atlantic University<br>**Director-relevant skills, experiences, and attributes:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Extensive experience building and leading health staffing, technology, and workforce solutions companies<br>&nbsp;&nbsp;&nbsp;&nbsp;• Institutional knowledge of Cross Country<br>&nbsp;&nbsp;&nbsp;&nbsp;• Governance experience based on prior and current board service<br>|

---

2<br>

------

#### **TABLE OF CONTENTS**

---

| | |
|:---|:---|
| ![](ny20055089x1_dallen.jpg)<br>**DWAYNE ALLEN,** 64<br>Chief Technology Officer, <br>Unisys Corporation <br>(2021-Present)<br>*Director since 2023* | **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;<br>• Global Digital Strategist, Microsoft Corp. (2019–2021)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Vice President & Chief Information Officer, Masonite International (2017–2019)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Chief Information Officer, Components, Cummins, Inc. (2011–2017)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Executive Director, Global Applications Development & Support, Cummins, Inc. (2009-2011)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Vice President, Information Technology, Fifth Third Bank (2003–2009)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Various positions, including Vice President and Division Chief Information Officer, Corporate Services Technology, Wells Fargo & Company, Inc. (2001–2003)<br>&nbsp;&nbsp;&nbsp;&nbsp;• IT Director, Strategy & Planning, Marriott International (1996–1998)<br>**Education:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• MBA, George Washington University<br>&nbsp;&nbsp;&nbsp;&nbsp;• BA, University of Virginia<br>**Director-relevant skills, experiences, and attributes:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Over 25 years of leadership experience creating IT platforms and advancing digital strategy across industries<br>&nbsp;&nbsp;&nbsp;&nbsp;• Track record of promoting digital innovation to enhance businesses<br>&nbsp;&nbsp;&nbsp;&nbsp;• Experience leveraging advanced analytics and big data to reduce friction and increase efficiencies<br>|

---

3<br>

------

---

| | |
|:---|:---|
| ![](ny20055089x1_vbhamidipati.jpg)<br>**VENKAT BHAMIDIPATI,** 59<br>Retired Executive Vice President and Chief Financial Officer, McAfee Corp. <br>*Director since 2022*<br>| **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Investor and Strategic Advisor, Technology and Healthcare Companies (2022)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Executive Vice President, Chief Financial Officer, McAfee Corp. (2020–2022)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Executive Vice President, Chief Financial Officer, Providence St. Joseph Health (2017–2020)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Managing Director, Business Development & Mergers & Acquisitions, Microsoft Corp. (2016–2017)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Chief Financial Officer, Worldwide Enterprise Group, Microsoft Corp. (2011-2016)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Chief Financial Officer, Operations & Technology, Microsoft Corp. (2004–2011)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Various positions, including Senior Finance Director, Exodus Communications (1999–2004)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Various positions, including Controller, Sales, Hitachi Data Systems (1993–1999)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Manager, Assurance, PricewaterhouseCoopers (1988-1990)<br>**Education:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• MBA, Kelly School of Business at Indiana University<br>&nbsp;&nbsp;&nbsp;&nbsp;• MA, Osmania University<br>**Director-relevant skills, experiences, and attributes:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Led a comprehensive digital transformation process at Providence<br>&nbsp;&nbsp;&nbsp;&nbsp;• Instrumental in leading Microsoft's cloud transition<br>&nbsp;&nbsp;&nbsp;&nbsp;• Deep background in finance, digital strategy, corporate development, operations, and supply chain management<br>&nbsp;&nbsp;&nbsp;&nbsp;• Seasoned investor and strategic advisor in technology and healthcare companies <br>|

---

4<br>

------

---

| | |
|:---|:---|
| ![](ny20055089x1_wlcash.jpg)<br>**W. LARRY CASH,** 76<br>Lead Independent Director<br>Retired President, Financial Services and Chief Financial Officer, Community Health Systems<br>*Director since 2001* | **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Director, AAC Holdings, Inc. (OTC: AACH) (2017–2019)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Various positions, including President of Financial Services, Chief Financial Officer and Director, Community Health Systems, Inc. (1997–2017)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Vice President and Group Chief Financial Officer of Columbia/HCA Healthcare Corporation (1996–1997)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Various positions, including Senior Vice President of Finance<br>and Operations, Humana, Inc. (1973–1996)<br>**Education and awards:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• BS, University of Kentucky at Lexington<br>&nbsp;&nbsp;&nbsp;&nbsp;• Recognized as one of the top three CFOs in the healthcare sector by *Institutional Investor* magazine for eleven consecutive years during his tenure at Community Health Systems<br>**Director-relevant skills, experiences, and attributes:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Experienced financial and operations executive with a keen understanding of healthcare industry dynamics<br>&nbsp;&nbsp;&nbsp;&nbsp;• Long track record in the acute and managed care sectors<br>&nbsp;&nbsp;&nbsp;&nbsp;• Oversaw revenue growth from $700 million to over $18 billion at Community Health Systems<br>&nbsp;&nbsp;&nbsp;&nbsp;• Governance experience with prior service on the board of AAC Holdings, Inc.<br>|

---

5<br>

------

---

| | |
|:---|:---|
| ![](ny20055089x1_gfitzgerald.jpg)<br>**GALE**<br>**FITZGERALD,** 74<br>Retired Principal of <br>TranSpend, Inc. <br>*Director since 2007*<br>| **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Founder and Principal, TranSpend, Inc. (2003–2022)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Director, Diebold Nixdorf, Inc. (NYSE: DBD) (1999–2019)<br>&nbsp;&nbsp;&nbsp;&nbsp;• President, QP Group, Inc. (1994–2000)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Various positions, including Chair and Chief Executive Officer, Computer Task Group, Inc. (1991–2000)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Various technical, marketing, and management positions, including Vice President, Professional Services, IBM, (1973–1991)<br>**Education:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• MA, Augustine Institute<br>&nbsp;&nbsp;&nbsp;&nbsp;• BA, Connecticut College<br>**Director-relevant skills, experiences, and attributes:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Led a publicly traded, multinational IT staffing company for nearly a decade<br>&nbsp;&nbsp;&nbsp;&nbsp;• Co-founded a strategic consulting firm focused on business process improvements and supply chain optimization<br>&nbsp;&nbsp;&nbsp;&nbsp;• Deep understanding of corporate strategic planning and risk mitigation<br>&nbsp;&nbsp;&nbsp;&nbsp;• Governance experience from prior service on the board of Diebold Nixdorf, Inc.<br>|

---

6<br>

------

---

| | |
|:---|:---|
| ![](ny20055089x1_jamartins.jpg)<br>**JOHN A. MARTINS**, <br>56<br>President and Chief Executive<br>Officer, Cross Country<br>Healthcare (April 2022–<br>Present)<br>*Director since 2022* | **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Group President, Delivery, Cross Country Healthcare, Inc. (May 2021–April 2022)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Group President, Nurse and Allied, Cross Country Healthcare, Inc. (February 2021–May 2021)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Senior Vice President of Operations Strategy, Aya Healthcare, Inc. (2017–2020)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Senior Vice President, General Manager, AMN Healthcare Services, Inc. (2015–2017)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Various positions, including President, Onward Healthcare (2008–2015)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Vice President, Access Nurses (2005–2008)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Financial Advisor, Morgan Stanley (2004–2005)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Various positions, including Vice President of Operations, The Et Al Group (1996–2004)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Developer, UPS (1994–1996)<br>**Education:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• BA, William Peterson University<br>**Director-relevant skills, experiences, and attributes:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Keen understanding of developing and deploying digital innovation and technology in the healthcare staffing industry<br>&nbsp;&nbsp;&nbsp;&nbsp;• Extensive knowledge of travel nurse and allied, per diem, locum tenens, and education staffing services<br>&nbsp;&nbsp;&nbsp;&nbsp;• Institutional knowledge of Cross Country Healthcare<br>|

---

7<br>

------

---

| | |
|:---|:---|
| ![](ny20055089x1_jenevin.jpg)<br>**JANICE E. NEVIN, M.D., MPH,** 65<br>President and CEO, ChristianaCare Health System (2014–Present)<br>*Director since 2020* | **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Various positions, including Chief Medical Officer and Chief Patient Safety Officer, ChristianaCare Health System (2002 – 2014)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Director, Sidney Kimmel Medical College (1995 – 2002)<br>**Education and awards:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• MD, Sidney Kimmel Medical College at Thomas Jefferson University<br>&nbsp;&nbsp;&nbsp;&nbsp;• MPH, University of Pittsburgh<br>&nbsp;&nbsp;&nbsp;&nbsp;• BA, Harvard University<br>&nbsp;&nbsp;&nbsp;&nbsp;• Inducted into Delaware Women's Hall of Fame in 2017<br>&nbsp;&nbsp;&nbsp;&nbsp;• Recognized among 100 Great Healthcare Leaders to Know by Becker's Hospital Review in 2017<br>&nbsp;&nbsp;&nbsp;&nbsp;• Named the 2016 Woman of Distinction by the Girl Scouts of the Chesapeake Bay<br>**Director-relevant skills, experiences, and attributes:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Experience leading the operations of a large healthcare system with first-hand knowledge of healthcare staffing<br>&nbsp;&nbsp;&nbsp;&nbsp;• Nationally recognized as a pioneer and thought leader in value- based care and population health; selected by Modern Healthcare as one of its 50 Most Influential Clinical Executives in 2020, 2021, and 2022<br>&nbsp;&nbsp;&nbsp;&nbsp;• Developed the unique data-driven care coordination platform CareVio™ to proactively address patients' social and behavioral health needs in addition to their medical needs, a program which earned the 2017 John M. Eisenberg Patient Safety and Quality Award<br>|

---

### OUR SKILLS, EXPERIENCES, AND ATTRIBUTES
Our Board has identified key skills, experiences, and attributes that are important to be represented on the Board in light of the Company's business strategy and anticipated future needs. These skills, experiences, and attributes include:

&nbsp;&nbsp;&nbsp;&nbsp;• Substantial executive leadership experience working at an array of health-care entities with staffing needs;

&nbsp;&nbsp;&nbsp;&nbsp;• Experience building and/or working for entities that address outsourcing staffing needs in both the health and digital fields;

&nbsp;&nbsp;&nbsp;&nbsp;• Investment, legal, financial, and accounting expertise;

&nbsp;&nbsp;&nbsp;&nbsp;• Significant healthcare expertise in large acute-care facilities;

&nbsp;&nbsp;&nbsp;&nbsp;• Experience creating IT platforms, advancing digital transformation, cybersecurity, and artificial intelligence; and

&nbsp;&nbsp;&nbsp;&nbsp;• High ethical standards, integrity, professionalism, and business judgment.

8<br>

------

#### **TABLE OF CONTENTS**
The following chart highlights some of our directors' core skills, experiences, and attributes and describes their importance to our business strategy.

**Board Skills and Tenure** <br>

Our director nominees bring to our Board a wide variety of skills, qualifications, and viewpoints that strengthen the Board's ability to carry out its oversight role on behalf of our stockholders. The table below is a summary of the range of skills and experiences that each director nominee brings to the Board, each of which we find to be relevant to our business. Because this chart is a summary, it does not include all of the skills, experiences, and qualifications that each director nominee offers, and the fact that a particular experience, skill, or qualification is not listed does not mean that a director nominee does not possess it. All of our director nominees exhibit high integrity, an appreciation for diversity of background and thought, innovative thinking, a proven record of success, and deep knowledge of corporate governance requirements and best practices.

![](ny20055089x1_boardskills.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;(1) We recognize that Mr. Martins, as the current CEO of the Company, and Mr. Clark, as the former CEO of the Company from January 2019 to March 31, 2022, are not considered independent directors. As an independent member of our Board, Mr. Cash serves as our Lead Director to work collaboratively with the Chairman, CEO, and other directors to ensure effective functioning of the Board and to serve as an independent liaison between management and the Board and between the Chairman and the independent directors to assist in maintaining high standards for oversight and other functions.

The Board does not believe that arbitrary term limits on directors' service are appropriate; however, directors are required to resign at the age of 75 and the Board may accept or reject such resignation at its discretion. Directors who have served on the Board for an extended period of time have institutional knowledge and are able to provide valuable insight into the operations and future of the Company based on their experience with and understanding of the Company's history, policies, and objectives. The Board self-evaluation process described below is an important determinant for Board tenure. Pursuant to the Company's policy that directors must resign at the age of 75, Mr. Cash tendered his resignation to the Board in 2023, which was rejected at the discretion of the Board. The Board determined that Mr. Cash provides

9<br>

------

valuable service as a Lead Independent Director, continuity based on his history and knowledge of the Company, expertise in the healthcare industry, and financial acumen, and he continues to serve on the Board and receive high ratings from fellow Board members in their annual assessments. The Board provided similar waivers in 2024 and 2025.

The charts below provide a snapshot of certain characteristics of our current Board. The information is as of October 27, 2025.

![](ny20055089x1_diversity.jpg)

10<br>

------

### HOW WE ARE SELECTED, ELECTED, AND SERVE
At the direction of our Board of Directors, the Governance and Nominating Committee, assisted as appropriate by other members of the Board and management:

&nbsp;&nbsp;&nbsp;&nbsp;• Develops recommendations for the size and composition of the Board, reflecting:

&nbsp;&nbsp;&nbsp;&nbsp;○ current and anticipated operational, business, financial, and sector needs, including needs for any specialized knowledge; and

&nbsp;&nbsp;&nbsp;&nbsp;○ core competencies, integrity, and leadership.

&nbsp;&nbsp;&nbsp;&nbsp;• Identifies opportunities for director refreshment.

&nbsp;&nbsp;&nbsp;&nbsp;• Identifies candidates, with assistance of a board search firm, for the Board to consider nominating to stand for election, including:

&nbsp;&nbsp;&nbsp;&nbsp;○ Considering director candidates recommended by stockholders on the same basis and in the same manner as other candidates and in compliance with established procedures;

&nbsp;&nbsp;&nbsp;&nbsp;○ Taking into account the following characteristics of each potential candidate:

&nbsp;&nbsp;&nbsp;&nbsp;■ Relevant experience, including in healthcare, staffing, IT, business, finance and accounting;

&nbsp;&nbsp;&nbsp;&nbsp;■ Personal and professional integrity;

&nbsp;&nbsp;&nbsp;&nbsp;■ Ability to commit the needed time and resources to be an effective director; and

&nbsp;&nbsp;&nbsp;&nbsp;■ Overall fit into the mix of Board-wide skills, experiences, and attributes.

All stockholder recommendations for director candidates must be submitted to our legal department at 6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida, 33487, Attn: General Counsel, which will forward all recommendations to the Governance and Nominating Committee.

There have been no changes to the procedures by which stockholders may recommend director nominees to our Board since our last disclosure of such procedures, which appeared in the definitive Proxy Statement for our 2024 Annual Meeting of Stockholders.

The Board currently consists of seven members. The Board previously consisted of eight directors; however, following the passing of Mark Perlberg on March 11, 2025, the Board reduced the size of the Board from eight directors to seven directors. The current terms of all seven directors expire at the Annual Meeting, and each of the directors are standing for re-election at the Annual Meeting.

Each director nominee elected will hold office until the 2026 Annual Meeting of Stockholders and until a successor has been duly elected and qualified unless, prior to such meeting, a director shall resign, or his or her directorship shall become vacant due to his or her death, resignation, or removal. All director nominees were elected at the 2024 Annual Meeting of Stockholders.

Each director nominee has agreed to serve, if elected, and management has no reason to believe that any of the director candidates will be unavailable to serve if elected. If any of the director nominees should be unavailable for election, the proxies will be voted for the election of such other person as may be recommended by the Board in place of such director nominee. Shares properly voted will be voted FOR each director nominee unless the stockholder indicates on the proxy that authority to vote the shares is withheld for one or more of the director nominees listed. A proxy cannot be voted for a greater number of persons than the seven director nominees.

11<br>

------

#### **TABLE OF CONTENTS**
There are no arrangements or understandings between any of the director nominees or executive officers and any other person pursuant to which our director nominees or executive officers have been selected for their respective positions.

### WHAT WE ACCOMPLISHED
In addition to fulfilling its ongoing, core oversight function, our Board achieved several significant accomplishments during 2024, including:

&nbsp;&nbsp;&nbsp;&nbsp;• Conducting a comprehensive succession planning exercise and implementing a thorough succession and continuity plan for each of the Company's principal executives;

&nbsp;&nbsp;&nbsp;&nbsp;• Identifying opportunities to refresh the Company's Board;

&nbsp;&nbsp;&nbsp;&nbsp;• Repurchasing 2.4 million shares in 2024, reflecting the strength of our financial position and our confidence in our ability to continue to execute on our strategy;

&nbsp;&nbsp;&nbsp;&nbsp;• Holding a Board-led strategy session to conduct an evaluation of the Company's strategy, business performance and configuration, risks and opportunities, and other topics central to long-term value creation;

&nbsp;&nbsp;&nbsp;&nbsp;• Evaluating various strategic alternatives that ultimately led to the pending acquisition by Aya Healthcare, Inc., which we expect to close during the fourth quarter;

&nbsp;&nbsp;&nbsp;&nbsp;• Supporting the attainment of SOC2 Type 2 certification for our Intellify platform, demonstrating a strong commitment to data security and maintaining effective internal controls; and

&nbsp;&nbsp;&nbsp;&nbsp;• Conducting ongoing Board training and education on new SEC regulations, fiduciary duties, and other matters.

### HOW WE ARE EVALUATED
The Governance and Nominating Committee is responsible for ensuring that the Board has a robust and effective performance process in place for the Board, as well as for the CEO and management. The Board's practice is to require each Board member, on an annual basis, to complete an anonymous assessment distributed by a third party regarding the performance of the full Board, his or her individual performance on the Board, and the effectiveness of the Committee or Committees on which he or she serves. The results are aggregated, and a detailed summary is provided to the Chairperson of the Governance and Nominating Committee and the Chairman of the Board. Thereafter, the results are communicated to the full Board and Chairpersons of the Committees and discussions occur to address any issues that may have been identified.

12<br>

------

#### **TABLE OF CONTENTS**

### HOW WE GOVERN AND ARE GOVERNED
**Board Independence** <br>

Our securities are listed on the Nasdaq Stock Market ("Nasdaq") and, as set forth in our Governance Guidelines, we use the standards of "independence" prescribed by Nasdaq requirements. Under Nasdaq rules, a majority of a listed company's board of directors must be independent directors. In addition, Nasdaq rules require that, subject to specified exceptions, each member of a listed company's audit committee and compensation committee be independent and satisfy additional independence criteria set forth in Rules 10A-3 and 10C-1, respectively, under the Exchange Act. Under Nasdaq rules, a director will only qualify as an "independent director" if, in the opinion of that company's board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

Annually, each member of the Board is required to complete a questionnaire designed in part to provide information to assist the Board in determining if the director is independent under the Nasdaq rules. Based upon information requested from and provided by each director concerning their background, employment, and affiliations, including family relationships, our Board has determined, upon the recommendation of our Governance and Nominating Committee, that the following directors are independent and have no material relationship with the Company: Dwayne Allen, Venkat Bhamidipati, W. Larry Cash, Gale Fitzgerald, and Janice E. Nevin, M.D., MPH. Additionally, during his tenure as a director, Mark Perlberg was determined by the Board to be independent. Mr. Cash serves as the Board's Lead Independent Director.

As Mr. Martins is our President and Chief Executive Officer, he is not independent, and as Mr. Clark was our former President and Chief Executive Officer from January 2019 to March 31, 2022, he is not independent. As an independent member of our Board, Mr. Cash serves as our Lead Director to work collaboratively with the Chairman, CEO, and other directors to ensure effective functioning of the Board and to serve as an independent liaison between management and the Board and between the Chairman and the independent directors to assist in maintaining high standards for oversight and other functions. The Board has also determined that each of the current members of our Audit Committee and our Compensation Committee satisfies the independence standards for such committee established by Rules 10A-3 and 10C-1 under the Exchange Act, the SEC rules, and the Nasdaq rules, as applicable, and that the current members of the Governance and Nominating Committee are also independent.

**Governance Policies** <br>

Our core governance frameworks and provisions are contained in our Governance Guidelines, Code of Conduct, and Business Ethics Policy. These can be found on our website at https://ir.crosscountryhealthcare.com/corporate-governance or provided in print, at no charge, upon request to our Corporate Secretary at 6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida 33487. We will disclose any changes in, or waivers from, our Code of Conduct and Business Ethics Policy by posting such information on the same website or by filing a Current Report on Form 8-K, in each case if such disclosure is required by the rules of the SEC or Nasdaq.

The Company has adopted the Securities Compliance Policy that applies to all employees, including officers, and non-employee directors of the Company and its subsidiaries, as well as the Company itself. The Company believes that the Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules, and regulations with respect to the purchase, sale, and/or other dispositions of the Company's securities, as well as the applicable rules and regulations of Nasdaq. A copy of our Insider Trading Policy is filed as Exhibit 19.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

**Delinquent Section 16(a) Reports** <br>

To our knowledge, based solely on our review of the Section 16(a) forms filed electronically with the SEC during the fiscal year ended December 31, 2024 ("Fiscal 2024"), and written representations that no other forms were required, with the exception of two inadvertently late Form 4 filings, reporting one transaction for each of August 28, 2017 and August 10, 2018, all reporting persons timely complied with the filing requirements of Section 16(a) of the Exchange Act.

13<br>

------

#### **TABLE OF CONTENTS**
**Board Committees** <br>

Our Board has three standing committees: the Audit Committee, the Compensation Committee, and the Governance and Nominating Committee. Each of these committees is comprised solely of independent directors within the meaning of Rule 5605(a)(2) of the Nasdaq Listing Rules. Each committee operates pursuant to a committee charter. The charters of the Audit Committee, the Compensation Committee, and the Governance and Nominating Committee are on our website at https://ir.crosscountryhealthcare.com/corporate-governance.

The following chart provides a summary of the committees' duties, responsibilities, and composition:

---

| | | |
|:---|:---|:---|
| **Committee**  | **Responsibilities and Duties**  | **Meetings** <br>**in 2024** |
| **Audit Committee** | • The Audit Committee is the principal agent of the Board in overseeing (i) the quality and integrity of our financial statements, (ii) legal and regulatory compliance, (iii) the independence, qualifications, and performance of our independent registered public accounting firm, (iv) the performance of our internal auditors, (v) the integrity of management and the quality and adequacy of disclosures to stockholders, (vi) the Company's systems and disclosure controls and procedures, (vii) risk management related to cybersecurity risks, and (viii) risk management related to environmental and climate risks.<br>• The Audit Committee is responsible for hiring and terminating our independent registered public accounting firm and approving all auditing services, as well as any audit-related and any other non- auditing services, to be performed by the independent registered public accounting firm.<br>• In carrying out its duties and responsibilities, the Audit Committee shall have the authority to engage outside legal, compliance, accounting, and other advisers and seek any information it requires from employees, officers, and directors. <br>• The Audit Committee may form and delegate authority to subcommittees consisting of one or more of its members, as the Audit Committee deems appropriate to carry out its responsibilities and exercise its powers, subject to such reporting to, or ratification by, the Audit Committee, as the Audit Committee shall direct.<br>Bhamidipati †\*♦<sup>(1)</sup><br>Allen♦ <br>Cash\*♦ <br>Nevin♦ | 12  |

---

14<br>

------

---

| | | |
|:---|:---|:---|
| **Committee**  | **Responsibilities and Duties**  | **Meetings** <br>**in 2024** |
| **Compensation** <br>**Committee** | • The role of the Compensation Committee includes (i) reviewing and approving corporate goals and objectives relevant to CEO compensation; (ii) evaluating the CEO's performance in light of the approved goals and objectives, and determining and approving the CEO's compensation level based on this evaluation; (iii) making recommendations to the Board with respect to compensation, incentive compensation plans and equity-based plans for all executive officers of the Company, and developing guidelines and reviewing compensation and overall performance of all executive officers of the Company; (iv) producing a Compensation Committee report on executive compensation, as required by the SEC, to be included in the Company's annual Proxy Statement or Annual Report on Form 10-K filed with the SEC; (v) evaluating on an annual basis the performance of the Compensation Committee in accordance with applicable rules and regulations; (vi) annually reviewing and making recommendations to the Board regarding non-employee director compensation; and (vii) overseeing the Company's policies and procedures relating to human capital management and retention risks.<br>Cash<sup>(2)</sup><br>Fitzgerald | 4 |

---

15<br>

------

---

| | | |
|:---|:---|:---|
| **Committee**  | **Responsibilities and Duties**  | **Meetings** <br>**in 2024** |
|  | • Under its charter, the Compensation Committee has the authority and may, in its sole discretion, obtain advice and seek assistance from internal and external legal, accounting, and other consultants. The Compensation Committee has the sole authority to select or receive advice from, and terminate, a compensation consultant or other advisor to the Compensation Committee (other than in-house legal counsel) to assist in the evaluation of the compensation of our CEO, other executive officers, and directors, including sole authority to approve such firm's fees and other retention terms, and we provide appropriate funding as determined by the Compensation Committee. In selecting advisers, the Compensation Committee will take into consideration certain independence factors.<br>|  |
|  | • The Compensation Committee may establish one or more subcommittees consisting of one or more members of the Board to focus on specific aspects of its duties and responsibilities and may delegate any of its responsibilities to any such subcommittee if it so chooses, provided that the subcommittee decisions are presented to the full Compensation Committee for ratification at its next scheduled meeting.<br>|  |
| **Governance and Nominating Committee** | &nbsp;&nbsp;&nbsp;&nbsp;• The role of the Governance and Nominating Committee is to: (i) develop and recommend to the Board a set of corporate governance principles and review them at least annually; (ii) determine the qualifications for Board membership and recommend nominees to the stockholders; (iii) ensure a robust and effective performance evaluation process is in place for the Board, the CEO, and senior management, as well as an effective succession planning process for these positions; (iv) oversee the Company's policies and procedures relating to governance, as well as risks relating to such policies and procedures; and (v) oversee the Board's structure and organization.<br>• The Governance and Nominating Committee has the sole authority to retain and terminate <br>external advisors to the extent additional<br>Fitzgerald†<sup>(2)</sup><br>Nevin  | 4 |

---

16<br>

------

---

| | | | |
|:---|:---|:---|:---|
| **Committee**  | **Responsibilities and Duties**  | **Members**  | **Meetings** <br>**in 2024** |
|  | &nbsp;&nbsp;&nbsp;&nbsp;expertise is deemed necessary in fulfilling the Governance and Nominating Committee's fiduciary responsibilities. <br>• The Governance and Nominating Committee may form and delegate authority to subcommittees consisting of one or more of its members, other Board members, and officers of the Company, as the Governance and Nominating Committee deems appropriate and as permitted under applicable rules and regulations, in order to carry out its responsibilities.<br>|  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;† Committee Chairperson

\* Audit Committee Financial Expert, as defined in the applicable SEC regulations

&nbsp;&nbsp;&nbsp;&nbsp;♦ Possesses requisite financial sophistication required by Nasdaq Rule 5605(c)(2)(A)

&nbsp;&nbsp;&nbsp;&nbsp;(1) Mr. Bhamidipati was appointed as Chairman of the Audit Committee in January 2024.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Until his passing on March 11, 2025, Mark Perlberg served as the Chairman of the Compensation Committee and as a member of the Governance and Nominating Committee. Subsequently, Mr. Cash was approved by the Board of Directors as the Chairman of the Compensation Committee.

**Board and Committee Meetings** <br>

During Fiscal 2024, there were eleven meetings of the Board. For Fiscal 2024, (i) six of the eight then-serving directors attended 100% of the total number of meetings of the Board and two directors attended 90% of the total number of Board meetings and (ii) each member attended at least 90% of the total number of meetings held by all committees on which he or she served (for the period that such director served on the Board and/or committee during Fiscal 2024). It is the practice of the Board to have the independent directors meet in an executive session at each meeting of the Board. While we do not have a formal policy, it is also our practice that all directors should attend the Annual Meeting of Stockholders. All then-serving directors attended the 2024 Annual Meeting of Stockholders, which was held virtually.

**Risk Oversight** <br>

The Board oversees executives' management of risks that are most relevant to the Company. In this role, the Board is responsible for the overall supervision of our risk management activities, which occurs at both the full Board level and at the committee level.

Our Audit Committee also has the responsibility to, among other things, review with management the Company's policies regarding major financial risk exposures and the steps management has taken to monitor and control such exposures. The Audit Committee also reviews with management the policies governing the process by which risk assessment and risk management are undertaken and has oversight for the effectiveness of management's enterprise risk management process that monitors key business risks facing us, such as cybersecurity, artificial intelligence, data privacy, environmental, and climate risks, among others. In addition to our Audit Committee, the other committees of the Board consider the risks within their areas of responsibility. For example, the Compensation Committee assesses risk that could result from the structure and design of our executive compensation programs, our incentive compensation plans, director compensation, perquisites, compliance with the Sarbanes-Oxley Act of 2002 regarding prohibitions on loans to executive officers and directors, human capital management, and retention risks, among others. The Governance and Nominating Committee evaluates risks with respect to, among other things, corporate

17<br>

------

governance matters, the structure of the Board, succession planning, and the experience and suitability of director nominees. Additionally, the Board continually evaluates our risks related to cybersecurity, liquidity, operations, credit, regulatory compliance, and fiduciary risks, and the processes in place to monitor and control such exposures. Management also provides regular updates throughout the year to the respective committees regarding management of the risks that each committee oversees, and each of these committees report their findings to the full Board, including any areas of risk that require Board attention. Additionally, the full Board reviews our short- and long-term strategies, including consideration of risks facing us and the potential impact of such risks.

![](ny20055089x1_boddiagram01.jpg)

While the full Board has overall responsibility for risk oversight, the Board has delegated responsibility related to certain risks to its committees. The Board and management evaluated the risks most relevant to the Company and specifically identified certain topics as appropriate to be delegated to committees in order to provide more focus and oversight of these areas:

---

| | |
|:---|:---|
| Key Topics Identified and Delegated to Committees  | Key Topics Identified and Delegated to Committees  |
| Audit Committee | Compensation Committee  |
| - Cybersecurity and Data Protection Risks | - Human Capital Management and Retention  |
| - Environmental and Climate Risks |  |

---

18<br>

------

**Board Leadership Structure** <br>

Our Company is led by Mr. John A. Martins, who serves as our President and Chief Executive Officer. Our Board is currently comprised of Mr. Martins, our President and Chief Executive Officer, Mr. Clark, our former President and Chief Executive Officer, and five independent directors. Mr. Clark has served as the non-executive Chairman of the Board since April 2022, and Mr. Cash has served as the Lead Independent Director of the Board since 2019.

The Board has determined that our current Board leadership structure is appropriate and helps to ensure proper risk oversight for us for a number of reasons, the most significant of which are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;• The Board determines the structure of the Board based on what it believes is in the best interest of the Company and its stockholders at any given time. The current Board structure separates the CEO and Chairman of the Board roles to allow the CEO to focus on running the day-to-day business of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;• The Chairman of our Board presides over the Board meetings, consults with our Lead Independent Director, other Board members, and the CEO to create and approve appropriate agendas for Board meetings and determine the appropriate time allocated to each agenda item in discussion of our short and long-term objectives and serves as the primary interface between management and the Board. The CEO consults with the Chairman and Lead Independent Director on relevant concerns of the Board members and recommends oral reports by senior executives to continually keep the Board informed on the Company's operations, risks, and overall performance.

&nbsp;&nbsp;&nbsp;&nbsp;• Our Lead Independent Director serves as an independent liaison for the Chairman of the Board, Board members, and the Company's stakeholders. Our Lead Independent Director supports the Chairman of the Board and monitors the relationship between the CEO and Chairman of the Board. Our Lead Independent Director also presides over independent director executive sessions and works with the CEO and Chairman of the Board to ensure Board agendas cover topics of interest or concerns to independent directors.

&nbsp;&nbsp;&nbsp;&nbsp;• Members of our Board are kept informed of our business by various documents sent to the directors before each meeting and as otherwise requested, as well as through oral reports made to the directors during Board meetings by our CEO, CFO, and other senior executives.

&nbsp;&nbsp;&nbsp;&nbsp;• Our Board structure provides strong oversight by independent directors, who regularly meet in executive session without management present. The Board is advised of all actions taken by the various committees of the Board and has full access to all of our books, records, and reports.

Members of the Board have direct access to the management team and those individuals are available at all times to answer questions from Board members. Our Board has extensive management experience in business and, in particular, the healthcare industry in which we operate. The continuity and tenure of our Board provides a valuable source of institutional knowledge.

### HOW YOU CAN COMMUNICATE WITH US
**Stockholder Engagement** <br>

We believe that effective corporate governance includes year-round engagement with our stockholders and other stakeholders. We meet regularly with our stockholders, including both large and small investors, to discuss business strategy, performance, compensation philosophy, corporate governance, and environmental and social topics. In a typical year, we will engage with dozens of stockholders, including our largest stockholders, two to three times per year; however, since the announcement of our pending merger with Aya Healthcare, Inc., the Company has refrained from attending roadshows, fireside chats, and other

19<br>

------

#### **TABLE OF CONTENTS**
similar events and reduced such engagement. This stockholder outreach is complementary to the hundreds of touchpoints our Investor Relations team has with stockholders each year. We find it beneficial to have ongoing dialogue with our stockholders throughout the year on a full range of investor priorities in order to receive feedback, instead of engaging with stockholders only prior to our annual meeting on issues to be voted on in the proxy statement.

Depending on the circumstances, our Chairman, Lead Independent Director, or other independent directors may engage in these conversations with stockholders as well. Our direct engagement with stockholders helps us better understand our stockholders' priorities, perspectives, and issues of concern, while giving us an opportunity to elaborate on our many initiatives and practices and to address the extent to which various aspects of these matters are, or are not, significant given the scope and nature of our operations and our existing practices. We take insights from this feedback into consideration and regularly share such insights with our Board as we review and evolve our practices and disclosures.

Our Board casts a wide net for information to inform its deliberations, oversight, and decision making. Our Board values regular input from investors and other stakeholders who have a shared financial interest in the Company. Our Board has created a number of ways for investors and other stakeholders to provide input, including:

&nbsp;&nbsp;&nbsp;&nbsp;• Attending the Annual Meeting of Stockholders and submitting questions to be addressed during the meeting;

&nbsp;&nbsp;&nbsp;&nbsp;• Attending quarterly earnings calls, investor conferences, and other similar opportunities;

&nbsp;&nbsp;&nbsp;&nbsp;• Calling our toll-free number, 1-800-354-7197;

&nbsp;&nbsp;&nbsp;&nbsp;• Sending an email to an individual director, a committee, or the full Board at governance@crosscountry.com ;

&nbsp;&nbsp;&nbsp;&nbsp;• Mailing a letter to us at 6551 Park of Commerce Blvd, N.W., Boca Raton, Florida 33487, Attn: General Counsel; or

&nbsp;&nbsp;&nbsp;&nbsp;• Requesting a stockholder engagement meeting via one of the means outlined above.

All such communications will be forwarded directly to the Board or any individual director or committee of the Board, as applicable.

### NON-EMPLOYEE DIRECTOR COMPENSATION
Annually, the Compensation Committee evaluates the Company's non-employee director compensation design, competitiveness and effectiveness, to help ensure that the director compensation program continues to facilitate the attraction and retention of highly qualified Board members. During Fiscal 2024, the Compensation Committee engaged Pearl Meyer & Partners, LLC ("Pearl Meyer") to review the competitiveness of our non-employee director compensation program relative to industry peers and other comparably-sized organizations and provide recommendations as deemed appropriate. The industry peer groups used in these periodic market studies are the same peer groups used to assess pay competitiveness for named executive officers. Following the Fiscal 2024 analysis, the Compensation Committee did not make any changes to Board compensation for 2024 or 2025. The non-employee director stock ownership requirement remains at three times the Board cash retainer value. The Compensation Committee annually reviews the independence of Pearl Meyer. Pearl Meyer does not perform any additional services for the Company other than its compensation consulting services to the Compensation Committee and is deemed to be independent under relevant stock exchange standards.

20<br>

------

#### **TABLE OF CONTENTS**
**Cash Compensation** <br>

In Fiscal 2024, our independent directors were awarded cash fees based on the schedule set forth below, payable on a quarterly basis. Only non-employee directors receive compensation for their services as directors. Compensation for Mr. Martins, our current President and Chief Executive Officer, is reflected in the Summary Compensation Table and discussed within "Compensation Discussion and Analysis" below.

---

| | |
|:---|:---|
| **Board Cash Retainer** | $75000  |
| **Chairman of Board Service** | $85000  |
| **Audit Committee Chairperson Service** | $25000  |
| **Compensation Committee Chairperson Service** | $15000  |
| **Governance and Nominating Committee Chairperson Service** | $12250  |
| **Lead Independent Director Service** | $25000 |

---

Consistent with historic practice, no payments were made for non-chairperson committee member services in Fiscal 2024.

**Equity Compensation** <br>

During Fiscal 2024, Messrs. Clark, Cash, Allen, Bhamidipati, and Perlberg and Mses. Fitzgerald and Nevin each received a grant of restricted shares of Common Stock on June 1, 2024, under the Company's Cross Country Healthcare, Inc. 2024 Omnibus Incentive Plan (the "2024 Omnibus Incentive Plan"). Each such grant consisted of a number of shares of restricted Common Stock equal to approximately $150,000, based on the closing price of our Common Stock on the date of grant. The vesting period for the restricted shares granted to directors is one year, which aligns with the Company's annual Board term.

**Travel Reimbursement** <br>

All independent directors are reimbursed for the reasonable travel expenses they incur in attending meetings of the Board or Board committees.

**Stock Ownership Requirement** <br>

Non-employee directors are required to hold an amount of the Company's Common Stock equal to three times the annual Board cash retainer of $75,000, which amount may be accumulated over five years. Unvested restricted shares and indirectly owned shares are included in determining whether the threshold has been achieved. As of October 14, 2025, all current directors are in compliance, or on track to gain compliance within his or her respective five-year grace period, with our stock ownership guidelines.

21<br>

------

### 2024 DIRECTOR COMPENSATION TABLE
The following table provides compensation information for our non-employee directors for Fiscal 2024.

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Fees Earned** <br>**or Paid** <br>**in Cash ($)** | **Stock** <br>**Awards** <br>**($)(1)(2)** | **Total ($)**  |
| Dwayne Allen | 75000 | 150000 | 225000  |
| Venkat Bhamidipati | 100000 | 150000 | 250000  |
| W. Larry Cash | 100000 | 150000 | 250000  |
| Kevin C. Clark | 160000 | 150000 | 310000  |
| Gale Fitzgerald | 87252 | 150000 | 237252  |
| Janice E. Nevin, M.D., MPH | 75000 | 150000 | 225000  |
| Mark Perlberg, JD(3) | 90000 | 150000 | 240000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Amounts in this column reflect the aggregate grant date fair value of awards of restricted stock granted under our 2024 Omnibus Incentive Plan and computed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 718, Compensation-Stock Compensation ("ASC Topic 718"). The assumptions used in determining the amounts in this column are set forth in Note 14 to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on March 6, 2025, as amended by Amendment No. 1 on Form 10-K/A (the "2024 Form 10-K"). The restricted stock was granted on June 1, 2024 with a grant date fair value per share of $15.12. All awards vested on the first anniversary of such award's grant date. Based on a grant date fair value of approximately $150,000, the actual number of shares of restricted stock granted to each director was 9,921 shares.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Aggregate restricted shares outstanding as of December 31, 2024 for each non-management director were as follows: Dwayne Allen: 9,921; Venkat Bhamidipati: 9,921; W. Larry Cash: 9,921; Kevin C. Clark: 9,921; Gale Fitzgerald: 9,921; Janice E. Nevin: 9,921; and Mark Perlberg: 9,921.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Mr. Perlberg served on the Board until his passing on March 11, 2025, subsequent to which the Board determined that all of his outstanding equity awards would vest on March 11, 2025.

22<br>

------

#### **TABLE OF CONTENTS**

### OUR COMPANY

### WHAT WE DO
Cross Country Healthcare is a tech-enabled business that finds the right people at the right time in the right capacities to work at thousands of entities that need qualified healthcare or educational talent and provides those individuals with optimal flexibility, compensation, and support.

Among others, we create opportunities for:

&nbsp;&nbsp;&nbsp;&nbsp;• Registered Nurses (RN)

&nbsp;&nbsp;&nbsp;&nbsp;• Licensed Practical Nurses (LPN/LVN)

&nbsp;&nbsp;&nbsp;&nbsp;• Certified Nursing Assistants (CNA)

&nbsp;&nbsp;&nbsp;&nbsp;• Physicians (MD)

&nbsp;&nbsp;&nbsp;&nbsp;• Advanced Practitioners (AP) (e.g., Nurse Practitioners, Physician Assistants, Medical Assistants)

&nbsp;&nbsp;&nbsp;&nbsp;• Allied Health professionals in roles such as:

&nbsp;&nbsp;&nbsp;&nbsp;○ Diagnostic Imaging

&nbsp;&nbsp;&nbsp;&nbsp;○ Rehabilitation

&nbsp;&nbsp;&nbsp;&nbsp;○ Medical Laboratory

&nbsp;&nbsp;&nbsp;&nbsp;○ Respiratory

&nbsp;&nbsp;&nbsp;&nbsp;○ Pharmacy

&nbsp;&nbsp;&nbsp;&nbsp;○ Social Worker

&nbsp;&nbsp;&nbsp;&nbsp;○ Dental

&nbsp;&nbsp;&nbsp;&nbsp;• Educational roles, including:

&nbsp;&nbsp;&nbsp;&nbsp;○ Speech Language Therapists

&nbsp;&nbsp;&nbsp;&nbsp;○ Physical Therapists

&nbsp;&nbsp;&nbsp;&nbsp;○ Teachers

&nbsp;&nbsp;&nbsp;&nbsp;○ Substitute Teachers

&nbsp;&nbsp;&nbsp;&nbsp;• Non-clinical health care roles, including:

&nbsp;&nbsp;&nbsp;&nbsp;○ Health Information Management

&nbsp;&nbsp;&nbsp;&nbsp;○ Administrative/Clerical

&nbsp;&nbsp;&nbsp;&nbsp;○ Dietary

&nbsp;&nbsp;&nbsp;&nbsp;○ Medical Billers/Medical Coders

&nbsp;&nbsp;&nbsp;&nbsp;○ Environmental Services

Our clients operate in diverse settings, such as:

&nbsp;&nbsp;&nbsp;&nbsp;• Ambulatory Care Facilities

&nbsp;&nbsp;&nbsp;&nbsp;• Correctional Facilities

&nbsp;&nbsp;&nbsp;&nbsp;• Home Health Services

&nbsp;&nbsp;&nbsp;&nbsp;• Hospice Care Services

&nbsp;&nbsp;&nbsp;&nbsp;• Hospitals

&nbsp;&nbsp;&nbsp;&nbsp;• Insurance Companies

&nbsp;&nbsp;&nbsp;&nbsp;• Long-Term Care/Skilled Nursing Facilities

&nbsp;&nbsp;&nbsp;&nbsp;• Physician Practices

&nbsp;&nbsp;&nbsp;&nbsp;• School Systems

&nbsp;&nbsp;&nbsp;&nbsp;• Urgent Care Centers

23<br>

------

#### **TABLE OF CONTENTS**
We use an array of digital and advanced management platforms (including Intellify<sup>®</sup>, our proprietary vendor management technology), databases, and solutions to provide these services and enable the people we place to find employment in their preferred formats, including full- and part-time work, per-diem arrangements, contract and travel roles, and other evolving models reshaping the nature of work globally.

### WHO WE ARE
Although we harness the power of advanced digital and management solutions, we are fundamentally a company of people who find people to help people in need of health care. Although we are required to feature information about our Board and executive officers, we think of ourselves more holistically as a company of over 9,000 people, including over 1,400 corporate employees and an average of more than 8,000 full-time equivalent field employees, providing value via a variety of arrangements to facilities in all 50 states.

In addition to our President and Chief Executive Officer, John A. Martins, whose biographical information is included above under "Board of Directors," the Company's current executive officers include:

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position**  |
| Susan E. Ball, JD, MBA, RN | 61 | EVP, Chief Administrative Officer, General Counsel and Secretary  |
| William J. Burns, MBA, CPA | 55 | EVP, Chief Financial Officer  |
| Cynthia A. Grieco | 51 | Vice President, Corporate Treasurer  |
| Marc Krug, JD, MBA | 58 | Group President  |
| Colin P. McDonald, MS | 57 | Chief Human Resources Officer  |
| Karen Mote | 61 | President, Cross Country Locums  |
| Phillip Noe | 55 | Chief Information Officer  |
| James V. Redd III, MBA, CPA  | 55 | Chief Accounting Officer |

---

---

| | |
|:---|:---|
| ![](ny20055089x1_seball.jpg)<br>**SUSAN E. BALL,** 61 <br>Executive Vice President, <br>Chief Administrative Officer, <br>General Counsel and Secretary<br>*Joined Company in 2002* | **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Corporate Counsel, Cross Country Healthcare, Inc. (2002 -2004) <br>&nbsp;&nbsp;&nbsp;&nbsp;• Attorney at Gunster, Yoakley & Stewart, P.A. (1998 - 2002) <br>&nbsp;&nbsp;&nbsp;&nbsp;• Attorney at Skadden, Arps, Slate, Meagher and Flom LLP(NY) (1996 - 1998) <br>&nbsp;&nbsp;&nbsp;&nbsp;• Registered nurse <br>**Education:** <br>&nbsp;&nbsp;&nbsp;&nbsp;• MBA, Florida Atlantic University<br>&nbsp;&nbsp;&nbsp;&nbsp;• JD, New York Law School<br>&nbsp;&nbsp;&nbsp;&nbsp;• BS, The Ohio State University <br>|

---

24<br>

------

#### **TABLE OF CONTENTS**

---

| | |
|:---|:---|
| ![](ny20055089x1_wjburns.jpg)<br>**WILLIAM J.** <br>**BURNS,** 55<br>Executive Vice President, <br>Chief Financial Officer <br>*Joined Company in 2014* | **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Chief Operating Officer, Cross Country Healthcare, Inc. (2018- 2019) <br>&nbsp;&nbsp;&nbsp;&nbsp;• Chief Financial Officer, Cross Country Healthcare, Inc. (2014 -2018) <br>&nbsp;&nbsp;&nbsp;&nbsp;• Group Vice President and Corporate Controller, Gartner, Inc. (2008 - 2014) <br>&nbsp;&nbsp;&nbsp;&nbsp;• Chief Accounting Officer, CA Technologies, Inc. (2006 -2008) <br>&nbsp;&nbsp;&nbsp;&nbsp;• Various accounting and finance roles, Time Warner, Coty, Inc., Honeywell, and Adecco North America (1995 - 2006) <br>&nbsp;&nbsp;&nbsp;&nbsp;• Auditor and Senior Auditor, Deloitte & Touche, LLC<br>(1992 -1995) <br>**Education:** <br>&nbsp;&nbsp;&nbsp;&nbsp;• MBA, New York University Stern School of Business<br>&nbsp;&nbsp;&nbsp;&nbsp;• BA, Queens College<br>&nbsp;&nbsp;&nbsp;&nbsp;• Certified Public Accountant <br>|
| ![](ny20055089x1_cgrieco.jpg)<br>**CYNTHIA A. GRIECO,** 51 <br>Vice President, Corporate <br>Treasurer <br>*Joined Company in 2016* | **Formerly:** <br>&nbsp;&nbsp;&nbsp;&nbsp;• Vice President, Treasury Operations, Cross Country Healthcare, Inc. (2018 - 2022)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Senior Director, Assistant Treasurer, Cross Country Healthcare, Inc. (2017 - 2018)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Director, Treasury Operations, Cross Country Healthcare, Inc. (2016 - 2017)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Various treasury positions, JM Family Enterprises<br>(2001 - 2015) <br>**Education:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• BBA, Florida Atlantic University <br>|

---

25<br>

------

---

| | |
|:---|:---|
| ![](ny20055089x1_mkrug.jpg)<br>**MARC KRUG,** 58 <br>Group President <br>*Joined Company in 2017* | **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Division President, Travel, Cross Country Healthcare, Inc. (2021 - 2022)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Division President Travel and Local, Cross Country Healthcare, Inc. (2021)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Senior Vice President, Travel Nurse and Allied Delivery, Cross Country Healthcare, Inc. (2020 - 2021)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Senior Vice President, Travel Allied, Cross Country Healthcare, Inc. (2018 - 2020)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Vice President, Allied, Cross Country Healthcare, Inc. <br>(2017 -2018)<br>&nbsp;&nbsp;&nbsp;&nbsp;• President, Jackson Therapy Partners (January 2016 - November 2016)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Executive Vice President, Noor Staffing Group (2011 - 2015)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Attorney in Massachusetts<br>**Education:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• MBA, Boston College Carroll School of Management<br>&nbsp;&nbsp;&nbsp;&nbsp;• JD, New England School of Law<br>&nbsp;&nbsp;&nbsp;&nbsp;• BA, University of Massachusetts <br>|
| ![](ny20055089x1_cmcdonald.jpg)<br>**COLIN MCDONALD,**<br>57<br>Chief Human Resources <br>Officer<br>*Joined Company in 2014* | **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Senior Vice President, Human Resources, Cross Country Healthcare, Inc. (2020 - 2022)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Vice President, Human Resources & Labor Relations, Cross Country Healthcare, Inc. (2014 - 2020) <br>&nbsp;&nbsp;&nbsp;&nbsp;• Various human resources roles at Carnival Cruise Lines, RandCol Staffing and Citrix<br>**Education:** <br>&nbsp;&nbsp;&nbsp;&nbsp;• MS, Mercy College<br>&nbsp;&nbsp;&nbsp;&nbsp;• BA, State University of New York at New Paltz <br>|

---

26<br>

------

---

| | |
|:---|:---|
| ![](ny20055089x1_kmote.jpg)<br>**KAREN MOTE,** 61<br>President, Cross Country<br>Locums<br>*Joined Company in 2002* | **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Vice President, Cross Country Advanced Practice (2015 -2019)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Director, Cross Country Advanced Practice (2009 - 2014)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Director, Medical Doctor Associates (2008 - 2009)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Manager, Medical Doctor Associates (2001 - 2008)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Staffing Consultant, Medical Doctor Associates (1998 - 2001)<br>**Education:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Clinical Laboratory Degree, North Georgia Technical College <br>|
| ![](ny20055089x1_pnoe.jpg)<br>**PHIL NOE,** 55 <br>Chief Information Officer <br>*Joined Company in 2021* | **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Chief Information Officer, Vaco, LLC (2018 - 2021)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Chief Information Officer, Adecco Group, NA (2013 - 2018)<br>**Education:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Master of Health Administration and Master of Information Management, Washington University<br>&nbsp;&nbsp;&nbsp;&nbsp;• BS, University of Florida <br>|

---

27<br>

------

---

| | |
|:---|:---|
| ![](ny20055089x1_jvredd.jpg)<br>**JAMES V. REDD III,** <br>55<br>*Chief Accounting Officer* <br>*Joined Company in 2017* | **Formerly:**<br>&nbsp;&nbsp;&nbsp;&nbsp;• Senior Vice President, Corporate Controller, Cross Country Healthcare, Inc. (2021 - 2022)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Vice President, Assistant Corporate Controller, Cross Country Healthcare, Inc. (2017 - 2021)<br>&nbsp;&nbsp;&nbsp;&nbsp;• Assistant Controller, Vision Group Holdings (2016 - 2017) <br>&nbsp;&nbsp;&nbsp;&nbsp;• Accounting, SOX Compliance and SEC Reporting, Tyco and ADT (2011 - 2016) <br>&nbsp;&nbsp;&nbsp;&nbsp;• Deloitte and Touche, Audit and Assurance (2005 - 2011) <br>**Education:** <br>&nbsp;&nbsp;&nbsp;&nbsp;• MBA, Florida Atlantic University<br>&nbsp;&nbsp;&nbsp;&nbsp;• Bachelor of Science, Randolph Macon College<br>&nbsp;&nbsp;&nbsp;&nbsp;• Certified Public Accountant<br>|

---

**Family Relationships** <br>

There are no immediate family relationships between any of our directors or executive officers and any other directors or executive officers.

28<br>

------

### HOW WE DO WHAT WE DO
As a company that finds people to fill roles in which they care for other human beings, we ourselves have to be attentive to how we recruit, educate, train, enable, support, inspire, and protect our own employees. Here are examples of some of the ways we try to do these things (all information is as of December 31, 2024):

&nbsp;&nbsp;&nbsp;&nbsp;• We protect employees' freedom of association

&nbsp;&nbsp;&nbsp;&nbsp;• We administer a human rights policy aligned with the International Labor Organization's Declaration of Human Rights and the United Nations Guiding Principles on Human Rights

&nbsp;&nbsp;&nbsp;&nbsp;• We do not tolerate discrimination or harassment

&nbsp;&nbsp;&nbsp;&nbsp;• Our programs and practices prioritize our employees' physical and mental health and safety

&nbsp;&nbsp;&nbsp;&nbsp;○ 24/7 hotline for injuries

&nbsp;&nbsp;&nbsp;&nbsp;○ Psychotherapist on call

&nbsp;&nbsp;&nbsp;&nbsp;○ Group therapy sessions monthly

&nbsp;&nbsp;&nbsp;&nbsp;○ Monthly webinars on health, safety, and well-being issues

&nbsp;&nbsp;&nbsp;&nbsp;• We address employees' work-life needs with a rewards package including health, retirement, paid time off, family leave, and other benefits, pursuant to applicable law

&nbsp;&nbsp;&nbsp;&nbsp;• Our philosophy is for corporate employees to work where and how they are most productive:

&nbsp;&nbsp;&nbsp;&nbsp;○ Remote environment or at an office

&nbsp;&nbsp;&nbsp;&nbsp;○ Flexible scheduling arrangements

&nbsp;&nbsp;&nbsp;&nbsp;○ Job sharing

&nbsp;&nbsp;&nbsp;&nbsp;• We maintain a wide array of fitness and other programs to enhance employee health and well-being in an era in which health-care professional burnout is a major risk

&nbsp;&nbsp;&nbsp;&nbsp;• We offer an array of in-person and digital education, training, and advancement opportunities

&nbsp;&nbsp;&nbsp;&nbsp;• We support our communities through numerous volunteer programs, charitable giving, and other programs, including partnerships with dozens of non-governmental organizations and professional organizations.

29<br>

------

#### **TABLE OF CONTENTS**

### HOW WE DID

---

| | |
|:---|:---|
| **2024 FINANCIAL HIGHLIGHTS** | **OTHER 2024 HIGHLIGHTS**  |
| • Fiscal 2024 revenue above $1.3 billion<br>| • Strengthened oversight of key risk topics <br>|
| • Fiscal 2024 Adjusted EBITDA\* of $49.1 million<br>| • Completed Phase I of ERP implementation <br>|
| • Fiscal 2024 Adjusted EBITDA\* margin of 3.7%<br>| • Completed a cybersecurity exercise <br>|
| • Fiscal 2024 Adjusted EPS\* of $0.46<br>| • Reviewed various strategic alternatives to enhance Company value that led to the execution of a merger agreement with Aya Healthcare, Inc. <br>|
| • Strong Fiscal 2024 cash flow of $120.1 million<br>|  |
| • Repurchased 2.4 million shares of Common Stock for $36.8 million in Fiscal 2024<br>|  |
| • No outstanding long-term debt<br>|  |
| • Physician Staffing and Homecare Staffing experienced annual double-digit revenue growth<br>|  |

---

\* Adjusted EBITDA and Adjusted EPS are non-GAAP financial measures. See Annex A of this Proxy Statement for a reconciliation of non-GAAP financial measures to our results as reported under GAAP.

### RELATED PARTY TRANSACTIONS
The Company documents its processes and controls surrounding the validity, accuracy, and completeness of related party transactions. We compile related party listings which management discusses during quarterly disclosure committee meetings. Accounting teams review general ledger and sub-ledger transactions based on the listings to identify and quantify related party transactions. Contracts associated with related party transactions are sent to our General Counsel, who discusses the contracts with the Chief Executive Officer and the Chief Financial Officer for further action. The Company has deemed it reasonable to establish a $0 threshold and to disclose all related party transactions, defined as those transactions between the Company and any "related party" as defined under applicable SEC regulations.

On an ongoing basis, the Audit Committee reviews all related party transactions, if any, for potential conflicts of interest. All such transactions must be approved by the Audit Committee.

30<br>

------

#### **TABLE OF CONTENTS**
The following summarizes all of the related party transactions for Fiscal 2024. All of the below transactions were approved in advance by the Audit Committee.

&nbsp;&nbsp;&nbsp;&nbsp;• Mark Fortunato is employed by Cross Country Healthcare, Inc. as Vice President of Corporate Development. He is the son-in-law of Kevin C. Clark, former President and Chief Executive Officer and current Chairman of the Board. In Fiscal 2024, Mr. Fortunato's compensation and benefits were comparable to those generally available to similarly situated employees.

&nbsp;&nbsp;&nbsp;&nbsp;• The Company transacts business with Recruitics, a company which provides digital marketing services and is related to Mr. Clark, former CEO and current Chairman of the Board. Expenses paid to this firm in Fiscal 2024 were $478,000.

&nbsp;&nbsp;&nbsp;&nbsp;• During Fiscal 2024, the Company provided services in the amount of $561,454 to ChristianaCare, a network of non-profit hospitals. Dr. Janice E. Nevin, a non-employee director of the Company, is President and Chief Executive Officer of ChristianaCare.

&nbsp;&nbsp;&nbsp;&nbsp;• During Fiscal 2024, the Company provided services in the amount of $4,327,062 to Beth Israel, a non-profit integrated health system. Gale Fitzgerald, a non-employee director of the Company, serves on the Board of Trustees of Beth Israel Deaconess Hospital.

The Company's Code of Conduct, which is signed by all employees on an annual basis, requires that all employees avoid any conflict, or the appearance of a conflict, between an individual's personal interests and the interests of the Company, and must disclose any such conflicts to the Company. Members of the Board and the Company's executive officers are each required to complete an annual questionnaire which includes disclosure of any interests they have in companies which transact business with Cross Country or any of its affiliates.

31<br>

------

#### OUR STOCKHOLDERS

#### SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information, as of October 14, 2025, regarding the beneficial ownership of our Common Stock by each person who is known by us to be the beneficial owner of 5% or more of our Common Stock, each of our named executive officers, each of our directors and director nominees, and all directors and executive officers as a group. The number of shares of Common Stock beneficially owned includes shares of Common Stock such individual or group has the right to acquire within 60 days of October 14, 2025. The percentages in the last column are based on 32,759,952 shares of Common Stock outstanding on October 14, 2025, plus the number of shares of Common Stock deemed to be beneficially owned by such individual or group pursuant to Rule 13d-3(d)(1) of the Exchange Act. In each case, except as otherwise indicated in the footnotes to the table, the shares shown in the second column are owned directly by the individual or members of the group named in the first column and such individual or group members have sole voting and dispositive power with respect to the shares shown. For purposes of this table, beneficial ownership is determined in accordance with federal securities laws and regulations. Persons shown in the table disclaim beneficial ownership of all securities not held by such persons directly and inclusion in the table of shares not owned directly by such persons does not constitute an admission that such shares are beneficially owned by the director or officer for purposes of Section 16 of the Exchange Act or any other purpose. The address of each director, director nominee, and named executive officer is c/o Cross Country Healthcare, Inc., 6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida 33487.

---

| | | |
|:---|:---|:---|
| **Name** | **Number of Shares** <br>**of Common Stock** <br>**Beneficially Owned** | **Percentage of** <br>**Outstanding** <br>**Common** <br>**Stock Owned**  |
| BlackRock Inc. <br>50 Hudson Yards <br>New York, NY 10001  | 2468424 <sup>(a)</sup> | 7.5% |
| AllianceBernstein L.P. <br>501 Commerce Street <br>Nashville, TN 37203  | 2343484<sup>(b)</sup> | 7.2%  |
| Magnetar Capital LLC <br>1603 Orrington Avenue <br>Evanston, IL 60201 | 2324229<sup>(c)</sup> | 7.1%  |
| Dimensional Fund Advisors LP<br>6300 Bee Cave Road, Building One <br>Austin, TX 78746 | 1913892<sup>(d)</sup> | 5.8%  |
| The Goldman Sachs Group, Inc.<br>200 West Street<br>New York, NY 10282 | 1887473<sup>(e)</sup> | 5.8%  |
| The Vanguard Group<br>100 Vanguard Blvd. <br>Malvern, PA 19355 | 1832936<sup>(f)</sup> | 5.6% |
| Dwayne Allen | 12609<sup>(g)</sup> | \*  |
| Susan E. Ball | 176032<sup>(h)</sup> | \*  |
| Venkat Bhamidipati | 11079<sup>(i)</sup> | \*  |
| William J. Burns | 242508<sup>(j)</sup> | \*  |
| W. Larry Cash | 199632<sup>(k)</sup> | \*  |
| Kevin C. Clark | 650459<sup>(l)</sup> | 2.0%  |
| Gale Fitzgerald | 175569<sup>(m)</sup> | \*  |
| Marc S. Krug | 34853<sup>(n)</sup> | \*  |
| John A. Martins | 150935<sup>(o)</sup> | \*  |
| Janice E. Nevin, M.D., MPH | 29936<sup>(p)</sup> | \*  |
| Phil Noe | 10320<sup>(q)</sup> | \*  |
| All directors and executive officers as a group (15 individuals) | 1768302 | 5.4% |

---

\*

Less than 1%

32<br>

------

#### **TABLE OF CONTENTS**
&nbsp;&nbsp;&nbsp;&nbsp;(a) The information regarding the beneficial ownership of shares by BlackRock, Inc. was obtained from the amendment to Schedule 13G filed with the SEC on July 16, 2025. Such statement disclosed that BlackRock, Inc. has sole voting power over 2,390,171 shares, shared voting power over 0 shares, has sole dispositive power over 2,468,424 shares, and shared dispositive power over 0 shares.

&nbsp;&nbsp;&nbsp;&nbsp;(b) The information regarding the beneficial ownership of shares by AllianceBernstein L.P. was obtained from the Schedule 13G filed with the SEC on May 14, 2025. Such statement disclosed that AllianceBernstein L.P. has sole voting power over 1,478,737 shares, shared voting power over 0 shares, has sole dispositive power over 2,343,484 shares, and shared dispositive power over 0 shares.

&nbsp;&nbsp;&nbsp;&nbsp;(c) The information regarding the beneficial ownership of shares by Magnetar Capital LLC was obtained from the amendment to Schedule 13D filed with the SEC on January 3, 2025. Such statement disclosed that Magnetar Capital LLC has sole voting power over 0 shares, shared voting power over 2,324,229 shares, sole dispositive power over 0 shares, and has shared dispositive power of 2,324,229 shares.

&nbsp;&nbsp;&nbsp;&nbsp;(d) The information regarding the beneficial ownership of shares by Dimensional Fund Advisors LP was obtained from the Form 13F-HR filed with the SEC on February 13, 2025. Such statement disclosed that Dimensional Fund Advisors LP possesses sole voting power over 1,872,111 shares and sole dispositive power over 1,913,892 shares.

&nbsp;&nbsp;&nbsp;&nbsp;(e) The information regarding the beneficial ownership of shares by The Goldman Sachs Group, Inc. was obtained from the amendment to Schedule 13G filed with the SEC on August 13, 2025. Such statement disclosed that The Goldman Sachs Group, Inc. possesses sole voting power over 0 shares, shared voting power over 1,887,051 shares, sole dispositive power over 0 shares, and shared dispositive power over 1,887,473 shares.

&nbsp;&nbsp;&nbsp;&nbsp;(f) The information regarding the beneficial ownership of shares by The Vanguard Group was obtained from the amendment to Schedule 13G filed with the SEC on January 30, 2025. Such statement disclosed that The Vanguard Group possesses shared voting power over 22,304 shares, sole dispositive power over 1,782,745 shares, and shared dispositive power over 50,191 shares.

&nbsp;&nbsp;&nbsp;&nbsp;(g) Includes 0 shares of Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(h) Includes 14,530 shares of Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(i) Includes 0 shares of Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(j) Includes 20,849 shares of Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(k) Includes 0 shares of Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(l) Includes 0 shares of Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(m) Includes 0 shares of Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(n) Includes 9,666 shares of Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(o) Includes 60,808 shares of Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(p) Includes 0 shares of Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(q) Includes 5,205 shares of Restricted Stock.

33<br>

------

### AUDIT MATTERS

### REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS
The Audit Committee oversees the Company's financial reporting process on behalf of the Board, including the Company's internal controls, the quality of its financial reporting, and the independence and performance of the Company's independent registered public accounting firm. The Board has adopted a written charter for the Audit Committee, a copy of which is available on our website at www.crosscountryhealthcare.com.

Management has the primary responsibility for the Company's financial statements and the overall reporting process, including the Company's system of internal controls. The Company's independent registered public accounting firm audits the annual financial statements prepared by management, expresses an opinion as to whether those financial statements fairly present the consolidated financial position, results of operations, and cash flows of the Company and its subsidiaries in conformity with U.S. generally accepted accounting principles, as well as expresses an opinion on the effectiveness of internal control over financial reporting, and discusses with us any issues they believe should be raised with us.

The Audit Committee reviewed the Company's unaudited financial statements for each calendar quarter of 2024, as well as the Company's audited financial statements for Fiscal 2024, and reviewed and discussed the financial statements with management and Deloitte & Touche LLP ("D&T"), the Company's independent registered public accounting firm. Management has represented to us that the financial statements were prepared in accordance with U.S. generally accepted accounting principles.

We have received from D&T the written disclosures and the letter required by the applicable rules and standards of the Public Company Accounting Oversight Board ("PCAOB") and discussed with D&T its independence from the Company and its management. The Audit Committee also discussed with D&T any matters required to be discussed by the applicable rules and standards of PCAOB.

Based on these reviews and discussions, the Audit Committee recommended to the Board that the Company's audited consolidated financial statements be included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

THE AUDIT COMMITTEE

Venkat Bhamidipati, Chairperson

Dwayne Allen, Member

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;W. Larry Cash, Member

Janice E. Nevin, M.D., MPH, Member

*THIS REPORT IS NOT SOLICITING MATERIAL, IS NOT DEEMED TO BE FILED WITH THE SEC, AND IS NOT TO BE INCORPORATED BY REFERENCE IN ANY FILING OF THE COMPANY UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, WHETHER MADE BEFORE OR AFTER THE DATE HEREOF AND IRRESPECTIVE OF ANY GENERAL INCORPORATION LANGUAGE IN ANY SUCH FILING.* 

34<br>

------

#### **TABLE OF CONTENTS**

### AUDIT FEES
D&T's fees for services rendered during the fiscal years ended December 31, 2024 and December 31, 2023 are set forth below.

---

| | | |
|:---|:---|:---|
|  | **2024** | **2023**  |
| Audit Fees | $2001560 | $1672878  |
| Audit-Related Fees | 30000 | 158965  |
| Tax Fees | 37800 | 50000  |
| All Other Fees | 1895 | 1895  |
| Total | $2071255 | $1883738 |

---

*Audit Fees consist of the fees billed for professional services rendered in connection with our annual audit and review of the financial statements included in our quarterly reports and services that are provided in connection with statutory and regulatory filings or engagements. Audit Fees for 2024 and 2023 included three quarterly reviews for each year. This category also includes fees for comfort letters, consents, assistance with and review of documents filed with the SEC, Section 404 attestation services, work done by tax professionals in connection with the audit or quarterly review, and accounting consultations billed as audit services, as well as other accounting and financial reporting consultation and research work necessary to comply with generally accepted auditing standards. The increase in audit fees from fiscal year 2023 to 2024 was primarily due to the Company's implementation of a new enterprise resource planning technology in 2024.* 

*Audit-Related Fees consist of the fees for assurance and related services, including due diligence services related to mergers and acquisitions, that are reasonably related to the performance of the audit and review of our financial statements and are not reported under Audit Fees.* 

*Tax Fees consist of services rendered for tax compliance, advice, and planning.* 

*All Other Fees consist of subscription fees for D&T's accounting research tool.* 

All of the fees described above were approved by the Audit Committee or the Chairperson of the Audit Committee in advance, as allowed by the Audit Committee charter. The Audit Committee has considered, and is satisfied that, the provision of the services provided by D&T represented under the headings "Audit-Related Fees," "Tax Fees," and "All Other Fees" is compatible with maintaining the principal accountant's independence.

35<br>

------

#### **TABLE OF CONTENTS**

### POLICY ON AUDIT COMMITTEE PRE-APPROVAL OF AUDIT AND NON-AUDIT SERVICES OF THE INDEPENDENT REGISTERED ACCOUNTING FIRM
It is the Company's policy that the Audit Committee pre-approve all audit and non-audit services provided by the independent registered public accounting firm. These services may include audit services, audit-related services, tax services, and other services. The Audit Committee will consider annually and, if appropriate, approve the scope of the audit services to be performed during the fiscal year. The Chairperson of the Audit Committee has been vested with the authority to approve or pre-approve services to be provided by the independent auditors when expedition of services is necessary, provided that the Chairperson reports any approval or pre-approval decisions to the Audit Committee at its next scheduled meeting.

The Audit Committee is prohibited from delegating its responsibility to pre-approve services of the independent auditor to management. None of the services of the independent auditors were approved by the Audit Committee pursuant to a waiver of the SEC's rules regarding pre-approval.

36<br>

------

#### **TABLE OF CONTENTS**

### COMPENSATION DISCUSSION AND ANALYSIS
This Compensation Discussion and Analysis is designed to provide our stockholders with a clear understanding of our compensation philosophy and objectives, compensation-setting process, and the compensation paid to our named executive officers ("NEOs"), in Fiscal 2024. As discussed in Proposal No. 3, we are conducting a say-on-pay vote this year that requests your approval, on an advisory basis, of the 2024 compensation of our NEOs as described in this section and in the tables and accompanying narrative.

Our NEOs for Fiscal 2024 were:

---

| | |
|:---|:---|
| Name | Position  |
| John A. Martins | President and Chief Executive Officer  |
| William J. Burns, MBA, CPA | EVP, Chief Financial Officer  |
| Susan E. Ball, JD, MBA, RN | EVP, Chief Administrative Officer, General Counsel and Secretary  |
| Marc Krug, JD, MBA | Group President  |
| Phil Noe | Chief Information Officer  |
| Daniel J. White<sup>(1)</sup> | Former Chief Commercial Officer |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Mr. White's position was eliminated as part of a reorganization, and he ceased to be employed by the Company effective March 31, 2024.

37<br>

------

#### **TABLE OF CONTENTS**

### COMPENSATION PHILOSOPHY AND OBJECTIVES

---

| | | | |
|:---|:---|:---|:---|
| **What we do** | **What we do** | **What we don't do**  | **What we don't do**  |
| ☑ | Majority of compensation is incentive-based and at- risk, with a significant portion tied to Company performance | X | No guaranteed incentive payments  |
| ☑ | Engage independent compensation consultants | X | No 280G excise tax gross-ups  |
| ☑ | Engage in peer group benchmarking to ensure NEO target pay remains competitive and within reasonable levels | X | No supplemental executive pension or retirement plans  |
| ☑ | Due diligence in setting compensation targets and goals to tie incentives to multiple performance metrics over multiple time horizons, with capped award opportunities | X | No option repricing  |
| ☑ | Periodically assess the compensation programs to ensure that they are not reasonably likely to incentivize employee behavior that would result in any material adverse risks to the Company | X | Limited perquisites  |
| ☑ | Severance payments require double-trigger in the event of change in control | X | No pledging and no hedging  |
| ☑ | Maintain policy allowing for recoupment of equity and cash incentive payments in the event of a qualifying restatement |  |  |
| ☑ | Stock ownership guidelines: Chief Executive Officer (CEO) (3x base salary) and other senior executives (1x base salary), to be accumulated over three years |  |  |

---

The philosophy of our executive compensation program is to align pay with performance and key strategic objectives, keep overall compensation competitive, and ensure that we can recruit, motivate, and retain high quality executive officers. Accordingly, our NEOs' compensation is heavily weighted toward compensation that is performance-based and/or equity-based. Our NEO compensation design for Fiscal 2024 reflects this commitment, as do incentive award funding outcomes, with short-term incentive payouts well below target for Fiscal 2024 and performance shares below target for the three-year measurement period ending December 31, 2024.

Under the guidance of the Board, the Compensation Committee structured the Fiscal 2024 executive compensation program with the goal of ensuring that total direct compensation levels were sufficiently competitive to attract, motivate, and retain high quality executives, that performance-based, "at-risk" incentive compensation was a substantial portion of total compensation opportunities, and that long-term incentive compensation aligned NEOs' interests with our stockholders' interests to create long-term stockholder value. Fiscal 2024 long-term incentives were structured with the goals of retaining key NEOs and linking a meaningful portion of NEO total compensation opportunities to longer-term sustainable performance and value creation. The equity-based incentive compensation was also redesigned to reinforce the Company's near-term and longer-term strategic objectives and to provide NEOs with the opportunity to acquire a stake in our growth and prosperity. The executive compensation program was also structured to incentivize and reward NEOs for making sound business decisions, developing a high performance team environment, accomplishing strategic and operational objectives, and increasing stockholder value, all of which we believe are essential to improving our financial performance and creating success.

38<br>

------

#### **TABLE OF CONTENTS**
Our NEOs' compensation for Fiscal 2024 consisted of a base salary, an annual cash incentive (or bonus), and long-term equity awards, 50% of which were time-based restricted share awards that vest over three years and 50% of which were performance-based share awards that are earned based on the achievement of certain predetermined performance measures. In Fiscal 2024, the performance-based restricted share awards were based on two performance metrics: (i) three-year cumulative Adjusted EBITDA (a non-GAAP financial measure) (weighted 75%) and (ii) three-year cumulative Adjusted EPS (a non-GAAP financial measure) (weighted 25%). See Annex A of this Proxy Statement for a reconciliation of non-GAAP financial measures to our results as reported under GAAP.

For Fiscal 2024, 79% of target total direct compensation for our CEO, and an average of approximately 63% of target total direct compensation for our other NEOs, was performance-based or equity-based. We do not provide defined benefit pension, supplemental retirement benefits, or executive perquisites to our NEOs, as they are not tied to performance.

Our compensation philosophy serves as the basis of the Compensation Committee's decisions regarding each of the following three components of pay, each of which is discussed below:

&nbsp;&nbsp;&nbsp;&nbsp;• base salary;

&nbsp;&nbsp;&nbsp;&nbsp;• short-term (annual) incentive compensation; and

&nbsp;&nbsp;&nbsp;&nbsp;• long-term (equity) compensation.

**Consideration of Say-on-Pay Vote** <br>

As part of its compensation setting process, the Compensation Committee also considers the results of the prior year's say-on-pay vote, which provides useful feedback regarding the perceived effectiveness of our executive compensation program and the program's ability to align pay with performance and stockholder interests. For the thirteenth straight year, our executive compensation program received substantial stockholder support, with 95.3% of the votes cast in favor of the 2023 compensation of our NEOs at the 2024 Annual Meeting of Stockholders. As our Compensation Committee believes that the results of the vote reflected our stockholders' strong support of the compensation decisions made by the Compensation Committee, our Compensation Committee did not approve any significant changes to our NEOs' 2024 compensation program design as a result of the say-on-pay vote at the 2024 Annual Meeting of Stockholders.

### DETERMINATION OF COMPENSATION
**Role of the Compensation Committee** <br>

The Compensation Committee is composed solely of independent directors and is responsible for determining the compensation of our CEO and other NEOs. The Compensation Committee receives assistance from its independent compensation consultant, Pearl Meyer.

Our NEO compensation program is reviewed throughout the year and typically is approved annually during the first quarter, which coincides with the completion of our annual financial statement audit and release of annual earnings, as well as the approval of the budget for the then-current year. Award funding levels for any completed short-term and long-term incentive performance cycles are determined by the Compensation Committee and paid out, to the extent earned, during the first quarter of the following year. Current year target objectives are also established and any adjustments to base salaries are typically determined by the Compensation Committee during the first quarter.

Under guidance from the Board, the Compensation Committee takes many factors into account when making NEO compensation decisions, including benchmarking, the NEO's individual performance, the financial and operational results of individual business units, our financial and operational results as a whole, the NEO's historical compensation, internal pay equity, and any retention concerns. As part of the

39<br>

------

#### **TABLE OF CONTENTS**
process, the CEO provides the Compensation Committee with the CEO's assessment of the other NEOs' performance and other factors used in developing the CEO's recommendation for the other NEOs' compensation, including salary adjustments, cash incentives, and equity grant levels for the then-current year. In looking at historical compensation, the Compensation Committee considers the progression of salary increases over time, each NEO's actual versus planned performance and corresponding incentives earned, the potential realizable value of any outstanding equity grants, total overall compensation, and an evaluation of historical performance, overall economic outlook, and our stock performance. The Compensation Committee uses the same general factors in evaluating the CEO's performance and compensation as it uses for the other NEOs; provided, however, that the CEO does not participate in the assessment or compensation deliberations and decisions with respect to the CEO.

Upon receipt of the information discussed above, the Compensation Committee discusses proposed compensation decisions for the CEO and other NEOs. Pursuant to our Governance Guidelines, the Compensation Committee is required to approve annually the compensation goals and objectives for the CEO and other NEOs and evaluate their performance in light of these goals before setting their salaries, bonus, and other incentive and equity compensation. The Compensation Committee works to ensure that each NEO's individual objectives are aligned with the business strategy, specific, measurable and set within an established timeframe. The Compensation Committee believes that maintaining the flexibility to make upward or downward adjustments to the various components of the NEOs' compensation programs allows the Compensation Committee to appropriately provide incentives to the NEOS and ensures the alignment of the NEOs' interests with those of our stockholders.

**Role of Management** <br>

The CEO provided the Compensation Committee with the CEO's assessment of the other NEOs' performance and other factors used in developing the CEO's recommendation for the other NEOs' compensation, including salary adjustments, cash incentives and equity grant guidelines for the other NEOs' compensation. After considering the CEO's recommendations, the Compensation Committee made all decisions regarding the Fiscal 2024 compensation of our NEOs. The CEO did not participate in the assessment of or compensation deliberations and decisions with respect to the CEO.

**Role of the Compensation Consultant** <br>

Annually, the Compensation Committee evaluates the Company's executive compensation design, competitiveness, and effectiveness. Pearl Meyer assists the Compensation Committee with its evaluation by regularly participating in meetings and periodically conducting external market reviews and updates on executive pay trends and regulatory developments. No external market review was conducted in 2023 due to then-current economic conditions and the Compensation Committee's decision not to modify NEO pay opportunities for Fiscal 2024. During Fiscal 2024, the Compensation Committee engaged Pearl Meyer to review the compensation components for our NEOs against our 2024 Peer Group and market data of like-sized companies. Pearl Meyer's study did not impact Fiscal 2024 pay opportunities for NEOs.

40<br>

------

**Role of Benchmarking** <br>

At the beginning of the executive compensation setting process each year, the Compensation Committee, in consultation with Pearl Meyer, determines the process by which it will work to ensure that the Company's compensation programs are competitive. For Fiscal 2024, the Compensation Committee, upon the recommendation of Pearl Meyer, determined that it would be appropriate to maintain the group of peer companies which it had established in 2023. Accordingly, the peer group used in Fiscal 2024 was the same as that used in Fiscal 2023 and is composed of companies from both the healthcare services and staffing and general staffing industry sectors, and includes the following twelve companies (the "2024 Peer Group"):

---

| | | |
|:---|:---|:---|
| **2024 PEER GROUP**  | **2024 PEER GROUP**  | **2024 PEER GROUP**  |
| Addus HomeCare Corporation | Kelly Services, Inc. | Paycom Software, Inc.  |
| Amedisys, Inc. | Kforce, Inc. | Pediatrix Medical Group, Inc.  |
| AMN Healthcare Services, Inc. | Korn/Ferry International | R1 RCM Inc.  |
| Heidrick & Struggles Int'l Inc. | National Healthcare Corporation | ZipRecruiter, Inc. |

---

The Compensation Committee determined, in consultation with Pearl Meyer, that the 2024 Peer Group reflects companies falling within a generally comparable size range and that we compete with for business, executive talent, and investor capital.

Factors such as revenue, business mix, profitability, business strategy, compensation philosophy, and incentive plan design vary among the peer companies and such differing factors affect the compensation that they provide to their executives. While informative to the Compensation Committee, such peer practices are not the only factors that influence the Compensation Committee's NEO compensation decisions. The Compensation Committee also makes decisions based on the collective experience and knowledge of its members. Generally, our policy has been to position NEOs' base salaries and target total direct compensation opportunities at or near the 50th percentile of market values for comparable positions at industry peers. Pearl Meyer's 2024 analysis found that target total direct compensation (sum of base salary plus target short-term and long-term incentives) opportunities were below 50th percentile market values for all current NEOs, and below a competitive range (defined as 85% to 115%) of the 50th percentile for three of the five NEOs excluding Mr. White, who was not included in the study due to his departure on March 31, 2024.

### COMPONENTS OF FISCAL 2024 NEO COMPENSATION PROGRAM
The Compensation Committee uses various compensation elements to provide an overall competitive total compensation and benefits package to the NEOs that is designed to create stockholder value, commensurate with our financial results, and align with our business strategy. The Compensation Committee's specific rationale, design, reward, process, and related information is outlined below.

**Base Salary** <br>

We provide the NEOs with a base salary to compensate them for services rendered during the fiscal year. The NEOs' salaries are determined based on each NEO's position, performance, and level of responsibility and are reviewed annually. Peer group and market data from like-sized companies are utilized in the Compensation Committee's review. Merit increases for NEOs are considered based on periodic external market studies and annual performance review, and are adjusted only as needed, not necessarily annually. We generally seek to position NEO base salaries within a competitive range, defined as 90% to 110% of median market values for comparable roles at our industry peers and other companies of like size.

41<br>

------

#### **TABLE OF CONTENTS**
For 2024, the Compensation Committee decided to maintain base salaries at 2023 levels for all NEOs, based on its review of benchmarking information as described above.

---

| | | | |
|:---|:---|:---|:---|
| **NEO** | **2024 Base** <br>**Salary**<br>**($)** | **2023 Base** <br>**Salary**<br>**($)** | **% Increase vs** <br>**Prior Year**  |
| John A. Martins | 875000 | 875000 | 0%  |
| William J. Burns | 550000 | 550000 | 0%  |
| Susan E. Ball | 500000 | 500000 | 0%  |
| Marc Krug | 450000 | 450000 | 0%  |
| Phillip L. Noe | 411950 | 411950 | 0%  |
| Daniel White | 450000 | 450000 | 0% |

---

**Annual Cash Incentive Program** <br>

The Annual Cash Incentive Program is a core component of our "pay-for-performance" philosophy. The program is heavily weighted on our financial results for the Company or relevant business units and the goals are closely linked to our business strategy. The components of this program have historically included the incentive award opportunity (expressed as a percentage of base salary) and performance metrics determined by the Compensation Committee. To ensure the integrity of the performance metrics and minimize the risk of unanticipated outcomes, each performance metric has a minimum, target, and maximum performance range with corresponding percentages for award payout opportunities. The Compensation Committee may adjust performance measures for certain special, unusual, or non-recurring items at its sole discretion. See 2024 discussion below.

Each annual target cash incentive award opportunity is expressed as a percentage of the NEO's base salary, which may be earned based on both the achievement of certain financial objectives (the "Objective Bonus" component, representing 80% of target award opportunities) and individual subjective considerations that are tied primarily to individual objectives (the "Subjective Bonus" component, representing 20% of target award opportunities). If results fall below pre-established threshold levels, no cash award is payable under the Objective Bonus component, although a Subjective Bonus may still be paid at the discretion of the Compensation Committee based on the achievement of applicable individual and strategic goals. If results exceed pre-established outstanding goals, the maximum cash award payable under the Objective Bonus component is capped at 200% of the target award opportunity. The Compensation Committee believes that having a maximum cap disincentivizes excessive risk taking, reduces the likelihood of windfalls, and manages the Annual Cash Incentive Program's costs. The award opportunity is established for each NEO with the desired emphasis on at-risk, variable pay (more at-risk, variable pay for senior executives) and internal pay equity (comparably positioned executives should have comparable award opportunities).

The Subjective Bonus opportunity is capped at a maximum amount of 100% of the target award opportunity for that component, subject to the sole discretion of the Compensation Committee. The Subjective Bonus may include various pre-established quantitative and qualitative goals for each NEO. The use of subjective criteria enables the Compensation Committee to consider a variety of subjective factors relative to each NEO's specific responsibilities. This process allows the Compensation Committee to evaluate performance and to recognize individual contributions in light of our changing needs and strategic priorities, and to continue incentivizing sustainable profitable growth.

Consistent with the prior year, the Compensation Committee determined that the Objective Bonus component performance metrics for Fiscal 2024 would be Company Annual Revenue and Company Annual Adjusted EBITDA (a non-GAAP measure). Incentive payouts under the Annual Cash Incentive Program, at a reduced threshold level, begin upon achievement of a predetermined percentage of targeted objectives (generally 80% or higher for Company Annual Adjusted EBITDA and 90% for Company Annual Revenue), which can vary from year to year and from one performance metric to another, based on our internal business

42<br>

------

plan, current macroeconomic conditions, and market volatility. For Fiscal 2024, incentive award funding for threshold performance was set at 20% of corresponding target award opportunities. Payouts may exceed 100% (up to 200%) of target award opportunities if performance exceeds 100% of the target objectives as described above and set forth in the table below. Straight-line interpolation is used to determine award funding for performance results between minimum (or threshold), target, and maximum levels. We believe that an "all or nothing" approach could provide a disincentive compared to our variable funding approach that is better aligned with our overall operating objectives and ensures that pay varies in proportion to performance.

Historically, the Compensation Committee has established performance metrics and the weighting of each metric during its first Compensation Committee meeting of each year. The process for setting the performance metrics begins with the management team establishing preliminary goals based on the prior year's results, the budget, strategic initiatives, industry performance, and projected economic conditions. The Compensation Committee assesses the difficulty of the goals and their implications for share price appreciation, revenue growth, and other related factors. For Fiscal 2024, Company Annual Adjusted EBITDA (a non-GAAP financial measure) and Company Annual Revenue targets for Fiscal 2024 were set at $80 million and $1.475 billion, respectively.

The table below sets forth the percentages of the portion of the Fiscal 2024 annual incentive bonus that was payable upon achievement of the minimum, target, and maximum levels (with interpolation between levels) of the applicable performance metrics for each of our NEOs, except for Mr. White, as he did not participate in the Fiscal 2024 Annual Cash Incentive Program.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Performance Metric** | **Attainment** <br>**Range**<br>**(Minimum/** <br>**Target/** <br>**Maximum)** | **Payout** <br>**Percentage**<br>**(Minimum/** <br>**Target/** <br>**Maximum)** | **Martins** | **Burns** | **Ball** | **Krug** | **Noe**  |
| Company Annual Revenue (Objective Bonus) | 90%/100%/105% | 20%/100%/200% | 20% | 20% | 20% | 20% | 20%  |
| Company Annual Adjusted EBITDA\* (Objective Bonus) | 80%/100%/120% | 20%/100%/200% | 60% | 60% | 60% | 60% | 60%  |
| Individual Objectives (Subjective Bonus) | n/a | 0%/100%/\*\* | 20% | 20% | 20% | 20% | 20%  |
| Totals |  |  | 100% | 100% | 100% | 100% | 100% |

---

\* This is a non-GAAP measure. See Annex A of this Proxy Statement for further discussion regarding how Company Annual Adjusted EBITDA was calculated from our Consolidated Financial Statements and a reconciliation of Company Annual Adjusted EBITDA to our results as reported under GAAP. 

\*\* As noted above, payout in excess of 100% of the Subjective Bonus is solely at the discretion of the Compensation Committee. 

During the second quarter of Fiscal 2024, the Compensation Committee introduced an additional element to the Annual Cash Incentive Plan that was designed to allow management to realize up to 65% of their individual incentive tied to the Company Annual Adjusted EBITDA. The threshold for minimum attainment was established at $50 million with a goal of achieving $60 million for the full year 2024, utilizing

43<br>

------

linear interpolation to determine the actual payout. In making its determination to make this one-time adjustment to the Annual Cash Incentive Plan, the Compensation Committee considered the extremely challenging market conditions, the probability of attaining the previously approved targets, and the need to preserve the motivational impact of the annual cash incentive program.

The Compensation Committee determined that for Fiscal 2024, the Company did not achieve its minimum performance threshold for Company Annual Adjusted EBITDA of $64 million under the Annual Incentive Plan or $50 million pursuant to the additional element added during the year, but did slightly exceed the threshold performance hurdle of $1.33 billion for Company Annual Revenue. As a result of the below-target results, our NEOs earned 29.0% of the target award opportunity for the Annual Revenue portion of the Objective Bonus component for Fiscal 2024. Individual objectives may differ between NEOs, and the Compensation Committee assesses specific NEO attainment both qualitatively and quantitatively, with consideration given to factors such as business conditions and competing priorities or other significant individual contributions. For Fiscal 2024, individual objectives included, but were not limited to, continuing to advance our technology roadmap, implementing Phase I of our enterprise resource planning (ERP) implementation, improving productivity across the business, managing overall costs and improving cash collections, as well as various organizational goals and other special projects that align with our strategy. The Compensation Committee determined that for Fiscal 2024, our NEOs met or exceeded all of their respective individual objectives, each earning 119.5% of the target award for this component. Resulting total awards for our NEOs were 29.7% of total target annual incentive award opportunities, as noted below, well below payouts earned in Fiscal 2021 and Fiscal 2022 but similar to those in Fiscal 2023. In approving these awards, the Compensation Committee took into consideration our NEOs' strong contributions to protect and manage the business and seamlessly maintain operations during a time of cost-cutting measures by healthcare facilities, and the overall uncertainty of the economy.

---

| | | | |
|:---|:---|:---|:---|
|  | **Target Bonus** <br>**Opportunity** | **Annual Incentive Bonus Earned**  | **Annual Incentive Bonus Earned**  |
| **NEOs** | **% of Base** <br>**Salary** | $**% of Target Bonus** <br>**Opportunity** <br>**Earned** | **$**  |
| John A. Martins | 100% | 29.7% | 259875  |
| William J. Burns | 85% | 29.7% | 138848  |
| Susan E. Ball | 75% | 29.7% | 111375  |
| Marc Krug | 100% | 29.7% | 133650  |
| Phillip L. Noe | 50% | 29.7% | 61175 |

---

**Long-Term Incentive Compensation** <br>

The Company uses equity-based awards to focus NEOs on long-term performance, to align NEOs' financial interests with those of stockholders, and to create retention platforms. Equity-based awards for NEOs are generally made based on each NEO's position, experience and performance, and competitive equity-based compensation levels. Further, the Compensation Committee determines the terms and conditions of equity grants taking into account market practices and the objectives of the compensation program. Retaining key talent is a significant factor for the Compensation Committee in determining the level of equity awards and the vesting schedule.

44<br>

------

In Fiscal 2024, 50% of the equity awards granted to the NEOs were in the form of time-based restricted share awards ("RSAs") and 50% were in the form of performance-based share awards ("PSAs") under our 2020 Omnibus Incentive Plan, as amended (the "2020 Plan"). This target value mix was used to enhance NEO retention and equity stakes, while also tying a meaningful portion of NEO compensation to specific longer-term financial performance goals and to focus management on maximizing stockholder value. The total targeted long-term opportunities and mix for our NEOs, except with respect to Mr. White, for Fiscal 2024 are set forth in the following table:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **RSA Component**<br>**(50% Weighting in 2024)** | **RSA Component**<br>**(50% Weighting in 2024)** | **PSA Component**<br>**(50% Weighting in 2024)**  | **PSA Component**<br>**(50% Weighting in 2024)**  | **Total Target LTI Opportunity**  | **Total Target LTI Opportunity**  |
| **Name** | **$ Value** | **% of Salary** | **$ Value** | **% of Salary** | **$ Value** | **% of Salary**  |
| John A. Martins | $1203125 | 137.5% | $1203125 | 137.5% | $2406250 | 275.0%  |
| William J. Burns | $412500 | 75.0% | $412500 | 75.0% | $825000 | 150.0%  |
| Susan E. Ball | $287500 | 57.5% | $287500 | 57.5% | $575000 | 115.0%  |
| Marc Krug | $191250 | 42.5% | $191250 | 42.5% | $382500 | 85.0%  |
| Phillip L. Noe | $102987 | 25.0% | $102987 | 25.0% | $205975 | 50.0% |

---

The Compensation Committee approves the number of RSAs and the target number of PSAs to be granted to the NEOs on March 31<sup>st</sup> of each year. If March 31st falls on a weekend or holiday, the grant date value is based on the immediately preceding business day. The grant date values of the RSAs and PSAs granted in Fiscal 2024 are set forth below and were based on the closing price of our Common Stock on the grant date. Awards are based on a percentage of each NEO's respective base salary at the time the awards were granted, with target award opportunities unchanged from Fiscal 2023 levels. The percentages and eligibility are based on the terms of employment for certain NEOs or as may be determined by the Compensation Committee. In Fiscal 2024, the RSA and PSA target award values were each equally weighted.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Grant Date** <br>**Value of RSAs**<br>**(per share)** | **Number** <br>**of RSAs** | **Grant Date Value** <br>**of PSAs at Target**<br>**(per share)** | **Target Number** <br>**of PSAs**  |
| John A. Martins | $18.72 | 64270 | $18.72 | 64270  |
| William J. Burns | $18.72 | 22036 | $18.72 | 22036  |
| Susan E. Ball | $18.72 | 15358 | $18.72 | 15358  |
| Marc Krug | $18.72 | 10217 | $18.72 | 10217  |
| Phillip L. Noe | $18.72 | 5502 | $18.72 | 5502 |

---

All of the RSAs granted to the NEOs in Fiscal 2024 provide for vesting of 33.33% of the award on each of the first, second and third anniversaries of the grant date, subject to the NEO's continued employment with the Company through the vesting date.

45<br>

------

Consistent with Fiscal 2023, the PSAs granted to the NEOs in Fiscal 2024 provide for the issuance of a number of shares based on the level of attainment of cumulative Adjusted EBITDA (a non-GAAP financial measure) (weighted 75%) and cumulative Adjusted EPS (a non-GAAP financial measure) (weighted 25%), both measured over the three-year performance period ending December 31, 2026, as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Performance Level** | **3-year Cumulative** <br>**Adjusted EBITDA\*** <br>**Achieved (in** <br>**thousands) ($000s)** | **Percentage of the** <br>**Target Shares Earned** | **3-year Cumulative** <br>**Adjusted EPS\*** <br>**Achieved** | **Percentage of the** <br>**Target Shares Earned**  |
| Below Threshold | Less than $243,750 | 0% | Less than $3.42 | 0%  |
| Threshold | $243750 | 25% | $3.42 | 25%  |
| Target | $325000 | 100% | $4.56 | 100%  |
| Maximum | $406250 | 175% | $5.70 | 175% |

---

\* This is a non-GAAP measure. See Annex A of this Proxy Statement for a reconciliation of non-GAAP financial measures to our results as reported under GAAP.

On December 3, 2024, we entered into a Merger Agreement with Aya Healthcare, Inc. ("Aya" or "Aya Healthcare") and certain of its subsidiaries, pursuant to which a subsidiary of Aya will merge with and into the Company, with the Company surviving the merger as a wholly-owned indirect subsidiary of Aya (the "Aya Merger"). The completion of the Aya Merger is currently expected to occur in the fourth quarter of 2025, subject to the satisfaction of customary closing conditions. The Aya Merger was approved by our stockholders at a special meeting held on February 28, 2025. Following the completion of the Aya Merger, the Company will become a private company, and its common stock will no longer trade on Nasdaq. Upon the completion of the Aya Merger, the RSAs that are outstanding immediately prior to the closing of the Aya Merger, other than certain RSAs granted after March 28, 2025 (which will be forfeited upon the closing of the Aya Merger) will vest in full, and the 2023 and 2024 PSA grants that are outstanding immediately prior to the closing of the Aya Merger will be deemed vested at 50% of target, in each case contingent upon the closing of the Aya Merger. No new grants were made to date in 2025.

46<br>

------

### OTHER COMPENSATION AND BENEFITS
**Nonqualified Deferred Compensation Plans** <br>

We maintain the 2003 Deferred Compensation Plan and the 2017 Nonqualified Deferred Compensation Plan, each a non-qualified deferred compensation arrangement, intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the "Code").

Under the deferred compensation plans, designated employees, including our NEOs, may elect to defer the receipt of a portion of their annual base salary, bonus, and commission to our deferred compensation plans. We may also make a discretionary contribution to the deferred compensation plans on behalf of certain participants. Discretionary contributions to the 2003 Deferred Compensation Plan generally become vested three years from the date such contribution is made to the plan, upon the occurrence of a change in control, or upon a participant's retirement, death during employment, or disability. Discretionary contributions to the 2017 Nonqualified Deferred Compensation Plan are subject to such vesting period as determined by the Company at the time of the contribution. We did not make any discretionary contributions to the plans in Fiscal 2024. Generally, payments under the deferred compensation plans automatically commence upon a participant's retirement, termination of employment, or death during employment. Under certain limited circumstances described in the deferred compensation plans, participants may receive distributions during employment. To enable us to meet our financial commitment under the deferred compensation plans, assets may be set aside in a corporate-owned vehicle, which assets remain available to all our general creditors in the event of our insolvency. Participants of the deferred compensation plans are our unsecured general creditors with respect to the deferred compensation plan benefits.

**401(k) Plan and Other Benefits** <br>

We maintain a 401(k) plan. The plan permits eligible employees, including the NEOs, to make voluntary, pre-tax contributions to the plan, up to a specified percentage of compensation, subject to applicable tax limitations. We may make a discretionary matching contribution to the plan equal to a pre-determined percentage of an employee's voluntary, pre-tax contributions and may make an additional discretionary profit-sharing contribution to the plan, subject to applicable tax limitations. Our NEOs are eligible for matching contributions, subject to regulatory limits on contributions to 401(k) plans. Eligible employees who elect to participate in the plan are generally vested in any matching contribution after three years of service with us and fully vested at all times in their employee contributions to the plan. The plan is intended to be tax-qualified under Section 401(k) of the Code, so that contributions to the plan and income earned on plan contributions are not taxable to employees until withdrawn from the plan, and so that our contributions, if any, will be deductible by us when made.

In addition to the 401(k) plan, we provide our NEOs with the opportunity to elect health and dental coverage, company-paid group term life insurance, disability insurance, paid time off, and paid holidays programs applicable to other employees in their locality. These benefits are designed to be competitive with overall market practices and are in place to attract and retain the necessary talent in the business.

**Perquisites** <br>

Our NEOs are not entitled to any perquisites that are not otherwise available to all of our employees. Additionally, we do not provide defined benefit pension arrangements, post-retirement health coverage, or similar benefits for our executives or employees.

47<br>

------

#### **TABLE OF CONTENTS**
**Employment Agreements** <br>

#### Mr. Martins, President and Chief Executive Officer

#### 2022 Employment Agreement
On January 14, 2022, the Company appointed Mr. Martins as President and Chief Executive Officer ("CEO") and as a member of the Board effective March 31, 2022 (the "Effective Date"), and entered into a new employment agreement (the "Martins Employment Agreement") with Mr. Martins, setting forth the terms of his employment and compensation as President and CEO of the Company. The initial term (the "Initial Term") of the Martins Employment Agreement was three years, commencing on April 1, 2022 and expiring on March 31, 2025. Thereafter, the Martins Employment Agreement automatically renews for successive one-year terms, unless either party has given at least 90 days prior written notice of such party's intention not to renew the Martins Employment Agreement.

The Martins Employment Agreement provided for an initial base salary of $725,000 per annum, which was increased to $825,000 following the first anniversary of the Effective Date. In Fiscal 2023, the Board increased Mr. Martins' base salary to $875,000 to align more closely with 50th percentile market values. The Board, in consultation with the Compensation Committee, will review Mr. Martins base salary on an annual basis, and will determine, in its sole discretion, whether to increase (but not decrease) his base salary. Pursuant to the Martins Employment Agreement, Mr. Martins is eligible to participate in the Company's annual bonus plan and receive an annual incentive cash bonus with a target award opportunity equal to no less than 100% of his base salary and a maximum opportunity equal to 180% of his base salary as determined by the Compensation Committee. In addition, during the Initial Term of the Martins Employment Agreement, Mr. Martins received an annual equity award pursuant to the 2020 Plan; the target value of the annual equity award was required to be equal to 200% of his base salary for the first year and 275% of his base salary for the second and third years. Mr. Martins is also entitled to four weeks of paid vacation and is eligible to participate in all benefit plans and fringe benefit arrangements generally available to the Company's senior executives.

Pursuant to the Martins Employment Agreement, if Mr. Martins' employment is terminated by the Company without cause (as defined in the Martins Employment Agreement) or by Mr. Martins for good reason (as defined in the Martins Employment Agreement), he will be entitled to receive the following payments and benefits: (i) any unpaid base salary through the date of termination; (ii) reimbursement for unreimbursed business expenses incurred through the termination date; (iii) any unpaid bonus for the year immediately preceding the year in which such termination occurs; (iv) payment of unused vacation and sick time in accordance with the Company's policy; (iv) all other applicable payments or benefits provided for by any applicable compensation arrangement or benefit, equity, or fringe benefit plan or program; and (v) subject to his execution of a release, a severance payment equal to the sum of (a) two years of his base salary plus (b) an amount equal to two times the average actual bonus paid in the immediately prior three calendar years or, in the event Mr. Martins was not an employee during such three-year period, an amount equal to two times the bonus he would have earned during the year in which the termination occurs (but not less than two times 50% of his target bonus for the year of termination) plus, (c) payment in lieu of continued benefits elected by Mr. Martins at the time of such termination, in accordance with the Company's policies, for a period of 24 months. Additionally, any and all of Mr. Martins' unvested stock appreciation rights, restricted stock, performance share awards (at target level performance), stock options, or other equity will immediately vest upon such termination.

In the event that Mr. Martins' employment is terminated because the Company has provided notice of non-renewal of the Martins Employment Agreement, he will be entitled to receive items (i) through (iv) in the immediately preceding paragraph and, subject to his execution of a release of claims, continued payments of his base salary for a period of 18 months.

48<br>

------

#### **TABLE OF CONTENTS**
Pursuant to the Martins Employment Agreement, during Mr. Martin's employment and for a period of two years thereafter, Mr. Martins may not compete with the Company in any jurisdiction in which the Company's business is conducted nor may he intentionally interfere with the Company's relationship with any of its suppliers, customers, or employees.

Mr. Martins is entitled to participate in the Company's Executive Severance Plan Amended and Restated as of May 28, 2010 (the "Executive Severance Plan"); <u>provided</u>, <u>however</u>, that any severance payments or benefits that would become due under the Martins Employment Agreement described above, to the extent the same as the payments and benefits owed under the Executive Severance Plan, will be paid or provided to Mr. Martins on the same schedule as under the Martins Employment Agreement and any payments or benefits under the Executive Severance Plan that are in excess of payments or benefits that would be paid or provided under the Martins Employment Agreement will be paid or provided to Mr. Martins in accordance with the terms of the Executive Severance Plan. In all cases severance relating to base salary and bonuses will be paid in equal installments in accordance with the Company's payroll practices during the 24-month period following Mr. Martins' termination date.

#### Mr. Burns, Executive Vice President and Chief Financial Officer
On February 1, 2019, the Company amended its employment agreement with Mr. Burns to appoint him as its Executive Vice President and Chief Financial Officer. Mr. Burns previously served as the Company's Chief Operating Officer from January 2018 to February 2019 and as the Company's Chief Financial Officer from April 2013 to January 2018. The agreement provides for a minimum base salary of $525,000 per year, subject to annual review by the Compensation Committee. His base salary was increased to $550,000 beginning in Fiscal 2022. He is eligible to participate in the Company's annual bonus plan with a target bonus of 75% of his base salary, and 85% of his base salary beginning in Fiscal 2022, based on achieving performance goals to be established by the Compensation Committee. Per the agreement, Mr. Burns is also eligible to participate in the Company's long-term incentive plan and receive target awards valued at 125% of his base salary, increased to 150% of his base salary beginning in Fiscal 2022, based on the level of achievement of performance goals as Chief Financial Officer to be established by the Compensation Committee.

Mr. Burns is eligible to participate in the Company's equity incentive plan, as well as all benefit plans and fringe benefit arrangements available to our senior executives. If Mr. Burns' employment is terminated by the Company without cause (as defined in his employment agreement) or Mr. Burns terminates his employment for good reason (as defined in his employment agreement), and if he is not otherwise entitled to receive severance benefits under our Executive Severance Plan, subject to his execution of a release, he will be entitled to a severance payment equal to one year's base salary and health insurance benefits.

Mr. Burns is entitled to participate in the Company's Executive Severance Plan; <u>provided</u>, <u>however</u>, that if he is or becomes eligible to receive severance benefits under such plan, he will cease to be eligible for severance payments under his employment agreement described above and the Company's sole obligation will be to pay him the amounts and benefits provided in the Executive Severance Plan, subject to the terms and conditions thereof.

During Mr. Burns' employment and for a period of two years thereafter, Mr. Burns may not compete with the Company in any jurisdiction in which the Company's business is conducted, nor may he intentionally interfere with the Company's relationship with any of its suppliers, customers, or employees.

49<br>

------

#### **TABLE OF CONTENTS**

#### Ms. Ball, Executive Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary
Ms. Ball joined the Company as its Corporate Counsel pursuant to the terms and conditions of an offer letter entered into on March 18, 2002 (the "Ball Offer Letter"). The Company most recently amended the Ball Offer Letter on February 22, 2021 to increase her base salary to $430,000 and change her title to include Chief Administrative Officer. Her base salary is reviewed for increase on an annual basis by the Board or the Compensation Committee. Beginning in Fiscal 2022, her base salary was increased to $500,000. For each calendar year during the term, Ms. Ball is eligible to participate in the Company's annual bonus plan with a target bonus of 75% of her base salary, based on achieving performance goals to be established by the Compensation Committee. In addition, for each calendar year during the term, Ms. Ball is eligible to participate in the Company's long-term incentive plan and receive target awards valued at 100% of her base salary, increased to 115% of her base salary beginning in Fiscal 2022. Such awards are based upon terms and conditions determined by the Compensation Committee. Ms. Ball is also eligible to participate in all other benefit plans and fringe benefit arrangements available to the Company's senior executives.

If Ms. Ball's employment is terminated by the Company without cause (as defined in the Ball Offer Letter) or if Ms. Ball terminates her employment for good reason (as defined in the Ball Offer Letter) she will be entitled to the following payments and benefits: (i) any unpaid base salary through the date of termination; (ii) reimbursement for unreimbursed business expenses incurred through the termination date; (iii) payment of unused vacation and sick time, in accordance with the Company's policy; (iv) all other benefits under any applicable compensation arrangement or benefit, equity, or fringe benefit plan, program or grant, pursuant to the terms and conditions of such plans; and (v) continued payments of base salary in effect at the time of termination in accordance with the Company's regular payroll practices for a period of twelve months following the date of termination.

Ms. Ball is entitled to participate in the Company's Executive Severance Plan; <u>provided</u>, <u>however</u>, that if she is or becomes eligible to receive severance benefits under such plan, she will cease to be eligible for severance payments under the Ball Offer Letter described above and the Company's sole obligation will be to pay her the amounts and benefits provided in the Executive Severance Plan, subject to the terms and conditions thereof.

During Ms. Ball's employment and for a period of one year thereafter, she may not, among other things, compete with the Company in any jurisdiction in which the Company's business is conducted nor may she intentionally interfere with the Company's relationship with any of its suppliers, customers, or employees.

#### Mr. Krug, Group President
Mr. Krug joined the Company as Vice President, Advanced Practice pursuant to the terms and conditions of an offer letter entered into on March 24, 2017 (the "Krug Offer Letter"). The Company most recently amended the Krug Offer Letter on April 1, 2022, when Mr. Krug was promoted to Group President, with an increase of his annual base salary to $430,000, which is subject to annual review by the Compensation Committee. Beginning in Fiscal 2023, the Board increased Mr. Krug's base salary to $450,000 to align more closely with 50th percentile market values. Beginning in Fiscal 2023, Mr. Krug's target bonus was increased to 100% of his base salary, based on achieving performance goals to be established by the Compensation Committee. In addition, beginning in Fiscal 2023, Mr. Krug's target long-term incentive award opportunity was increased to 85% of his base salary. Such awards will be upon terms and conditions determined by the Compensation Committee. Mr. Krug is also eligible to participate in all other benefit plans and fringe benefit arrangements available to the Company's senior executives.

50<br>

------

#### **TABLE OF CONTENTS**
Mr. Krug is entitled to participate in the Company's Executive Severance Plan. During Mr. Krug's employment and for a period of one year thereafter, he may not, among other things, compete with the Company in any jurisdiction in which the Company's business is conducted nor may he intentionally interfere with the Company's relationship with any of its suppliers, customers, or employees.

#### Mr. Noe, Chief Information Officer
Mr. Noe joined the Company as Chief Information Officer pursuant to the terms and conditions of an offer letter entered into on April 5, 2021 (the "Noe Offer Letter"). Mr. Noe's annual base salary increased from $385,000 to $411,950 in March 2022, pursuant to the terms of his offer letter, and is subject to annual review by the Compensation Committee. Mr. Noe's target bonus is 50% of his base salary, based on achieving performance goals to be established by the Compensation Committee. In addition, Mr. Noe's target long-term incentive award opportunity is 50% of his base salary. Such awards will be upon terms and conditions determined by the Compensation Committee. Mr. Noe is also eligible to participate in all other benefit plans and fringe benefit arrangements available to the Company's senior executives.

Mr. Noe is entitled to participate in the Company's Executive Severance Plan. During Mr. Noe's employment and for a period of one year thereafter, he may not, among other things, compete with the Company in any jurisdiction in which the Company's business is conducted nor may he intentionally interfere with the Company's relationship with any of its suppliers, customers, or employees.

#### Mr. White, Former Chief Commercial Officer
On February 14, 2024, the Company entered into a separation agreement (the "Separation Agreement") with Mr. White. As part of the Company's commitment to growth and efficiency, the Company restructured the organization and Mr. White's position was eliminated. Mr. White continued to be employed through March 31, 2024 (the "Effective Date") and assisted with the realignment and transition of certain responsibilities pursuant to the Company's restructuring strategy. The Separation Agreement provided for continued payment of Mr. White's base salary for a period of six months following the Effective Date. Refer to the section below, "Potential Payments Upon Termination or Change in Control," for additional information regarding Mr. White's departure from the Company.

**Severance & Change of Control Arrangements** <br>

We maintain an Executive Severance Plan pursuant to which, subject to executing a release, each NEO is entitled to receive certain severance payments and benefits if, within 90 days prior to, or within 18 months after, a "Change of Control" (as defined in the Executive Severance Plan) of the Company, such NEO is terminated without cause or incurs an "involuntary termination" (i.e., a resignation for good reason). The Executive Severance Plan provides for a "double-trigger" policy, which means that (1) the "Change of Control" must occur *and* (2) the NEO must be terminated without Cause (as defined in the Executive Severance Plan) or the NEO terminates for "Good Reason" (as defined in the Executive Severance Plan).

Under the Executive Severance Plan, as of December 31, 2024, Messrs. Martins and Burns, and Ms. Ball are entitled to receive continued base salary for a period of two years following termination, plus two times the amount of their applicable target bonus for the year in which a Change of Control occurs; and Messrs. Krug and Noe are entitled to receive continued base salary for a period of one year following termination, plus one times the amount of their applicable target bonus of the year in which a Change of Control occurs. In addition, during such two or one year period, as applicable, we would continue to make group health, life, or other similar insurance plans available to such NEO and his or her dependents pursuant to the terms of our Executive Severance Plan, and we would pay for such coverage to the extent we paid for such coverage prior to the termination of employment. The severance benefits payable under the Executive Severance Plan are subject to the execution of a release and subject to reduction to avoid any excise tax on "parachute payments" if the NEO would benefit from such reduction as compared to paying the excise tax.

51<br>

------

#### **TABLE OF CONTENTS**
Under our general severance pay policy for all of our eligible employees, if an NEO (other than Messrs. Martins and Burns and Ms. Ball, whose arrangements are included in their respective employment agreements or offer letters) is terminated without Cause (as defined in our general severance pay policy) other than in connection with a Change of Control (as defined in the Executive Severance Plan), the NEO, subject to executing a release, would be entitled to one week's base salary for each full year of continuous service with us.

The Form DEFM14A, filed by the Company with the SEC on January 22, 2025, discusses potential severance and change of control benefits that the NEOs may be entitled to in connection with the completion of the Aya Merger. These benefits are consistent with our Executive Severance Plan (and the executive's employment agreement, as applicable) as described above.

**Anti-Hedging Policy** <br>

Pursuant to our Securities Compliance Policy and Securities Disclosure Compliance Agreement for Employees and Non-Employee Directors, our NEOs, directors, and employees may not buy or sell or participate in puts, calls, transferable options, or other speculative rights and obligations with respect to equity securities of the Company. In addition, our NEOs, directors, and employees may not make a "short sale" (i.e., the sale of securities that they do not own at the time of the sale or that will not be delivered for more than 20 days).

**Stock Ownership Guidelines** <br>

Under our stock ownership guidelines, our Chief Executive Officer must hold shares of Common Stock equal to three times the CEO's base salary, to be accumulated over three years, and the Company's other NEOs must hold shares of Common Stock equal to one times such NEO's base salary, to be accumulated over three years. Both unvested and fully vested RSAs and fully vested PSAs, as well as directly- and indirectly-held shares, count towards this ownership requirement. As of October 14, 2025, all currently-employed NEOs are either in compliance with our stock ownership guideline, or on track to gain compliance within such NEO's respective three-year grace period.

**Impact of Accounting and Tax Matters** <br>

As a general matter, the Compensation Committee reviews and considers the various tax and accounting implications of the compensation vehicles that we utilize. With respect to accounting matters, the Compensation Committee examines the accounting cost associated with equity compensation in light of Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 718, Compensation-Stock Compensation ("ASC Topic 718").

With respect to tax matters, the Compensation Committee considers the impact of Section 162(m) of the Code. Section 162(m) limits the income tax deduction by the Company for compensation paid to certain executive officers to $1 million per year. As a result of amendments to Section 162(m) as part of the Tax Cuts and Jobs Acts of 2017, the Company is generally no longer able to take a deduction for any compensation paid to its current or former NEOs in excess of $1 million.

**Compensation Recoupment Policy** <br>

In August 2023, the Company adopted the Compensation Recoupment Policy for executive officers (the "Recoupment Policy"), effective as of December 1, 2023, to comply with final rules under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act"), requirements of the SEC, and listing rules of the Nasdaq Stock Market. The Recoupment Policy provides for the mandatory recoupment of erroneously awarded incentive-based compensation in the event of an accounting restatement and also provides the Compensation Committee with discretion to recoup in the

52<br>

------

event of fraud or misconduct. The Recoupment Policy further strengthens the Company's risk mitigation program (as discussed below) by defining the economic consequences that misconduct has on the executive officer's incentive-based compensation. The Recoupment Policy is in addition to any other requirements that might be imposed pursuant to applicable law.

**Compensation Risk Management** <br>

Our Compensation Committee has specifically reviewed and, in consultation with Pearl Meyer, considered whether our executive compensation programs and policies create risks that are reasonably likely to have a material adverse effect on us. To avoid such risks, we design our programs in a balanced and diversified manner while also creating significant, yet appropriate, incentives for strong performance based on our business and strategic plan. In most cases, each component of our performance-based compensation program is subject to a limit on the amount paid. We believe that our compensation programs reflect a balance of short-term, long-term, fixed and performance-based compensation in order to not encourage excessive risk-taking. A significant portion of our compensation program includes performance-based compensation. We believe that this design ensures that our NEOs and other employees focus on the health of our business that will deliver stockholder value over time and discourages excess risk-taking by our NEOs and other employees. Our Recoupment Policy, anti-hedging policy, and stock ownership requirements also help to manage potential risks and promote alignment with stockholder interests. Accordingly, there were no material adjustments made to our compensation policies and practices during Fiscal 2024. We will continue to monitor our compensation policies and practices to determine whether our risk management objectives are being met with respect to incentivizing the Company's employees.

53<br>

------

### COMPENSATION COMMITTEE REPORT
The Compensation Committee of the Company has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with management and, based on such review and discussions, the Compensation Committee recommended to the Board that the Compensation Discussion and Analysis be included in the Proxy Statement.

THE COMPENSATION COMMITTEE

W. Larry Cash, Chairman

Gale Fitzgerald, Member

*THIS REPORT IS NOT SOLICITING MATERIAL, IS NOT DEEMED TO BE FILED WITH THE SEC, AND IS NOT TO BE INCORPORATED BY REFERENCE IN ANY FILING OF THE COMPANY UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, WHETHER MADE BEFORE OR AFTER THE DATE HEREOF AND IRRESPECTIVE OF ANY GENERAL INCORPORATION LANGUAGE IN ANY SUCH FILING.* 

#### POLICIES AND PRACTICES RELATED TO THE GRANT OF CERTAIN EQUITY AWARDS

#### CLOSE IN TIME TO THE RELEASE OF MATERIAL NONPUBLIC INFORMATION
The Company does not currently grant new awards of stock options, stock appreciation rights, or similar option-like instruments. Accordingly, the Company has no specific policy or practice on the timing of awards of such options in relation to the disclosure of material nonpublic information by the Company. In the event the Company determines to grant new awards of such options, the Board and the Committee will evaluate the appropriate steps to take in relation to the foregoing.

#### DETERMINATION OF NO ERRONEOUSLY AWARDED INCENTIVE-BASED COMPENSATION
As previously disclosed, the Company identified an error in the consolidated financial statements of prior periods that it concluded was not material to the previously issued financial statements. A summary of the error revisions to the impacted financial statement line items in the previously issued financial statements is set forth in Note 19 - Immaterial Financial Restatement to Prior Period Financial Statements to the Company's consolidated financial statements included in the 2024 Form 10-K. The error revisions required a recovery analysis of incentive-based compensation under the Company's Compensation Recoupment Policy. Updated results including the errors were entered into the previous calculations for bonuses and performance shares related to the applicable periods, which resulted in no change to the awarded amounts for any given year. Thus, it was determined that there was no erroneously awarded incentive-based compensation subject to recovery as a result of the errors in any given year.

54<br>

------

#### **TABLE OF CONTENTS**

#### SUMMARY COMPENSATION TABLE
The following table provides a summary of the compensation received by our NEOs for the fiscal years ended December 31, 2024, 2023, and 2022.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name and Principal** <br>**Position** | **Year** | **Salary** <br>**($)** | **Stock** <br>**Awards** <br>**($)(1)** | **Non-Equity** <br>**Incentive** <br>**Plan** <br>**Compensation**<br>**($)** | **All Other** <br>**Compensation** <br>**($)(2)** | **Total** <br>**($)**  |
| John A. Martins <br>President and Chief Executive Officer | 2024 | 875000 | 2406269 | 259875 |  | 3541144  |
| John A. Martins <br>President and Chief Executive Officer | 2023 | 869231 | 2406275 | 236250 |  | 3511756  |
| John A. Martins <br>President and Chief Executive Officer | 2022 | 646712 | 1450026 | 1189000 |  | 3285738  |
| William J. Burns EVP, <br>Chief Financial Officer | 2024 | 550205 | 825028 | 138848 |  | 1514081  |
| William J. Burns EVP, <br>Chief Financial Officer | 2023 | 550000 | 825036 | 126225 |  | 1501261  |
| William J. Burns EVP, <br>Chief Financial Officer | 2022 | 548077 | 825.020 | 766700 |  | 2139797  |
| Susan E. Ball, EVP, <br>Chief Administrative Officer, General Counsel and Secretary | 2024 | 500000 | 575004 | 111375 |  | 1186379  |
| Susan E. Ball, EVP, <br>Chief Administrative Officer, General Counsel and Secretary | 2023 | 500000 | 575008 | 101250 |  | 1176258  |
| Susan E. Ball, EVP, <br>Chief Administrative Officer, General Counsel and Secretary | 2022 | 495129 | 575035 | 615000 |  | 1685164  |
| Marc Krug <br>Group President | 2024 | 450000 | 382524 | 133650 |  | 966174  |
| Marc Krug <br>Group President | 2023 | 449231 | 382520 | 121500 |  | 953251  |
| Marc Krug <br>Group President | 2022 | 408872 | 322536 | 528900 |  | 1260308  |
| Phillip L. Noe <br>Chief Information Officer | 2024 | 411950 | 205995 | 61175 |  | 679120  |
| Daniel J. White <br>Former Chief Commercial Officer | 2024 | 121154 |  |  | 254252 | 375406  |
| Daniel J. White <br>Former Chief Commercial Officer | 2023 | 450000 | 382520 | 72000 |  | 904520  |
| Daniel J. White <br>Former Chief Commercial Officer | 2022 | 327115 | 382535 | 547940 |  | 1257590 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Amounts in this column reflect the aggregate grant date fair value of awards of RSAs and PSAs granted under the 2020 Plan and computed in accordance with ASC Topic 718 using the assumptions described in Note 14 of the notes to our consolidated financial statements contained in the 2024 Form 10-K. The aggregate grant date fair value per share of stock awards granted on March 31, 2024 was $18.72. The grant date fair value of the PSAs is based on the probable outcome of the performance conditions as of the grant date. The fair value of awards at the maximum level of achievement for the 2024 PSAs is as follows: Mr. Martins, $3,308,629; Mr. Burns, $1,134,413; Ms. Ball, $790,639; Mr. Krug, $525,976; and Mr. Noe, $283,252. Mr. White, who departed the Company on March 31, 2024 due to a restructuring that resulted in the elimination of his position, was not granted any equity awards in Fiscal 2024. Further information regarding the Fiscal 2024 awards is included in the "Grants of Plan-Based Awards" and "Outstanding Equity Awards at 2024 Year-End."

&nbsp;&nbsp;&nbsp;&nbsp;(2) During Fiscal 2024, Mr. White received $254,252 in severance compensation in accordance with the terms of his Separation Agreement.

55<br>

------

#### **TABLE OF CONTENTS**

#### GRANTS OF PLAN-BASED AWARDS
The following table summarizes equity and non-equity incentive plan awards granted to our NEOs during Fiscal 2024.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name**  | **Grant**<br>**Date** | **Committee** <br>**Action** <br>**Date** | **Estimated Future Payouts** <br>**Under Non-Equity** <br>**Incentive Plan Awards(1)** | **Estimated Future Payouts** <br>**Under Non-Equity** <br>**Incentive Plan Awards(1)** | **Estimated Future Payouts** <br>**Under Non-Equity** <br>**Incentive Plan Awards(1)** | **Estimated Future Payouts** <br>**Under Equity Incentive** <br>**Plan Awards(2)** | **Estimated Future Payouts** <br>**Under Equity Incentive** <br>**Plan Awards(2)** | **Estimated Future Payouts** <br>**Under Equity Incentive** <br>**Plan Awards(2)** | **All Other** <br>**Stock** <br>**Awards:** <br>**Number** <br>**Of** <br>**Shares** <br>**of** <br>**Stock Or** <br>**Units**<br>**(#)(3)** | **Grant** <br>**Date** <br>**Fair Value** <br>**Of Stock** <br>**Awards**<br>**($)(4)**  |
| **Name**  | **Grant**<br>**Date** | **Committee** <br>**Action** <br>**Date** | **&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**<br>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**<br>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**<br>**Threshold** <br>**($)** | **Target** <br>**($)** | **Maximum** <br>**($)** | **Threshold** <br>**(#)** | **Target** <br>**(#)** | **Maximum** <br>**(#)**  | **All Other** <br>**Stock** <br>**Awards:** <br>**Number** <br>**Of** <br>**Shares** <br>**of** <br>**Stock Or** <br>**Units**<br>**(#)(3)** | **Grant** <br>**Date** <br>**Fair Value** <br>**Of Stock** <br>**Awards**<br>**($)(4)**  |
| John A. Martins | 3/31/24 | 3/22/24 | 315000 | 875000 | 1750000 |  |  |  |  | —  |
| John A. Martins | 3/31/24 | 3/22/24 |  |  |  | 16068 | 64270 | 112473 |  | 1203134  |
| John A. Martins | 3/31/24 | 3/22/24 |  |  |  |  |  |  | 64270 | 1203134  |
| William J. Burns | 3/31/24 | 3/22/24 | 168300 | 467500 | 841500 |  |  |  |  | —  |
| William J. Burns | 3/31/24 | 3/22/24 |  |  |  | 5509 | 22036 | 38563 |  | 412514  |
| William J. Burns | 3/31/24 | 3/22/24 |  |  |  |  |  |  | 22036 | 412514  |
| Susan E. Ball | 3/31/24 | 3/22/24 | 135000 | 375000 | 675000 |  |  |  |  | —  |
| Susan E. Ball | 3/31/24 | 3/22/24 |  |  |  | 3840 | 15358 | 26877 |  | 287502  |
| Susan E. Ball | 3/31/24 | 3/22/24 |  |  |  |  |  |  | 15358 | 287502  |
| Marc Krug | 3/31/24 | 3/22/24 | 162000 | 450000 | 810000 |  |  |  |  | —  |
| Marc Krug | 3/31/24 | 3/22/24 |  |  |  | 2554 | 10217 | 17880 |  | 191262  |
| Marc Krug | 3/31/24 | 3/22/24 |  |  |  |  |  |  | 10217 | 191262  |
| Phillip L. Noe | 3/31/24 | 3/22/24 | 74151 | 205975 | 370755 |  |  |  | —  |  |
| Phillip L. Noe | 3/31/24 | 3/22/24 |  |  |  | 1376 | 5502 | 9629 |  | 102997  |
| Phillip L. Noe | 3/31/24 | 3/22/24 |  |  |  |  |  |  | 5502 | 102997  |
| Daniel J. White (5) |  |  |  |  |  |  |  |  |  | —  |
| Daniel J. White (5) |  |  |  |  |  |  |  |  |  | —  |
| Daniel J. White (5) |  |  |  |  |  |  |  |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Constitutes threshold, target, and maximum award opportunities for our NEOs under the Company's Annual Cash Incentive Program, as described in the Compensation Discussion and Analysis section.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Constitutes threshold, target, and maximum number of shares related to the PSAs granted to the NEOs for Fiscal 2024. PSAs have a three-year performance period ending on December 31, 2026. The PSAs provide for the issuance of a number of shares after the three-year performance period based on the level of attainment of cumulative Adjusted EBITDA (a non-GAAP financial measure) (weighted 75%) and cumulative Adjusted EPS (a non-GAAP financial measure) (weighted 25%) at the end of the three-year period, as discussed in the Compensation Discussion and Analysis section.

&nbsp;&nbsp;&nbsp;&nbsp;(3) All other stock awards include RSAs granted to the NEOs for Fiscal 2024, as described in the Compensation Discussion and Analysis section.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Grant date fair value of each equity award is computed in accordance with ASC Topic 718. The grant date fair value of the PSAs is based on the probable outcome of the performance conditions as of the grant date. Refer to the footnotes to the Summary Compensation Table.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Mr. White did not receive any equity awards during Fiscal 2024, nor did he participate in the Company's Annual Cash Incentive Program.

56<br>

------

#### **TABLE OF CONTENTS**

#### OUTSTANDING EQUITY AWARDS AT 2024 YEAR-END
The following table summarizes the outstanding equity awards as of December 31, 2024 held by our NEOs.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Grant** <br>**Date** | **Stock Awards**  | **Stock Awards**  | **Stock Awards**  | **Stock Awards**  |
| **Name** | **Grant** <br>**Date** | **Number of**<br>**Shares or**<br>**Units of**<br>**Stock That**<br>**Have Not**<br>**Vested**<br>**(#)(1)(2)** | **Market**<br>**Value of**<br>**Shares**<br>**or Units**<br>**of Stock**<br>**That**<br>**Have Not**<br>**Vested**<br>**($)(2)** | **Equity**<br>**Incentive Plan**<br>**Awards:**<br>**Number of**<br>**Unearned**<br>**Shares, Units**<br>**or Other**<br>**Rights That**<br>**Have Not**<br>**Vested**<br>**(#)(1)(3)** | **Equity**<br>**Incentive**<br>**Plan**<br>**Awards:**<br>**Market or**<br>**Payout Value**<br>**of Unearned** <br>**Shares, Units**<br>**or Other**<br>**Rights That**<br>**Have Not**<br>**Vested**<br>**($)(3)**  |
| John A. Martins | 3/31/22 | 36411 | 661224 |  | —  |
| John A. Martins | 3/31/23 | 35392 | 652525 | 53904 | 978897  |
| John A. Martins | 3/31/24 | 64270 | 1167143 | 64270 | 1167143  |
| William J. Burns | 3/31/22 | 20716 | 376203 |  | —  |
| William J. Burns | 3/31/23 | 12320 | 223731 | 18842 | 335633  |
| William J. Burns | 3/31/24 | 22036 | 400174 | 22036 | 400174  |
| Susan E. Ball | 3/31/22 | 14439 | 262212 |  | —  |
| Susan E. Ball | 3/31/23 | 8586 | 155922 | 12881 | 233919  |
| Susan E. Ball | 3/31/24 | 15358 | 278901 | 15358 | 278901  |
| Marc Krug | 3/31/22 | 8098 | 147060 |  | —  |
| Marc Krug | 3/31/23 | 5712 | 103730 | 8569 | 155613  |
| Marc Krug | 3/31/24 | 10217 | 185541 | 10217 | 185541  |
| Phillip L. Noe  | 3/31/22 | 5172 | 93924 |  | —  |
| Phillip L. Noe  | 3/31/23 | 3076 | 55860 | 4615 | 83808  |
| Phillip L. Noe  | 3/31/24 | 5502 | 99916 | 5502 | 99916  |
| Daniel J. White (4) | 4/18/22 |  |  |  | —  |
| Daniel J. White (4) | 3/31/23 |  |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) RSA awards granted to the NEOs vest in three equal installments on the anniversary of the grant date, provided that the NEO continues to be employed with us through each vesting date. PSA awards, if earned, provide for the issuance of a number of shares after the three-year performance period (at which time the performance condition is deemed to be achieved), with the underlying shares vesting and paid out on the third anniversary of the grant date.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Awards in this column include RSAs that were granted in Fiscal 2022, Fiscal 2023, and Fiscal 2024, and the PSAs that were granted in Fiscal 2022, which are deemed to be earned because the performance condition was achieved as of December 31, 2024, but that had not yet vested and paid out as of that date. The market value of the shares in this column is measured by reference to the Company's closing stock price as of December 31, 2024 of $18.16. Fiscal 2022 PSAs were earned and vested at 75.5% of target levels.

57<br>

------

#### **TABLE OF CONTENTS**
&nbsp;&nbsp;&nbsp;&nbsp;(3) Awards in this column include PSAs granted in Fiscal 2023 and Fiscal 2024, for which the performance period will lapse as of December 31, 2025 and December 31, 2026, respectively. The market value of the shares in this column is measured by reference to the Company's closing stock price as of December 31, 2024 of $18.16. The amounts reflected in this column assume that all goals under the PSAs will be achieved at the target level. The amounts indicated are not necessarily indicative of the amounts that may be realized by our NEOs.

&nbsp;&nbsp;&nbsp;&nbsp;(4) In connection with his departure from the Company on March 31, 2024, Mr. White forfeited all outstanding, unvested equity awards.

#### OPTION EXERCISES AND STOCK VESTED IN 2024

---

| | | |
|:---|:---|:---|
|  | **Stock Awards**  | **Stock Awards**  |
| **Name** | **Number of**<br>**Shares Acquired**<br>**on Vesting**<br>**(#)** | **Value Realized**<br>**on Vesting**<br>**($)(1)**  |
| John A. Martins | 43845 | 820778  |
| William J. Burns | 42463 | 794907  |
| Susan E. Ball | 28345 | 530618  |
| Marc Krug | 17813 | 322849  |
| Phillip L. Noe | 9522 | 169038  |
| Daniel J. White | 6002 | 112357 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Value realized upon vesting of the stock awards represents the total number of shares vested multiplied by the closing price on the vesting date.

#### NONQUALIFIED DEFERRED COMPENSATION 2024

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Executive**<br>**Contribution**<br>**in Last FY** <br>**($)(a)(1)** | **Registrants** <br>**Contributions** <br>**in Last FY** <br>**($)(b)** | **Aggregate** <br>**Earnings in**<br>**Last FY** <br>**($)(c)** | **Aggregate** <br>**Withdrawals/** <br>**Distributions** <br>**($)(d)(2)** | **Aggregate** <br>**Balance at** <br>**Last FYE** <br>**($)(e)(3)**  |
| John A. Martins |  |  |  |  | —  |
| William J. Burns |  |  |  |  | —  |
| Susan E. Ball |  |  |  |  | —  |
| Marc Krug |  |  |  |  | —  |
| Phillip L. Noe |  |  |  |  | —  |
| Daniel J. White | 96231 |  | 8739 | 200770 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes aggregate deferred cash compensation in Fiscal 2024, and is included in the NEO's compensation for 2024 as reflected in the Summary of Compensation Table.

&nbsp;&nbsp;&nbsp;&nbsp;(2) During Fiscal 2024, as a result of the elimination of his position, Mr. White received a nonqualified deferred compensation distribution.

&nbsp;&nbsp;&nbsp;&nbsp;(3) A description of the Nonqualified Deferred Compensation Plans is set forth in the Compensation Discussion and Analysis section.

**Potential Payments Upon Termination or Change in Control** <br>

The tables below describe and estimate the amounts and benefits that our NEOs, except with respect to Mr. White, would have been entitled to receive upon a change of control or a termination of their employment in certain circumstances, assuming such events occurred as of December 31, 2024 (based on the plans and arrangements in effect on such date). Where applicable, the amounts payable assume an $18.16 fair value of our Common Stock (the closing price on December 31, 2024). The estimated payments

58<br>

------

#### **TABLE OF CONTENTS**
are not necessarily indicative of the actual amounts any of our NEOs would have received in such circumstances. The tables exclude (i) compensation amounts accrued through December 31, 2024 that would be paid in the normal course of continued employment, such as accrued but unpaid salary and (ii) vested account balances under our retirement plans that are generally available to all of our salaried employees.

As discussed above, on February 14, 2024, the Company entered into the Separation Agreement with Mr. White, whose position was eliminated effective March 31, 2024 as part of our corporate restructuring. Accordingly, the amounts set forth below for Mr. White represent the actual amounts that he received in connection with the termination of his employment.

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***John A. Martins:*** | **Non-Change**<br>**of Control**<br>**Termination**<br>**without Cause**<br>**($)(1)** | **Termination**<br>**for Cause or**<br>**Resignation**<br>**($)** | **Change of**<br>**Control**<br>**Termination**<br>**without**<br>**Cause or for**<br>**Good Reason**<br>**($)** | **Change of**<br>**Control**<br>**without**<br>**Termination**<br>**($)**  |
| Cash Payment | 3500000(2) |  | 3500000(2) | —  |
| Health and Life Insurance Benefits | 51234(3) |  | 51234(3) | —  |
| Acceleration of Equity Awards | 4626932(4) |  | 4626932(4) | 4626932(4)  |
| **Total Termination Benefits:** | 8178166 |  | 8178166 | 4626932 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***William J. Burns:*** | **Non-Change**<br>**of Control**<br>**Termination**<br>**without Cause**<br>**($)(1)** | **Termination**<br>**for Cause or**<br>**Resignation**<br>**($)** | **Change of**<br>**Control**<br>**Termination**<br>**without**<br>**Cause or for**<br>**Good Reason**<br>**($)** | **Change of**<br>**Control**<br>**without**<br>**Termination**<br>**($)**  |
| Cash Payment | 550000(5) |  | 2035000(2) | —  |
| Health and Life Insurance Benefits | 25617(5) |  | 51234(3) | —  |
| Acceleration of Equity Awards |  |  | 1735914(4) | 1735914(4)  |
| **Total Termination Benefits:** | 575617 |  | 3822148 | 1735914 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***Susan E. Ball:*** | **Non-Change**<br>**of Control**<br>**Termination**<br>**without Cause**<br>**($)(1)** | **Termination**<br>**for Cause or**<br>**Resignation**<br>**($)(6)** | **Change of**<br>**Control**<br>**Termination**<br>**without**<br>**Cause or for**<br>**Good Reason**<br>**($)(7)(8)** | **Change of**<br>**Control**<br>**without**<br>**Termination**<br>**($)**  |
| Cash Payment | 500000(10) |  | 1750000(2) | —  |
| Health and Life Insurance Benefits |  |  | 37756(3) | —  |
| Acceleration of Equity Awards |  |  | 1209856(4) | 1209856(4)  |
| **Total Termination Benefits:** | 500000 |  | 2997612 | 1209856 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***Marc Krug:*** | **Non-Change**<br>**of Control**<br>**Termination**<br>**without Cause**<br>**($)(1)** | **Termination**<br>**for Cause or**<br>**Resignation**<br>**($)(6)** | **Change of**<br>**Control**<br>**Termination**<br>**without**<br>**Cause or for**<br>**Good Reason**<br>**($)(7)(8)** | **Change of**<br>**Control**<br>**without**<br>**Termination**<br>**($)**  |
| Cash Payment | 60577(9) |  | 900000(11) | —  |
| Health and Life Insurance Benefits |  |  | 25576(12) | —  |
| Acceleration of Equity Awards |  |  | 777484(4) | 777484(4)  |
| **Total Termination Benefits:** | 60577 |  | 1703060 | 777484 |

---

59<br>

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***Phillip L. Noe:*** | **Non-Change**<br>**of Control**<br>**Termination**<br>**without Cause**<br>**($)(1)** | **Termination**<br>**for Cause or**<br>**Resignation**<br>**($)(6)** | **Change of**<br>**Control**<br>**Termination**<br>**without**<br>**Cause or for**<br>**Good Reason**<br>**($)(7)(8)** | **Change of**<br>**Control**<br>**without**<br>**Termination**<br>**($)**  |
| Cash Payment | 23766(9) |  | 617925(11) | —  |
| Health and Life Insurance Benefits |  |  | 25545(12) | —  |
| Acceleration of Equity Awards |  |  | 433425(4) | 433425(4)  |
| **Total Termination Benefits:** | 23766 |  | 1076895 | 433425 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***Daniel J. White:*** | **Non-Change**<br>**of Control**<br>**Termination**<br>**without Cause**<br>**($)(1)** | **Termination**<br>**for Cause or**<br>**Resignation**<br>**($)** | **Change of**<br>**Control**<br>**Termination**<br>**without**<br>**Cause or for**<br>**Good Reason**<br>**($)** | **Change of**<br>**Control**<br>**without**<br>**Termination**<br>**($)**  |
| Cash Payment | 225000(13) |  |  | —  |
| Health and Life Insurance Benefits |  |  |  | —  |
| Acceleration of Equity Awards |  |  |  | —  |
| **Total Termination Benefits:** | 225000 |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) "Cause" is generally defined under Mr. Martin's employment agreement as: (i) an act or acts of fraud or dishonesty which results in the personal enrichment of him or another person or entity at the expense of the Company; (ii) his admission, confession, pleading of guilty or nolo contendere to, or conviction of (x) any felony (other than third degree vehicular infractions), or (y) of any other crime or offense involving misuse or misappropriation of money or other property; (iii) his knowing, intentional, and material breach of the Company's Code of Conduct for Senior Officers; or (iv) his gross negligence or willful misconduct with respect to his duties that results in material harm to the Company.

"Cause" is generally defined under Mr. Burns' employment agreement as: (i) an act or acts of fraud or dishonesty which results in the personal enrichment of him or another person or entity at the expense of the Company; (ii) admission, confession, pleading of guilty or nolo contendere to, or conviction of (x) any felony (other than third degree vehicular infractions), or (y) of any other crime or offense involving misuse or misappropriation of money or other property; (iii) continued material breach of the Company's Code of Conduct or any obligations under the employment agreement for 30 days after the Company has given notice thereof in reasonable detail, if such breach has not been cured by him during such period; or (iv) gross negligence or willful misconduct with respect to his duties or gross misfeasance of office.

"Cause" is generally defined under Ms. Ball's, Mr. Krug's, Mr. Noe's, and Mr. White's offer letters as: (i) an act or acts of fraud or dishonesty which results in the personal enrichment of him/her or another person or entity at the expense of the Company; (ii) pleading of guilty or nolo contendere to, or conviction of (x) any felony (other than third degree vehicular infractions), or (y) of any other crime or offense involving misuse or misappropriation of money or other property; (iii) knowing, intentional, and material breach of the Company's Code of Conduct for Senior Officers; or (iv) gross negligence or willful misconduct with respect to his or her duties or gross misfeasance of office that results in material harm to the Company.

"Good Reason" is generally defined under Mr. Martin's employment agreement as, without his written consent, the occurrence of any of the following events that are not cured by the Company within 30 days of written notice specifying the occurrence of such Good Reason event, which notice will be given to the Company within 90 days after the occurrence of the Good Reason event: (i) a material diminution in his

60<br>

------

then authority, duties, or responsibilities; (ii) a material diminution in his compensation components; (iii) a relocation of his principal business location to a location more than 25 miles outside of Boca Raton, Florida; or (iv) any material breach of the employment agreement by the Company.

"Good Reason" is generally defined under Mr. Burns' employment agreement as, without his written consent, the occurrence of any of the following events that are not cured by the Company within 30 days of written notice specifying the occurrence of such Good Reason event, which notice will be given to the Company within 90 days after the occurrence of the Good Reason event: (i) a material diminution in his then authority, duties, or responsibilities; (ii) a material diminution in his base salary; (iii) a relocation of his principal business location to a location more than 50 miles outside of Boca Raton, Florida; or (iv) any material breach of the employment agreement by the Company.

"Good Reason" is generally defined under Ms. Ball's, Mr. Krug's, Mr. Noe's and Mr. White's offer letters as, without his or her written consent, the occurrence of any of the following events that are not cured by the Company within 30 days of written notice specifying the occurrence of such Good Reason event, which notice will be given to the Company within 90 days after the occurrence of the Good Reason event: (i) a material diminution in his or her then authority, duties or responsibilities or assignment of duties that are inconsistent with his or her status, title or position; (ii) a material diminution in his or her base salary or other compensation components; (iii) a relocation of his or her principal business location to a location more than 50 miles outside of Boca Raton, Florida; or (iv) any material breach of the employment agreement by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Represents two times the sum of base salary and target bonus. The severance benefits payable under the Executive Severance Plan are subject to reduction to avoid any excise tax on "parachute payments" if the NEO would benefit from such reduction as compared to paying the excise tax. Severance payments are paid pro-rata over one year in accordance with the Company's normal payroll practices starting 60 days after separation from service.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Represents two years of continued health and life insurance benefits, paid in accordance with the Company's normal practices.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Represents the value of unvested restricted stock (RSAs) that would accelerate and vest on a change in control (as defined in the 2024 Omnibus Incentive Plan). The value is calculated by multiplying the number of shares of restricted stock (RSAs) that accelerate by the per share closing price of the Common Stock on December 31, 2024 of $18.16. Awards issued on or after June 20, 2014, including performance-based share awards (PSAs), do not vest on change in control except at the discretion of the Compensation Committee. The above table assumes that all RSA awards will vest upon a change in control. Under Mr. Martins' employment agreements, awards will also vest upon a non-change of control termination without cause.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Represents the sum of one year base salary and one year of benefits for Mr. Burns, paid pro-rata over one year in accordance with the Company's normal payroll practices.

&nbsp;&nbsp;&nbsp;&nbsp;(6) "Cause" is generally defined under our Executive Severance Plan as: (i) an NEO engaging in actions that are injurious to us (monetarily or otherwise) or (ii) an NEO's conviction for any felony or any criminal violation involving dishonesty or fraud.

&nbsp;&nbsp;&nbsp;&nbsp;(7) Under the Executive Severance Plan, "cause" is as defined under an NEO's employment agreement with us, but (i) if the NEO does not have an employment agreement with us that defines "cause," then "cause" is defined as termination due to an NEO's insubordination, dishonesty, fraud, incompetence, moral turpitude, misconduct, refusal to perform his or her duties or responsibilities for any reason other than illness or incapacity, or materially unsatisfactory performance of his or her duties for us or an affiliate as determined by the Compensation Committee in its sole discretion; or (ii) in the case where there is an employment agreement, or similar agreement, in effect between us or an affiliate and the NEO at the termination date that defines "cause" (or words of like import), "cause" as defined under such agreement; provided, however, that with regard to any agreement that conditions "cause" on

61<br>

------

occurrence of a change of control, such definition of "cause" shall not apply until a change of control actually takes place and then only with regard to a termination thereafter. Notwithstanding the foregoing, an NEO shall be deemed to be terminated for "Cause" if the NEO: (i) breaches the terms of any agreement between the Company or an affiliate and the NEO including, without limitation, an employment agreement or non-competition agreement or (ii) discloses to anyone outside of the Company or its affiliates, or uses in other than the Company's or its affiliates' business, without written authorization from the Company, any confidential information or proprietary information relating to the business of the Company or its affiliates acquired by the NEO prior to the termination date.

&nbsp;&nbsp;&nbsp;&nbsp;(8) "Good reason" (called an "involuntary termination" under the Executive Severance Plan) is generally defined under the Executive Severance Plan as: (i) without the employee's express written consent, a significant reduction of the employee's duties, position or responsibilities relative to the NEO's duties, position or responsibilities in effect immediately prior to such reduction, or the removal of the NEO from such position, duties, and responsibilities, unless the NEO is provided with comparable duties, position and responsibilities; provided, however, that a reduction in duties, position, or responsibilities solely by virtue of the Company being acquired and made part of a larger entity shall not constitute an "Involuntary Termination"; (ii) a reduction by the Company of the NEO's base salary as in effect immediately prior to such reduction; (iii) a material reduction by the Company in the kind or level of employee benefits to which the NEO is entitled immediately prior to such reduction with the result that the NEO's overall benefits package is materially reduced (unless such reduction is applicable to all employees); or (iv) without the NEO's express written consent, the relocation of the NEO to a facility or a location more than 35 miles from his or her current location.

&nbsp;&nbsp;&nbsp;&nbsp;(9) Represents one week of base salary for each full year of continuous service with us.

&nbsp;&nbsp;&nbsp;&nbsp;(10) Represents one year of base salary for Ms. Ball, paid pro-rata over one year in accordance with the Company's normal payroll practices.

&nbsp;&nbsp;&nbsp;&nbsp;(11) Represents the sum of one year of base salary plus target bonus, paid pro-rata over one year in accordance with the Company's normal payroll practices. The severance benefits payable under the Executive Severance Plan are subject to reduction to avoid any excise tax on "parachute payments" if the NEO would benefit from such reduction as compared to paying the excise tax.

&nbsp;&nbsp;&nbsp;&nbsp;(12) Represents one year of continued health and life insurance benefits, paid in accordance with the Company's normal practices.

&nbsp;&nbsp;&nbsp;&nbsp;(13) Represents six months of base salary for Mr. White, whose position was eliminated effective March 31, 2024 as part of our corporate restructuring, paid in accordance with his Separation Agreement.

**CEO Pay Ratio** <br>

As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, we are providing the following information about the relationship of the annual total compensation of the individual identified as our "median" paid employee and the annual total compensation of John A. Martins, our President and Chief Executive Officer.

For purposes of determining our pay ratio for Fiscal 2024, the annual total compensation of our median employee (excluding our PEO) was $27,384 and the total compensation of our PEO was $3,541,144. Based on this information, the ratio of the annual total compensation of our PEO to that of our median employee for Fiscal 2024 was 129 to 1.

The methodology and material assumptions, adjustments, and estimates used to identify our median employee for this purpose were as follows:

We determined that, as of December 31, 2024, our employee population, including our full-time, part-time, and temporary employees, consisted of approximately 10,113 individuals, with 9,543 of these individuals located in the U.S. and 570 individuals located outside the U.S. Under SEC rules, which provide

62<br>

------

an exemption for a de minimis number of employees located outside of the U.S., we excluded 570 employees located in India from this employee population. For purposes of determining our pay ratio, our designated employee population included a total of 9,543 U.S. employees and 0 non-U.S. employees.

To identify the median employee, we used total cash compensation as our consistently applied compensation measure. For new employees, who were hired in Fiscal 2024 but did not work for the Company for the entire fiscal year, compensation was annualized for the full year and compensation for part-time employees was annualized but not converted into a full-time equivalent. We did not make any cost-of-living adjustments in identifying the median employee. Using this methodology, we determined our new median employee based on the actual cash compensation, consisting of salary, overtime pay, bonus and commissions, and other cash earnings, paid to each employee in the identified employee population for the period from January 1, 2024 through December 31, 2024.

Once we identified our median employee, the employee's total compensation for 2024 was determined in accordance with Item 402(c)(2)(x) of Regulation S-K, resulting in the annual total compensation amount reported above. With respect to our PEO's annual total compensation, we used the amount reported in the Total column in the Summary Compensation Table of this Proxy Statement.

We believe the above pay ratio disclosure is a reasonable estimate calculated in a manner consistent with SEC rules and guidance; however, due to the flexible approaches permitted in calculating the PEO pay ratio, comparisons among companies may not be very meaningful.

63<br>

------

**Pay versus Performance** <br>

As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation actually paid and the Company's financial performance for the fiscal years listed below. You should refer to our Compensation Discussion and Analysis ("CD&A") for a complete description of how executive compensation relates to Company performance and how the Compensation Committee makes its decisions.

The following table discloses information on "compensation actually paid" ("CAP") to our principal executive officers ("PEOs") and to our other NEOs on an average basis ("non-PEO NEOs") during the specified years alongside total shareholder return ("TSR") and net income metrics, as well as a Company-selected measure of Adjusted EBITDA, which is a non-GAAP measure. See Annex A of this Proxy Statement for a reconciliation of non-GAAP financial measures to our results as reported under GAAP.

The Company believes that Adjusted EBITDA is the most important financial metric in linking actual incentives earned by our NEOs to Company performance. The majority (60%) of target annual cash incentive award opportunities for our NEOs are tied to Adjusted EBITDA goals. The PSAs granted to the NEOs in Fiscal 2024 provided for the issuance of shares based on the level of attainment of cumulative Adjusted EBITDA over a three-year performance period (weighted 75%) and cumulative Adjusted EPS over the three-year performance period (a non-GAAP financial measure) (weighted 25%).

Pursuant to SEC rules, the TSR figures assume an initial investment of $100 on December 31, 2019. As permitted by SEC rules, the peer group referenced for purposes of the TSR comparison is the group of companies included in the Dow Jones US Business Training & Employment Agencies Index, which is the industry peer group used for purposes of Item 201(e) of Regulation S-K.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  |  | **Value of Initial Fixed $100** <br>**Investment Based On:** | **Value of Initial Fixed $100** <br>**Investment Based On:** | **Value of Initial Fixed $100** <br>**Investment Based On:** |  |  |
| **Year** <br>(a) | **Summary** <br>**Compensation** <br>**Table Total** <br>**for PEO –** <br>**Clark** <br>**($)(b)** | **Summary** <br>**Compensation** <br>**Table Total** <br>**for PEO –** <br>**Martins** <br>**($)(b)** | **Compensation** <br>**Actually** <br>**Paid to** <br>**PEO –** <br>**Clark** <br>**($)(c)** | **Compensation** <br>**Actually** <br>**Paid to** <br>**PEO –** <br>**Martins** <br>**($)(c)** | **Average** <br>**Summary** <br>**Compensation** <br>**Table** <br>**Total for** <br>**Non-PEO** <br>**NEOs** <br>**($)(d)(1)** | **Average** <br>**Compensation** <br>**Actually** <br>**Paid to** <br>**Non-PEO** <br>**NEOs** <br>**($)(e)(1)** | **Total** <br>**Share** <br>**holder** <br>**Return** <br>**($)(f))** | **Peer Group** <br>**Total** <br>**Shareholder** <br>**Return** <br>**($)(g)** | **Net Income** <br>**($)(h)** | **Company** <br>**Selected** <br>**Measure** <br>**Adjusted** <br>**EBITDA** <br>**($)(i)**  |
| 2024(2) | N/A | 3541144 | N/A | 1466865 | 944232 | 440337 | 156.28 | 91.71 | (14556062) | 49073400  |
| 2023(3) | N/A | 3511756 | N/A | 1516035 | 1133823 | 335914 | 196.70 | 95.97 | 72630799 | 144420693  |
| 2022(4) | 483840 | 3285738 | (1659783) | 4131136 | 1585715 | 1636920 | 230.84 | 97.12 | 188460809 | 301716323  |
| 2021(5) | 4446758 | N/A | 17863020 | N/A | 1446211 | 3577462 | 240.83 | 142.34 | 132002036 | 162053021  |
| 2020(6) | 4126562 | N/A | 3401723 | N/A | 1311344 | 1138485 | 77.06 | 105.21 | (12961764) | 36321949 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The following non-PEO NEOs are included in the average figures shown in columns (d) and (e):

2024: William J. Burns, Susan E. Ball, Marc Krug, Phillip L. Noe, and Daniel J. White

2022 and 2023: William J. Burns, Susan E. Ball, Daniel J. White, and Marc Krug

2021: John A. Martins, William J. Burns, Susan E. Ball, and Buffy S. White

2020: William J. Burns, Susan E. Ball, Stephen A. Saville, and Buffy S. White

64<br>

------

The methodology for calculating amounts presented in the columns "Compensation Actually Paid to PEO" and "Average Compensation Actually Paid to Non-PEO NEOs," including details regarding the amounts that were deducted from, and added to, the Summary Compensation Table totals to arrive at the values presented for CAP, are provided in the below footnotes to the table.

---

| | | |
|:---|:---|:---|
| **Note (2) - 2024 Adjustments** | **PEO - Martins**<br>**($)** | **Average**<br>**non-PEO NEOs**<br>**($)**  |
| Deductions for Amounts Reported under the "Stock Awards" and "Option Awards" Columns in the Summary Compensation Table for Applicable FY | (2406269) | (397710)  |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End | 1167143 | 192906  |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date |  | —  |
| Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End | (663279) | (129491)  |
| Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date | (171874) | (85614)  |
| Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End |  | (83986)  |
| Increase based on Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date |  | —  |
| Increase based on Incremental Fair Value of Options/SARs Modified during Applicable FY |  | —  |
| Deduction for Change in the Actuarial Present Values reported under the "Change in Pension Value and Nonqualified Deferred Compensation Earnings" Column of the Summary Compensation Table for Applicable FY |  | —  |
| Increase for Service Cost and, if applicable, Prior Service Cost for Pension Plans |  | —  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Adjustments | (2074279) | (503895)  |
| Summary Compensation Table Total | 3541144 | —  |
| Average Summary Compensation Table Total |  | 944232  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation Actually Paid | 1466865 | —  |
| &nbsp;&nbsp;&nbsp;&nbsp;Average Compensation Actually Paid |  | 440337 |

---

65<br>

------

---

| | | |
|:---|:---|:---|
| **Note (3) - 2023 Adjustments** | **PEO - Martins**<br>**($)** | **Average**<br>**non-PEO NEOs**<br>**($)**  |
| Deductions for Amounts Reported under the "Stock Awards" and "Option Awards" Columns in the Summary Compensation Table for Applicable FY | (2406275) | (541271)  |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End | 1525483 | 343145  |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date |  | —  |
| Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End | (1043746) | (447151)  |
| Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date | (71183) | (152632)  |
| Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End |  | —  |
| Increase based on Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date |  | —  |
| Increase based on Incremental Fair Value of Options/SARs Modified during Applicable FY |  | —  |
| Deduction for Change in the Actuarial Present Values reported under the "Change in Pension Value and Nonqualified Deferred Compensation Earnings" Column of the Summary Compensation Table for Applicable FY |  | —  |
| Increase for Service Cost and, if applicable, Prior Service Cost for Pension Plans |  | —  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Adjustments | (1995721) | (797909)  |
| Summary Compensation Table Total | 3511756 | —  |
| Average Summary Compensation Table Total |  | 1133823  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation Actually Paid | 1516035 | —  |
| &nbsp;&nbsp;&nbsp;&nbsp;Average Compensation Actually Paid |  | 335914 |

---

66<br>

------

---

| | | | |
|:---|:---|:---|:---|
| **Note (4) - 2022 Adjustments** | **PEO - Clark**<br>**($)** | **PEO - Martins**<br>**($)** | **Average** <br>**non-PEO NEOs**<br>**($)**  |
| Deductions for Amounts Reported under the "Stock Awards" and "Option Awards" Columns in the Summary Compensation Table for Applicable FY | (125009) | (1450026) | (526282)  |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End | 191331 | 2355724 | 865732  |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date |  |  | —  |
| Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End | (433563) | (26220) | (59505)  |
| Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date | (1776382) | (34080) | (228740)  |
| Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End |  |  | —  |
| Increase based on Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date |  |  | —  |
| Increase based on Incremental Fair Value of Options/SARs Modified during Applicable FY |  |  | —  |
| Deduction for Change in the Actuarial Present Values reported under the "Change in Pension Value and Nonqualified Deferred Compensation Earnings" Column of the Summary Compensation Table for Applicable FY |  |  | —  |
| Increase for Service Cost and, if applicable, Prior Service Cost for Pension Plans |  |  | —  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Adjustments | (2143623) | 845398 | 51205  |
| Summary Compensation Table Total | 483840 | 3285738 | —  |
| Average Summary Compensation Table Total |  |  | 1585715  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation Actually Paid | (1659783) | 4131136 | —  |
| &nbsp;&nbsp;&nbsp;&nbsp;Average Compensation Actually Paid |  |  | 1636920 |

---

67<br>

------

---

| | | |
|:---|:---|:---|
| **Note (5) - 2021 Adjustments** | **PEO - Clark**<br>**($)** | **Average**<br>**non-PEO NEOs**<br>**($)**  |
| Deductions for Amounts Reported under the "Stock Awards" and "Option Awards" Columns in the Summary Compensation Table for Applicable FY | (2268758) | (432826)  |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End | 5395467 | 1029328  |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date |  | —  |
| Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End | 9726542 | 1434406  |
| Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date | 563011 | 100343  |
| Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End |  | —  |
| Increase based on Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date |  | —  |
| Increase based on Incremental Fair Value of Options/SARs Modified during Applicable FY |  | —  |
| Deduction for Change in the Actuarial Present Values reported under the "Change in Pension Value and Nonqualified Deferred Compensation Earnings" Column of the Summary Compensation Table for Applicable FY |  | —  |
| Increase for Service Cost and, if applicable, Prior Service Cost for Pension Plans |  | —  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Adjustments | 13416262 | 2131251  |
| Summary Compensation Table Total | 4446758 | —  |
| Average Summary Compensation Table Total |  | 1446211  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation Actually Paid | 17863020 | —  |
| &nbsp;&nbsp;&nbsp;&nbsp;Average Compensation Actually Paid |  | 3577462 |

---

68<br>

------

---

| | | |
|:---|:---|:---|
| **Note (6) - 2020 Adjustments** | **PEO - Clark**<br>**($)** | **Average**<br>**non-PEO NEOs**<br>**($)**  |
| Deductions for Amounts Reported under the "Stock Awards" and "Option Awards" Columns in the Summary Compensation Table for Applicable FY | (2268758) | (430320)  |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End | 2558209 | 485221  |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date |  | —  |
| Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End | (620484) | (119689)  |
| Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date | (393806) | (108071)  |
| Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End |  | —  |
| Increase based on Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date |  | —  |
| Increase based on Incremental Fair Value of Options/SARs Modified during Applicable FY |  | —  |
| Deduction for Change in the Actuarial Present Values reported under the "Change in Pension Value and Nonqualified Deferred Compensation Earnings" Column of the Summary Compensation Table for Applicable FY |  | —  |
| Increase for Service Cost and, if applicable, Prior Service Cost for Pension Plans |  | —  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Adjustments | (724839) | (172859)  |
| Summary Compensation Table Total | 4126562 | —  |
| Average Summary Compensation Table Total |  | 1311344  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation Actually Paid | 3401723 | —  |
| &nbsp;&nbsp;&nbsp;&nbsp;Average Compensation Actually Paid |  | 1138485 |

---

As required, below is an unranked list of the most important measures used by the Company to link compensation actually paid to all our NEOs, including the PEO, to Company performance for Fiscal 2024. For further information regarding these performance metrics and their function in our executive compensation program, please see "Compensation Discussion and Analysis."

**2024 Most Important Measures (Unranked)** <br>

Revenue

Adjusted EBITDA

Adjusted EPS

**Relationship between "Compensation Actually Paid" and Performance Measures** <br>

The charts below show, for the past five years, the relationship of the Company's TSR relative to its peers as well as the relationship between the PEO and non-PEO CAP and (i) the Company's TSR; (ii) the Company's net (loss) income; and (iii) the Company's Adjusted EBITDA.

CAP, as required under SEC rules, reflects adjusted values to unvested and vested equity awards during the years shown in the table based on year-end stock prices, various accounting valuation assumptions, and projected performance modifiers but does not reflect actual amounts paid under those awards. CAP generally fluctuates due to stock price achievement and varying levels of projected and actual achievement of performance goals (as reflected in the significant increase to 2021 CAP). For a discussion of

69<br>

------

how our Compensation Committee assessed our performance and our NEOs' pay each year, see "Compensation Discussion and Analysis" in this Proxy Statement and in the proxy statements for the Annual Meetings of Stockholders held in 2020 through 2024.

![](ny20055089x1_pvp01.jpg)

Total Shareholder return in the above chart, in the case of both the Company and the Dow Jones US Business Training & Employment Agencies Index as noted in the Pay versus Performance table, reflects the cumulative return of $100 as if invested on December 31, 2019.

![](ny20055089x1_pvp02.jpg)

70<br>

------

In Fiscal 2022, the PEO compensation included two PEOs, Mr. Clark, who retired on March 31, 2022, and Mr. Martins, who was appointed as PEO on March 31, 2022. Mr. Clark transitioned to the role of Chairman of the Board. As a result, his compensation includes the grant he was awarded on June 1, 2022 as a member of the Board.

![](ny20055089x1_pvp03.jpg)

![](ny20055089x1_pvp04.jpg)

Compensation of the PEO and non-PEO NEOs includes long-term incentive awards, of which a certain percentage, ranging from 33% in Fiscal 2020 to 50% in Fiscal 2024, are tied to the future performance of the Company, including Adjusted EBITDA.

71<br>

------

### OUR ANNUAL MEETING & OTHER INFORMATION

### OUR PROPOSALS

#### PROPOSAL NO. 1: ELECTION OF DIRECTORS
The Board currently consists of seven members, whose current terms expire at the Annual Meeting. Each of these directors are standing for re-election at the Annual Meeting.

Each director nominee elected will hold office until the 2026 Annual Meeting of Stockholders and until a successor has been duly elected and qualified unless, prior to such meeting, a director shall resign, or his or her directorship shall become vacant due to his or her death, resignation, or removal. All director nominees were elected at the 2024 Annual Meeting of Stockholders.

Each director nominee has agreed to serve, if elected, and management has no reason to believe that he or she will be unavailable to serve. If any of the director nominees should be unavailable for election, the proxies will be voted for the election of such other person as may be recommended by the Board in place of such director nominee. Shares properly voted will be voted FOR each director nominee unless the stockholder indicates on the proxy that authority to vote the shares is withheld for one or more of the director nominees listed. A proxy cannot be voted for a greater number of persons than the seven director nominees.

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position**  |
| Kevin C. Clark | 65 | Chairman of the Board and Director  |
| Dwayne Allen | 64 | Director  |
| Venkat Bhamidipati | 59 | Chairperson of the Audit Committee and Director  |
| W. Larry Cash | 76 | Lead Director  |
| Gale Fitzgerald | 74 | Chairperson of the Governance and Nominating Committee and Director  |
| John A. Martins | 56 | President, Chief Executive Officer and Director  |
| Janice E. Nevin, M.D., MPH | 65 | Director |

---

For information as to the shares of the Common Stock held by our director nominees, see "Security Ownership of Certain Beneficial Owners and Management" and for a biographical summary of our director nominees, see "Our Board of Directors." There are no arrangements or understandings between any of the director nominees or executive officers and any other person pursuant to which our director nominees or executive officers have been selected for their respective positions.

#### THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" EACH

#### OF THE DIRECTOR NOMINEES

#### (PROPOSAL NO. 1 ON YOUR PROXY CARD)
72<br>

------

#### **TABLE OF CONTENTS**

#### PROPOSAL NO. 2: RATIFICATION OF THE APPOINTMENT OF INDEPENDENT

#### REGISTERED PUBLIC ACCOUNTING FIRM
D&T has served as our independent registered public accounting firm since 2015. The Audit Committee annually evaluates the selection of our independent registered accounting firm and has reappointed D&T as the Company's independent registered public accounting firm to examine the consolidated financial statements of the Company and its subsidiaries for the fiscal year ending December 31, 2025. In deciding whether to reappoint D&T, the Audit Committee considered a number of factors, including, but not limited to D&T's independence, quality of services, effectiveness of communications, and technical expertise and knowledge of the industry. The Audit Committee is directly involved with the selection of the lead engagement partner, including in connection with the mandated rotation of the independent auditor's lead engagement partner every five years.

Although stockholder approval is not required for the appointment of an independent accounting firm, the Audit Committee and the Board believe that soliciting stockholder input is a matter of good corporate governance. If the stockholders fail to ratify the appointment of D&T, it will be considered as a directive to the Audit Committee and the Board to consider the appointment of another independent accounting firm; however, the Board and the Audit Committee are not required to do so. Even if D&T's appointment is ratified, the Board and the Audit Committee may select a different independent accounting firm at any time during the year if it is determined that such a change would be in the best interests of the Company and its stockholders.

Members of D&T are expected to be present by virtual participation at the Annual Meeting, will have an opportunity to make a statement if they desire to do so, and will be available to respond to appropriate questions.

The Audit Committee deems the ratification of the appointment of D&T as our independent registered public accounting firm to be in the best interest of the Company and its stockholders and recommends that holders of our Common Stock vote FOR Proposal No. 2.

The affirmative vote of holders of a majority of shares represented at the Annual Meeting, by virtual participation or by proxy and entitled to vote is required for the ratification of the Audit Committee's selection of D&T as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

#### THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" THE

#### RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS

#### THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

#### (PROPOSAL NO. 2 ON YOUR PROXY CARD)
73<br>

------

#### **TABLE OF CONTENTS**

#### PROPOSAL NO. 3: NON-BINDING ADVISORY VOTE TO APPROVE COMPENSATION

#### OF OUR NAMED EXECUTIVE OFFICERS
We urge stockholders to read the "Compensation Discussion and Analysis" beginning on page [37](#tCDA) of this Proxy Statement, which describes in more detail how our executive compensation policies and procedures operate and are designed to achieve our compensation objectives, as well as the Summary Compensation Table and other related compensation tables and narrative, beginning on page [55](#tSCT), which provide detailed information on the compensation of our named executive officers. The Compensation Committee and the Board believe that our executive compensation program has been effective in aligning NEO pay with performance outcomes and in reinforcing key business and strategic objectives in support of long-term value creation.

In accordance with Section 14A of the Exchange Act, and as a matter of good corporate governance, we are asking stockholders to approve the following advisory resolution at the Annual Meeting:

"RESOLVED, that the stockholders of the Company approve, on an advisory basis, the compensation of the Company's named executive officers disclosed in the Compensation Discussion and Analysis, the Summary Compensation Table and the related compensation tables, notes, and narrative in the Proxy Statement for the Company's 2025 Annual Meeting of Stockholders."

This advisory resolution, commonly referred to as a "say-on-pay" resolution, is non-binding on the Board. This proposal gives the Company's stockholders the opportunity to express their views on the compensation of its named executive officers in accordance with Section 14A of the Exchange Act. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the Company's compensation philosophy, policies, and practices described in this Proxy Statement.

The Board and the Compensation Committee value the opinions of the Company's stockholders and, to the extent that any significant vote against the named executive officer compensation occurs, the Board will consider the stockholders' concerns, and the Compensation Committee will evaluate whether any actions are necessary to address those concerns. However, neither the Board nor the Compensation Committee will have any obligation to take such actions.

The Board has adopted a policy providing for an annual "say-on-pay" advisory vote. At our 2023 annual meeting of stockholders, our stockholders voted to conduct the "say-on-pay" advisory vote on an annual basis. Unless the Board modifies the Company's policy, the next say-on-pay advisory vote will be held at our 2026 Annual Meeting of Stockholders, and the next say-on-frequency advisory vote will be held at our 2029 Annual Meeting of Stockholders.

#### THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE

#### "FOR" THE ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO OUR

#### NAMED EXECUTIVE OFFICERS IN 2024

#### (PROPOSAL NO. 3 ON YOUR PROXY CARD)
74<br>

------

#### **TABLE OF CONTENTS**

### GENERAL PROXY INFORMATION

### ANNUAL MEETING AND VOTING INFORMATION
The Proxy Statement is furnished in connection with the solicitation by the Board of Cross Country Healthcare, Inc. ("Cross Country," the "Company," "our," "we," or "us"), a Delaware corporation, of proxies to be voted at our 2025 Annual Meeting, or at any adjournment, postponement, or continuation thereof.

---

| | | |
|:---|:---|:---|
| **2025 Annual Meeting of Stockholders**  | **2025 Annual Meeting of Stockholders**  | **2025 Annual Meeting of Stockholders**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•  | **Time and Date:**  | December 9, 2025, at 12:00 p.m. Eastern Time\*\*\*  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• | **Virtual Meeting Site:**  | <u>www.virtualshareholdermeeting.com</u>/CCRN2025  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•  | **Record Date:** | October 14, 2025  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•  | **Voting:** | Stockholders of the Company as of the record date, October 14, 2025, are entitled to vote on the proposals being acted upon at the meeting. Each share of the Company's Common Stock is entitled to one vote for each director nominee and one vote for each of the other proposals to be voted upon at the Annual Meeting. |

---

**\*\*\*** **As previously disclosed, if the merger with Aya Healthcare is completed prior to the December 9, 2025 meeting date, the Company's 2025 Annual Meeting of Stockholders will not occur.\*\*\*** 

**Matters to be Voted Upon** <br>

The purposes of the Annual Meeting are to seek stockholder approval of the following three proposals:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. To elect seven directors to serve for a one-year term;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. To approve, on a non-binding, advisory basis, the compensation paid to our named executive officers in 2024 ("say on pay" vote).

We also will consider and act upon any other matters that properly come before the Annual Meeting or any adjournment, postponement, or continuation thereof.

**How to Attend the Virtual Annual Meeting** <br>

The Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted via live audio cast. You are entitled to participate in the Annual Meeting only if you were a stockholder as of the close of business on October 14, 2025 (the "Record Date") or if you hold a valid proxy for the Annual Meeting.

To be admitted to and to participate in the Annual Meeting at <u>www.virtualshareholdermeeting.com//CCRN2025</u> you must enter the 16-digit control number on your proxy card or voting instruction form that you previously received. You also will be able to vote your shares online, submit questions electronically, and examine a list of stockholders during the Annual Meeting. During the live Q&A session of the meeting, members of our executive leadership team will answer questions as they are submitted, as time permits. To ensure the meeting is conducted in a manner that is fair to all stockholders, the Chairman of the Board may exercise broad discretion in recognizing stockholders who wish to participate, the order in which questions are asked, and the amount of time devoted to any one question. However, we reserve the right to edit or reject questions we deem inappropriate.

75<br>

------

#### **TABLE OF CONTENTS**
The meeting webcast will begin promptly at 12:00 p.m. Eastern Time on December 9, 2025. Online access will begin at 11:45 a.m. Eastern Time, and we encourage you to access the meeting prior to the start time.

We will have technicians ready to assist with any technical difficulties you may have. You will have the ability to test the systems before the Annual Meeting starts, and a technical phone number will be provided when the meeting opens.

**Who May Vote** <br>

Stockholders of record of our common stock, par value $0.0001 per share (the "Common Stock") as of the close of business on the Record Date are entitled to notice of, and to vote at, the Annual Meeting and any adjournment, postponement, or continuation thereof. As of the Record Date, we had 32,759,952 shares of Common Stock issued and outstanding. We have no other securities entitled to vote at the Annual Meeting. Each share of Common Stock is entitled to one vote on each matter. There is no cumulative voting.

If the shares you own are held in "street name" by a bank or brokerage firm, your bank or brokerage firm, as the record holder of your shares, is required to vote your shares according to your instructions. In order to vote your shares, you will need to follow the directions that your bank or brokerage firm provides to you. Many banks and brokerage firms solicit voting instructions over the internet or by telephone. Even if your shares are held in street name, you are welcome to participate in the Annual Meeting; however, you may not vote your shares online during the Annual Meeting. If you hold your shares in street name and wish to vote online during the Annual Meeting, please contact your bank or brokerage firm before the Annual Meeting to obtain the necessary proxy from the holder of record.

If the beneficial owner does not provide voting instructions, banks and brokerage firms cannot vote the shares with respect to "non-routine" matters, but can vote the shares with respect to "routine" matters. "Broker non-votes" occur when a beneficial owner of shares held in street name fails to provide instructions to the bank or brokerage firm holding the shares as to how to vote on matters deemed "non-routine." We believe Proposal No. 2 (the ratification of the appointment of our independent registered public accounting firm) is a "routine" matter and, as a result, we do not expect there to be any broker non-votes. Proposal No. 1 (the election of directors), and Proposal No. 3 (the non-binding advisory approval of the compensation of the Company's named executive officers for 2024) are "non-routine" matters, and banks and brokerage firms cannot vote your shares on such proposals if you have not given voting instructions.

The presence at the Annual Meeting of a majority of the outstanding shares of Common Stock as of the Record Date, represented by virtual attendance or by proxy, is required for a quorum. As long as one of the matters is deemed to be a "routine" matter, proxies reflecting broker non-votes (if any) will be counted towards the quorum requirement.

**Electronic Notice and Mailing** <br>

Pursuant to the rules promulgated by the Securities and Exchange Commission (the "SEC"), we are making our proxy materials available to you on the Internet. Accordingly, we will mail a Notice of Internet Availability of proxy materials (the "Notice of Internet Availability") to the beneficial owners of our Common Stock entitled to vote during the Annual Meeting on or about October 27, 2025. From the date of the mailing of the Notice of Internet Availability until the conclusion of the Annual Meeting, all beneficial owners entitled to vote during the Annual Meeting will have the ability to access all of the proxy materials at www.proxyvote.com. If you received a Notice of Internet Availability, you may request a paper copy or e-mail version of these proxy materials.

The Notice of Internet Availability will contain:

&nbsp;&nbsp;&nbsp;&nbsp;• the date, time, and instructions to virtually attend the Annual Meeting, the matters to be acted upon at the Annual Meeting, and the Board's recommendation with regard to each matter;

76<br>

------

&nbsp;&nbsp;&nbsp;&nbsp;• the Internet address where the proxy materials may be accessed;

&nbsp;&nbsp;&nbsp;&nbsp;• a comprehensive listing of all proxy materials available on the internet address;

&nbsp;&nbsp;&nbsp;&nbsp;• a toll-free phone number, e-mail address, and Internet address for requesting either a paper copy or e-mail version of proxy materials;

&nbsp;&nbsp;&nbsp;&nbsp;• the last reasonable date a stockholder can request a paper copy or e-mail version of the proxy materials and expect them to be delivered prior to the Annual Meeting; and

&nbsp;&nbsp;&nbsp;&nbsp;• instructions on how to access the proxy card.

You may also request a paper copy or e-mail version of the proxy materials on or before the date provided in the Notice of Internet Availability by calling 1-800-579-1639. We will fill your request within three business days. You will also have the option to establish delivery preferences that will be applicable for all your future mailings.

**How to Vote** <br>

If you were a record holder of shares of Common Stock on the Record Date, you may vote as follows:

&nbsp;&nbsp;&nbsp;&nbsp;•  ***By Internet:*** Go to the website www.proxyvote.com to vote via the Internet. You will need to follow the instructions on your proxy card and the website.

&nbsp;&nbsp;&nbsp;&nbsp;•  ***By Telephone:*** Call the toll-free number 1-800-690-6903 to vote by telephone. You will need to follow the instructions on your proxy card and the recorded instructions.

&nbsp;&nbsp;&nbsp;&nbsp;•  ***By Mail:*** If you prefer, you can contact us to obtain paper copies of all proxy materials, including proxy cards, by calling 1-800-579-1639, or by mail: Cross Country Healthcare, Inc., General Counsel, at 6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida, 33487. If you contact us to request a proxy card, please mark, sign, and date the proxy card and return it promptly in the self-addressed, stamped envelope that we will provide, if you are the stockholder of record, or by signing the voter instruction form provided by your bank or broker and returning it by mail, if you are the beneficial owner but not the stockholder of record. This way your shares will be represented whether or not you are able to virtually attend the meeting. If you sign and return your proxy card but do not give voting instructions, the shares represented by that proxy will be voted as recommended by the Board.

&nbsp;&nbsp;&nbsp;&nbsp;•  ***Virtual Participation:*** The Annual Meeting will be held entirely online via live audio cast. Stockholders may participate in the Annual Meeting by visiting the following website: www.virtualshareholdermeeting.com/CCRN2025. To participate in the Annual Meeting, you will need the 16-digit control number included on your Notice, on your proxy card, or on the instructions that accompanied your proxy materials. Shares held in your name as the stockholder of record may be voted electronically during the Annual Meeting. Shares for which you are the beneficial owner but not the stockholder of record also may be voted electronically during the Annual Meeting if you obtain a valid proxy from the record holder. However, even if you plan to virtually attend the Annual Meeting, the Company recommends that you vote your shares in advance, so that your vote will be counted if you later decide not to virtually attend the meeting.

If you vote via the Internet or by telephone, your electronic vote authorizes the named proxies to vote in the same manner as if you signed, dated, and returned your proxy card. If you vote via the Internet or by telephone, do not mail a proxy card.

77<br>

------

If your shares of Common Stock are held in "street name" through a bank, broker, or other institution, then that bank, broker, or other institution is considered the holder of record of your shares, and you should refer to information forwarded to you by such holder of record for your voting options. You may vote as follows:

&nbsp;&nbsp;&nbsp;&nbsp;•  ***By Internet or Telephone:*** You will receive instructions from your broker or other nominee if you are permitted to vote by internet or telephone.

&nbsp;&nbsp;&nbsp;&nbsp;•  ***By Mail:*** You will receive instructions from your broker or other nominee explaining how to vote your shares.

**Board's Voting Recommendations** <br>

The Board recommends a vote:

#### Proposal No. 1: " FOR " the election of each of the seven director nominees to serve on the Board for a one-year term.
***Proposal No. 2: "FOR" ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.***

#### Proposal No. 3: " FOR " approval, on an advisory basis, of compensation paid to our named executive officers in 2024.
**Required Vote** <br>

Shares of Common Stock represented by any proxy duly given will be voted at the Annual Meeting in accordance with the instructions of the stockholder. If no specific instructions are given, the shares will be voted "**FOR**" the election of each of the director nominees, "**FOR**" ratification of the independent registered public accounting firm, and "**FOR**" approval, on an advisory basis, of the compensation paid to our named executive officers in 2024. In addition, if any other matters come before the Annual Meeting, the persons named in the accompanying Proxy Card will vote in accordance with their best judgment with respect to such matters. Each share of Common Stock outstanding on the Record Date will be entitled to one vote on all matters.

The Company is incorporated in the State of Delaware and our shares are listed on Nasdaq. As a result, the Delaware General Corporation Law (the "DGCL") and Nasdaq listing rules govern the voting standards applicable to actions taken by our stockholders.

78<br>

------

#### **TABLE OF CONTENTS**
Under our Amended and Restated Bylaws ("Bylaws"), the affirmative vote of a majority of the votes cast (affirmatively or negatively) are required for the matters set forth for stockholder vote in Proposal Nos. 2 and 3. For Proposal No. 1, our Bylaws provide that a director nominee will be elected if the votes cast for director nominee's election exceed the votes cast against such director nominee's election. Please see the below chart for a summary of the required votes, as well as the impacts of abstentions and broker non-votes, for each proposal:

---

| | | | |
|:---|:---|:---|:---|
| **Proposal** | **Voting Approval** <br>**Standard** | **Effect of** <br>**Abstention<sup>(1)</sup>** | **Effect of Broker** <br>**Non-Vote<sup>(2)</sup>**  |
| 1. <br>Election of seven director nominees<br>| Votes cast for a director nominee's election exceed the votes cast against such director nominee's election | No effect | No effect  |
| 2. <br>Ratification of Deloitte &Touche LLP as the Company's independent registered public accounting firm for fiscal year December 31, 2025<br>| Majority of the votes cast | No effect | Not applicable  |
| 3. <br>Advisory vote to approve<br>the 2024 compensation of named executive officers (say on pay)<br>| Majority of the votes cast | No effect | No effect |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Under the DGCL, abstentions are not considered "votes cast" and, accordingly, shares that abstain with respect to Proposal Nos. 1, 2, and 3 have no impact on the result.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Proposal No. 2 is considered a "routine" proposal on which brokers are permitted to vote in their discretion even if the beneficial owners do not provide voting instructions. However, Proposal Nos. 1 and 3 are not considered to be routine matters and brokers will not be entitled to vote thereon unless beneficial owners provide voting instructions. Accordingly, broker non-votes will not be counted toward the tabulation of votes on Proposal Nos. 1 and 3.

**Revoking Your Proxy** <br>

If you are a holder of record, you may revoke your proxy and reclaim your right to vote up to and including the day of the Annual Meeting by giving written notice of revocation to us (to the attention of the Inspectors of Election), timely delivering a valid, later-dated proxy or virtually attending and voting online during the Annual Meeting. Please note that virtual attendance at the Annual Meeting will not by itself revoke a proxy; you must also vote online during the Annual Meeting to revoke a proxy. If your shares are held in "street name," you may revoke your voting instructions by following the specific directions provided to you by your bank or broker.

If the Annual Meeting is postponed, continued, or adjourned for any reason, at any subsequent reconvening of the Annual Meeting, all proxies will be voted in the same manner as the proxies would have been voted at the original convening of the Annual Meeting (except for any proxies that have at that time effectively been revoked or withdrawn).

79<br>

------

**Proxy Cards** <br>

All shares that have been properly voted and not revoked will be voted at the Annual Meeting in accordance with your instructions. If you sign and return your proxy card, or vote by internet or telephone but fail to give voting instructions, the shares represented by the proxy will be voted by the Proxy Committee as recommended by the Board. The Proxy Committee consists of Kevin C. Clark and John A. Martins.

Proxy cards, unless otherwise indicated by the stockholder, confer upon the Proxy Committee discretionary authority to vote all shares of stock represented by the proxies on any matter which may be properly presented for action at the Annual Meeting even if not covered herein.

**Quorum** <br>

The presence, in person (including virtually) or by proxy, of the holders of a majority of the voting power of the outstanding shares of Common Stock entitled to vote at the Annual Meeting constitutes a quorum. Abstentions and broker non-votes (i.e., proxies from brokers or nominees indicating that such persons have not received instructions from the beneficial owner or other persons entitled to vote shares as to a matter with respect to which the brokers or nominees do not have discretionary power to vote) are counted as present for purposes of determining the presence or absence of a quorum for the transaction of business.

**Solicitation of Proxies** <br>

The Board is soliciting your proxy in order to provide you with an opportunity to vote on all matters to be presented at the meeting whether or not you virtually attend the Annual Meeting. We will bear the cost of solicitation, including the preparation, assembly, printing, and mailing of the proxy materials. Copies of solicitation materials will be furnished to brokerage houses, fiduciaries, and custodians holding shares in their names that are beneficially owned by others so that they may forward this solicitation material to such beneficial owners. In addition, we may reimburse such persons for the costs in forwarding the solicitation materials to such beneficial owners. The original solicitation of proxies by mail may be supplemented by a solicitation by telephone, text message, email, or other means by our directors, officers, or other employees. No additional compensation will be paid to these individuals for any such services. In addition, we have hired Sodali & Co. to assist in soliciting proxies, if necessary. Sodali & Co. may solicit proxies by telephone, text message, email, or in person. We will pay Sodali & Co. a fee of approximately $15,000 plus expenses for providing such services.

**Information Regarding Director Nominations and Stockholder Proposals** <br>

Stockholder proposals intended to be included in the Proxy Statement and form of proxy for the Annual Meeting of Stockholders to be held in 2026, in addition to meeting certain eligibility requirements established by the SEC, must be in writing and received by the General Counsel at the Company's principal executive offices on or prior to June 29, 2026. If the date of next year's Annual Meeting is moved more than 30 days before or after the anniversary date of this year's Annual Meeting, the deadline for inclusion of proposals in our proxy materials is instead a reasonable time before we begin to print and mail our proxy materials. Notice of any stockholder proposal must include various matters as prescribed by the SEC, including a clear and concise description of the proposal, and the reasons for proposing it.

Any stockholder (i) who wishes to propose business to be considered by the stockholders at the Annual Meeting of Stockholders to be held in 2026, other than a proposal to be included in the Proxy Statement and form of proxy, or (ii) who wants to nominate a person for election to our Board at that meeting, must provide a written notice that sets forth the specified information described in our Bylaws concerning the proposed business or nominee. The notice must be delivered to the Corporate Secretary at our principal executive offices, at the address set forth on the first page of this Proxy Statement, no earlier than August 11, 2026 and no later than September 10, 2026. A copy of our Bylaws can be obtained upon request directed to

80<br>

------

the address set forth on the first page of this Proxy Statement or is available on our website at www.crosscountryhealthcare.com. In addition, stockholders who intend to solicit proxies in support of director nominees other than the Company's nominees must comply with the additional requirements of Rule 14a-19(b).

In addition to satisfying the above requirements, to comply with the universal proxy rules, shareholders who intend to solicit proxies in support of director nominees other than the Company's director nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than October 10, 2026 to the Corporate Secretary at our principal executive offices, at the address set forth on the first page of this Proxy Statement.

**Householding of Proxy Materials** <br>

The SEC has adopted rules that permit companies and intermediaries to satisfy delivery requirements for Notices of Internet Availability of proxy materials and, if applicable, proxy statements and annual reports to stockholders, with respect to two or more stockholders sharing the same address, by delivering a single copy of the material addressed to those stockholders. This process, commonly referred to as "householding," is designed to reduce duplicate printing and postage costs. We and some brokers may household Notices of Internet Availability of proxy materials and, if applicable, annual reports to stockholders and proxy materials, by delivering a single copy of the material to multiple stockholders sharing the same address unless contrary instructions have been received from the affected stockholders.

If a stockholder wishes in the future to receive a separate Notice of Internet Availability of proxy materials or, if applicable, the annual report to stockholders and proxy statement, or if a stockholder received multiple copies of some or all of these materials and would prefer to receive a single copy in the future, the stockholder should submit a request by telephone or in writing to the stockholder's broker if the shares are held in a brokerage account or, if the shares are registered in the name of the stockholder, to our transfer agent, at 877-219-7066 or Computershare, Shareholder Services, P.O. Box 43006, Providence, RI 02940-3006 (regular mail) or 150 Royall Street, Canton, MA 02021 (overnight packages). We promptly will send additional copies of the relevant material following receipt of a request for additional copies.

81<br>

------

### ANNUAL REPORT
We have filed our Annual Report for the fiscal year ended December 31, 2024 with the SEC, which is available free of charge through our Internet website, www.crosscountryhealthcare.com. Stockholders may obtain a printed copy of the Annual Report by writing to our Investor Relations department at 6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida, 33487. In response to such request, we will furnish, without charge, the Annual Report, including financial statements, financial schedules, and a list of exhibits.

A copy of our Annual Report for the year ended December 31, 2024, which includes the 2024 Form 10-K, is being mailed concurrently with this Proxy Statement to all stockholders entitled to notice of and to vote at the Annual Meeting and who request an Annual Report be mailed to them.

*Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended, or the Exchange Act, that might incorporate by reference this Proxy Statement or future filings made by the Company under those statutes, the Compensation Committee Report, the Audit Committee Report, references to the Audit Committee Charter and reference to the independence of the Audit Committee members are not deemed filed with the SEC, are not deemed soliciting material, and shall not be deemed incorporated by reference into any of those prior filings or into any future filings made by the Company under those statutes, except to the extent that the Company specifically incorporates such information by reference into a previous or future filing, or specifically requests that such information be treated as soliciting material, in each case under those statutes.* 

By Order of the Board of Directors,

![](sig_sball.jpg)

Susan E. Ball

Executive Vice President, Chief Administrative

Officer, General Counsel and Secretary

October 27, 2025

82<br>

------

#### **TABLE OF CONTENTS**

### ANNEX A

#### RECONCILIATION OF GAAP AND NON-GAAP FINANCIAL MEASURES
The Company reports its financial results in accordance with U.S. GAAP. However, management believes that certain non-GAAP financial measures provide additional financial information that is meaningful and uses these measures to help evaluate operational results and make financial, operating and planning decisions. Management also uses these non-GAAP financial measures as performance measures in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure typically used in the Company's credit facilities in calculating various ratios. We believe these non-GAAP measures should be considered by investors and others when reviewing the Company's performance.

We use Adjusted EBITDA and Adjusted EPS as supplemental measures to the financial measures we present in accordance with GAAP. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by revenue from services. These non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with U.S. GAAP. These non-GAAP financial measures are provided for consistency and comparability to prior year results, and management believes they are useful to investors when evaluating the Company's performance as they exclude certain items that management believes are not indicative of the Company's operating performance. These non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies.

#### Cross Country Healthcare, Inc.

#### Reconciliation of Non-GAAP Financial Measures

#### (Unaudited, amounts in thousands, except per share data)

---

| | | |
|:---|:---|:---|
|  | **Year Ended** <br>**December 31,**  | **Year Ended** <br>**December 31,**  |
|  | **2024** | **2023**  |
| **Reconciliation of Adjusted EPS(1)**<br>|  |  |
| Diluted EPS, GAAP | $(0.44) | $2.05  |
| &nbsp;&nbsp;&nbsp;Non-GAAP adjustments - pretax:<br>|  |  |
| &nbsp;&nbsp;&nbsp;Acquisition and integration-related costs | 0.13 | —  |
| &nbsp;&nbsp;&nbsp;Restructuring costs | 0.13 | 0.07  |
| &nbsp;&nbsp;&nbsp;Legal, bankruptcy, and other losses | 0.77 | 0.03  |
| &nbsp;&nbsp;&nbsp;Impairment charges | 0.09 | 0.02  |
| &nbsp;&nbsp;&nbsp;Other (income) expense, net | (0.02) | —  |
| &nbsp;&nbsp;&nbsp;Loss on early extinguishment of debt |  | 0.05  |
| &nbsp;&nbsp;&nbsp;System conversion costs | 0.13 | 0.07  |
| Tax impact of non-GAAP adjustments | (0.33) | (0.06)  |
| Adjusted EPS, non-GAAP | $0.46 | $2.23 |

---

83<br>

------

#### **TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  | **Year Ended** <br>**December 31,** | **Year Ended** <br>**December 31,** |
|  | **2024** | **2023**  |
| **Reconciliation of Adjusted EBITDA(2)**<br>|  |  |
| Net (loss) income attributable to common stockholders | $(14556) | $72631  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 2188 | 8094  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax (benefit) expense | (1842) | 30263  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 18200 | 18347  |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition and integration-related costs | 4219 | 59  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring costs | 4333 | 2553  |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal, bankruptcy, and other losses | 26041 | 1125  |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment charges | 2888 | 719  |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on disposal of fixed assets | 86 | 87  |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on lease termination |  | 104  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | (2050) | (83)  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income, net | (691) | (106)  |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity compensation | 6025 | 6579  |
| &nbsp;&nbsp;&nbsp;&nbsp;System conversion costs | 4232 | 2326  |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on early extinguishment of debt |  | 1723  |
| Adjusted EBITDA | $49073 | $144421 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Adjusted EPS, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders per diluted share before the diluted EPS impact of acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal, bankruptcy, and other losses, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on sale of business, other expense (income), net, system conversion costs, and nonrecurring income tax adjustments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Adjusted EBITDA, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders before interest expense, income tax expense (benefit), depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal, bankruptcy, and other losses, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on disposal of fixed assets, gain or loss on lease termination, gain or loss on sale of business, interest income, other expense (income), net, equity compensation, and system conversion costs.

84<br>

------

![](ny20055089x1-pc_1.jpg)

------

![](ny20055089x1-pc_2.jpg)